sinc
epidemiolog
clostridium
difficil
infect
cdi
investig
applic
mani
differ
type
fingerprint
method
studi
epidemiolog
cdi
type
method
high
discriminatori
power
typeabl
stabil
power
reproduc
epidemiolog
concord
requir
also
technic
advantag
eas
perform
rel
low
cost
high
throughput
grow
number
molecular
method
appli
c
difficil
earli
rapid
detect
outbreak
situat
method
restrict
enzym
analysi
arbitrari
prime
polymeras
chain
reaction
pcr
pulsedfield
gel
electrophoresi
pcr
ribotyp
commonli
use
longterm
epidemiolog
multilocu
sequenc
type
multilocu
variabl
number
tandem
repeat
analysi
mlva
amplifi
fragment
length
polymorph
interest
current
pcrribotyp
method
librari
pcr
ribotyp
cardiff
benchmark
type
studi
around
world
compar
convent
agaros
gelbas
pcr
ribotyp
easi
use
rel
cheap
analysi
fragment
length
hamper
poor
resolut
recent
capillari
gel
electrophoresisbas
pcr
ribotyp
assay
develop
significantli
reduc
handson
time
requir
c
difficil
pcr
ribotyp
result
highli
reproduc
independ
reagent
batch
brand
use
allow
interlaboratori
comparison
type
result
analysi
sequenc
c
difficil
genom
reveal
high
percentag
dna
consist
variabl
number
tandem
repeat
vntr
recent
new
mlva
method
develop
use
smal
short
tandem
repeat
bp
facilit
autom
fragment
analysi
multicolour
capillari
electrophoresi
instead
sequenc
studi
use
isol
laboratori
canada
netherland
unit
kingdom
unit
state
seven
c
difficil
type
techniqu
compar
rea
mlva
show
suffici
discrimin
distinguish
strain
differ
outbreak
mlva
also
appli
studi
local
outbreak
c
difficil
pcr
ribotyp
strain
mlva
current
discrimin
type
method
contribut
significantli
understand
epidemiolog
c
difficil
new
treatment
aspect
cdi
need
new
therapeut
altern
cdi
clear
current
recurr
rate
unaccept
high
optim
treatment
sever
cdi
infect
caus
strain
associ
poor
outcom
eg
c
difficil
ribotyp
multipl
recurr
unclear
sever
potenti
promis
new
cdi
treatment
approach
investig
includ
antibiot
antitoxin
bacteri
interfer
option
probiot
therapi
remain
unproven
benefit
new
option
becom
avail
prognost
data
need
guid
approri
therapeut
choic
oral
present
new
aspect
emerg
clostridium
difficil
infect
cdi
pro
con
molecular
fingerprint
clostridium
difficil
infect
ej
leiden
nl
sinc
epidemiolog
clostridium
difficil
infect
cdi
investig
applic
mani
differ
type
fingerprint
method
studi
epidemiolog
cdi
type
method
high
discriminatori
power
typeabl
stabil
power
reproduc
epidemiolog
concord
requir
also
technic
advantag
eas
perform
rel
low
cost
high
throughput
grow
number
molecular
method
appli
c
difficil
earli
rapid
detect
outbreak
situat
method
restrict
enzym
analysi
arbitrari
prime
polymeras
chain
reaction
pcr
pulsedfield
gel
electrophoresi
pcr
ribotyp
commonli
use
longterm
epidemiolog
multilocu
sequenc
type
multilocu
variabl
number
tandem
repeat
analysi
mlva
amplifi
fragment
length
polymorph
interest
current
pcrribotyp
method
librari
pcr
ribotyp
cardiff
benchmark
type
studi
around
world
compar
convent
agaros
gelbas
pcr
ribotyp
easi
use
rel
cheap
analysi
fragment
length
hamper
poor
resolut
recent
capillari
gel
electrophoresisbas
pcr
ribotyp
assay
develop
significantli
reduc
handson
time
requir
c
difficil
pcr
ribotyp
result
highli
reproduc
independ
reagent
batch
brand
use
allow
interlaboratori
comparison
type
result
analysi
sequenc
c
difficil
genom
reveal
high
percentag
dna
consist
variabl
number
tandem
repeat
vntr
recent
new
mlva
method
develop
use
smal
short
tandem
repeat
bp
facilit
autom
fragment
analysi
multicolour
capillari
electrophoresi
instead
sequenc
studi
use
isol
laboratori
canada
netherland
unit
kingdom
unit
state
seven
c
difficil
type
techniqu
compar
rea
mlva
show
suffici
discrimin
distinguish
strain
differ
outbreak
mlva
also
appli
studi
local
outbreak
c
difficil
pcr
ribotyp
strain
mlva
current
discrimin
type
method
contribut
significantli
understand
epidemiolog
c
difficil
need
new
therapeut
altern
cdi
clear
current
recurr
rate
unaccept
high
optim
treatment
sever
cdi
infect
caus
strain
associ
poor
outcom
eg
c
difficil
ribotyp
multipl
recurr
unclear
sever
potenti
promis
new
cdi
treatment
approach
investig
includ
antibiot
antitoxin
bacteri
interfer
option
probiot
therapi
remain
unproven
benefit
new
option
becom
avail
prognost
data
need
guid
approri
therapeut
choic
montreal
ca
clostridium
difficil
long
recognis
import
caus
antibiot
associ
diarrhoea
hospitalis
patient
although
commun
associ
diseas
describ
decad
recognis
import
caus
infecti
diarrhoea
patient
commun
c
difficil
mostli
recognis
nosocomi
pathogen
major
studi
clinic
c
difficil
infect
cdi
conduct
acut
care
hospit
mani
perform
outbreak
situat
hospit
environ
specif
characterist
like
import
determin
infecti
diseas
occurr
transmiss
cluster
suscept
host
increas
possibl
environment
contamin
physic
proxim
multipl
person
person
contact
similarli
demograph
hospit
patient
popul
also
differ
significantli
commun
hospit
preval
antibiot
use
high
highli
correl
mani
factor
could
import
express
cdi
recent
antibiot
believ
prerequisit
develop
cdi
studi
commun
acquir
diseas
consist
describ
diseas
occur
high
proport
patient
exposur
lead
research
examin
risk
factor
cdi
appear
increas
commun
especi
elderli
also
pediatr
popul
cdi
commun
may
precced
recent
antibiot
exposur
particularli
patient
without
recent
hospit
mani
recommend
diarrhea
test
alogarithm
result
diagnosi
miss
delay
could
import
implic
patient
care
control
outbreak
well
design
studi
c
difficil
commun
could
improv
understand
diseas
improv
abil
explor
risk
factor
antibiot
exposur
mayb
less
confound
extend
cohort
n
final
stage
observ
associ
test
replic
independ
casecontrol
studi
n
result
stage
found
snp
gene
lbp
associ
increas
suscept
meningococc
diseas
snp
replic
case
control
studi
stage
ci
separ
replic
studi
independ
confirmatori
cohort
stage
ci
subgroup
analysi
show
snp
confer
increas
risk
shock
patient
snp
function
lead
decreas
product
whole
blood
model
meningococc
sepsi
conclus
identifi
function
snp
associ
increas
risk
meningococc
septic
shock
possibl
snp
associ
increas
risk
meningococc
diseas
lbp
chromatin
madeup
dna
histon
nonhiston
protein
coval
modif
histon
acetyl
lysin
residu
strongli
influenc
structur
function
chromatin
wherea
acetyl
histon
result
relax
chromatin
structur
associ
activ
transcript
deacetyl
histon
result
compact
chromatin
structur
associ
repress
transcript
global
histon
acetyl
regul
oppos
action
histon
acetyltransferas
hat
histon
deacetylas
hdac
besid
histon
non
histon
protein
modifi
revers
acetyl
among
atubulin
transcript
regul
therefor
hdac
impact
mani
biolog
function
primarili
cell
differenti
growth
surviv
hdac
inhibitor
hdi
origin
develop
power
anticanc
activ
yet
recent
preclin
studi
suggest
hdi
possess
antiinflammatori
activ
base
observ
postul
hdi
could
impact
innat
immun
respons
microbi
infect
discuss
result
studi
effect
hdi
innat
immun
system
first
perform
genomewid
gene
express
analys
global
view
impact
hdi
transcriptom
rest
microbi
productstimul
primari
macrophag
studi
influenc
hdi
key
paramet
activ
intracellular
signal
transduct
pathway
product
cytokin
chemokin
express
costimulatori
chemokin
receptor
macrophag
dendrit
cell
whole
blood
activ
broad
rang
microbi
product
final
analyz
impact
hdi
preclin
model
nonsever
bacteri
fungal
infect
toxic
shock
sever
sepsi
overal
studi
demonstr
hdi
power
antiinflammatori
immunosuppress
drug
impair
innat
immun
respons
microbi
infect
vitro
vivo
result
suggest
hdi
may
repres
attract
adjunct
therapi
treat
patholog
situat
character
dysregul
inflammatori
respons
autoimmun
diseas
sever
sepsi
also
warn
hdi
may
increas
risk
develop
opportunist
infect
sepsi
especi
immunocompromis
cancer
patient
latest
trend
molecular
laboratori
studi
fungal
pathogen
invas
fungal
infect
diagnost
pcr
ifi
realli
work
invas
aspergillosi
ia
continu
high
mortal
partli
consequ
difficulti
earli
diagnosi
also
due
therapeut
limit
nowaday
ia
diagnosi
base
extens
use
galactomannan
gm
highresolut
chest
tomographi
hrct
despit
fact
posit
gm
prompt
earlier
treatment
ia
mortal
still
high
popul
show
diagnost
approach
taken
account
detect
nucleic
acid
pcrbase
method
mainli
appear
option
assess
although
date
mani
doubt
profit
type
method
diagnost
pcr
must
consid
addit
test
develop
use
refer
laboratori
lack
standard
stress
sinc
differ
laboratori
use
differ
approach
term
extract
probe
primer
pcr
condit
measur
furthermor
benefit
detect
dna
aspergillu
fumigatu
depend
clinic
sampl
use
pcr
techniqu
shown
high
diagnost
reliabl
tissu
biopsi
respiratori
sampl
high
neg
predict
valu
discreet
posit
predict
valu
lower
diagnost
reliabl
obtain
blood
sampl
high
neg
predict
valu
could
use
rule
presenc
infect
newer
approach
serial
determin
aspergillu
dna
serum
blood
detect
fungal
dna
higher
volum
blood
shown
greater
diagnost
applic
increas
combin
gm
quantif
highresolut
chest
tomographi
approach
higher
rate
sensit
specif
improv
earli
diagnosi
aspergillosi
fewer
data
avail
mycos
pcr
method
develop
detect
candida
endem
mycosi
emerg
pathogen
data
need
reliabl
conclus
drawn
f
hagen
b
theelen
k
khayhan
c
klaassen
j
mei
utrecht
nijmegen
nl
understand
caus
agent
fungal
diseas
chang
consider
recent
year
mainli
due
larg
scale
introduct
molecular
studi
one
stretch
dna
compar
across
wide
rang
fungi
includ
human
anim
pathogen
one
strike
discoveri
recognit
pneumocysti
fungu
organ
consid
previous
belong
parasit
mani
case
tradit
speci
turn
repres
speci
complex
mani
newli
recogn
clinic
relev
speci
may
differ
suscept
commonli
use
antifung
therefor
correct
identif
new
pathogen
import
proper
patient
manag
brief
overview
present
develop
fungal
taxonomi
implic
clinic
practic
exampl
given
main
lineag
fungal
kingdom
name
zygomycet
ascomycet
aspergillu
fusarium
candida
spp
basidiomycet
malassezia
trichosporon
cryptococcu
spp
due
experi
basidiomycet
yeast
give
depth
inform
fungi
number
recogn
speci
rapidli
increas
due
applic
molecular
systemat
avail
larg
databas
ribosom
dna
rdna
sequenc
notabl
domain
lsu
rdna
region
speci
gener
recogn
import
pathogen
human
anim
includ
cryptococcu
neoforman
cr
gattii
sever
trichosporon
speci
malassezia
spp
howev
sever
nonconvent
basidiomycet
yeast
speci
caus
infect
otherwis
involv
health
problem
hypersensit
pneumon
present
data
involv
emerg
basidiomycet
speci
c
adeliensi
c
diffluen
c
flavescen
c
laurentii
human
diseas
emphasi
cr
neoformanscr
gattii
malassezia
speci
complex
especi
role
newli
recogn
speci
diseas
virul
suscept
antifung
fr
main
applic
genotyp
investig
epidem
track
rout
contamin
sever
molecular
type
techniqu
develop
fungi
ideal
type
result
accur
reproduc
easi
interpret
importantli
method
transfer
set
mani
type
method
randomli
amplifi
polymorph
dna
restrict
fragment
length
polymorph
singlestrand
conform
polymorph
analysi
amplifi
fragment
length
polymorph
yield
fingerprint
profil
difficult
reproduc
differ
set
contrast
two
method
emerg
clinic
applic
provid
reliabl
portabl
easi
obtain
data
microsatellit
marker
multi
locu
sequenc
type
mlst
microsatellit
short
tandem
repeat
defin
tandemli
repetit
stretch
two
five
nucleotid
amplif
pcr
product
analyz
base
amplicon
length
present
limit
microsatellit
type
transfer
straightforward
univers
applic
method
achiev
calibr
use
allel
ladder
mlst
base
sequenc
sever
housekeep
gene
activ
mlst
scheme
publicli
avail
http
wwwmlstnet
yeast
main
advantag
mlst
abil
provid
indisput
data
base
sequenc
howev
mlst
labori
base
qualiti
sequenc
long
turnaround
time
associ
signific
cost
nosocomi
acquisit
invas
infect
investig
conclus
disappoint
invas
aspergillosi
unambigu
invas
candidiasi
howev
genotyp
suffici
sampl
collect
clinic
epidemiolog
data
compulsori
reach
meaning
conclus
anoth
interest
point
propag
given
clone
resist
phenotyp
alreadi
investig
aspergillu
fumigatu
candida
tropicali
get
piec
inform
genom
microorgan
probabl
part
futur
routin
laboratori
current
trend
toward
mass
sequenc
creat
opportun
technolog
might
lead
sever
modif
way
identifi
speci
character
isol
introduct
highli
activ
antiretrovir
therapi
haart
profoundli
influenc
cours
hiv
infect
improv
surviv
hiv
infect
patient
reduc
hivassoci
opportunist
infect
nevertheless
longterm
outcom
secondari
hiv
infect
seriou
concern
like
noninfecti
cardiovascular
complic
includ
cardiomegali
pericard
myocard
pulmonari
arteri
hypertens
lung
frequent
target
organ
disord
associ
hiv
infect
cardiopulmonari
vascular
system
sometim
involv
inde
hivrel
pulmonari
arteri
hypertens
hrpah
affect
hivinfect
individu
ie
uninfect
ie
case
per
million
peopl
averag
age
hrpah
patient
year
although
rang
span
infanc
old
age
trend
hrpah
hiv
viral
load
cell
count
sever
aid
patient
short
breath
common
symptom
clinic
cardiolog
radiolog
work
requir
diagnosi
cardiac
catheteris
gold
standard
final
diagnosi
mandatori
character
diseas
exclud
secondari
caus
definit
evid
hiv
causal
agent
hrpah
howev
viral
protein
interact
molecular
partner
infect
host
strong
candid
causeeffect
relationship
may
promot
apoptosi
growth
prolifer
least
three
hiv
protein
implic
patholog
pah
hiv
envelop
env
hiv
protein
tat
hiv
nef
neg
factor
nef
impair
vasomotor
function
pulmonari
arteri
cell
decreas
express
endotheli
nitric
oxid
synthas
increas
oxid
stress
suggest
strong
role
format
plexiform
lesion
lung
vasculatur
role
antiretrovir
therapi
art
hrpah
still
debat
literatur
review
surviv
rate
among
patient
treat
art
specif
therapi
pah
respect
p
thu
suggest
specif
therapi
pulmonari
arteri
hypertens
strongli
recommend
patient
role
combin
treatment
antiretrovir
influenc
outcom
hrpah
controversi
even
evid
seem
indic
benefici
effect
clinic
cours
diseas
fat
sampl
could
success
analys
show
mean
mgg
group
evalu
sampl
two
patient
mean
mgml
group
ii
evalu
sampl
three
patient
group
iii
sampl
six
patient
detect
limit
analyt
method
linear
regress
analysi
decreas
serum
daptomycin
concentr
per
minut
estim
confid
interv
object
higher
vancomycin
van
serum
trough
level
stl
recommend
mrsa
hap
suspect
howev
correl
van
stl
clinic
outcom
safeti
still
poorli
understood
method
attain
random
methodolog
ident
doubleblind
phase
clinic
trial
patient
hospitalacquir
pneumonia
hap
analyz
baselin
characterist
outcom
patient
aureu
sa
random
van
g
iv
h
day
function
median
van
stl
van
could
adjust
renal
function
andor
institut
polici
alltreat
popul
includ
random
patient
receiv
dose
studi
medic
analysi
limit
subset
sainfect
patient
van
stl
result
van
patient
aureu
stl
tabl
median
van
trough
level
mgml
n
n
n
pvalu
number
trough
valu
per
patient
median
rang
mgml
chi
mgml
clinic
respons
cure
visa
previous
report
result
cell
wall
remodel
antimicrobi
suscept
chang
favor
blactam
activ
evalu
activ
van
oxacillin
oxa
cefoxitin
cfx
potenti
synergi
combin
vanoxa
collect
clinic
heterogen
visa
hvisa
visa
strain
j
black
k
leder
b
bigg
richard
l
pollissard
c
luxemburg
e
matchett
padaglion
woolley
p
schlagenhauf
gherardin
j
torresi
melbourn
au
lyon
fr
zurich
ch
object
estim
incid
densiti
influenza
dengu
japanes
enceph
je
australian
travel
asia
method
prospect
cohort
studi
australian
travel
south
south
east
asia
year
period
travel
year
age
recruit
travel
clinic
complet
valid
questionnair
provid
pre
posttravel
blood
sampl
serolog
test
demograph
data
destin
travel
pattern
vaccin
detail
histori
flaviviru
infect
obtain
serolog
test
dengu
igg
elisa
panbio
assay
influenza
b
complement
fixat
antibodi
je
inhous
indirect
fluoresc
antibodi
perform
result
among
travel
enrol
return
followup
lost
followup
pair
sera
test
travel
femal
median
age
year
born
oversea
short
term
travel
day
main
travel
type
vacationholiday
goer
busi
travel
report
prior
travel
asia
receiv
je
influenza
vaccin
respect
dengu
seropreval
acut
seroconvers
dengu
viru
infect
demonstr
travel
test
translat
incid
dengu
viru
infect
per
day
travel
ci
travel
posit
dengu
igg
prior
travel
indic
past
exposur
travel
acut
dengu
infect
travel
china
n
india
n
thailand
n
two
travel
receiv
je
vaccin
influenza
seropreval
evid
recent
influenza
infect
incid
influenza
viru
infect
per
day
travel
ci
je
seropreval
acut
je
seroconvers
cohort
conclus
knowledg
largest
prospect
studi
estim
incid
respiratori
arbovir
infect
travel
travel
asia
risk
acquir
dengu
interepidem
period
low
incid
densiti
infect
per
day
travel
risk
acquir
influenza
well
vaccin
cohort
equal
low
je
infect
observ
find
import
implic
practition
advis
prospect
travel
cr
lebbad
copenhagen
dk
solna
se
object
diagnosi
intestin
protist
pcr
employ
diagnost
research
laboratori
data
molecular
characteris
intestin
protist
raw
materi
current
futur
effort
develop
improv
diagnost
pcr
apart
abil
sampl
correctli
extract
dna
parasit
directli
faec
import
issu
includ
primer
specif
sensit
impact
predict
valu
diagnost
assay
thu
import
awar
genet
divers
among
parasit
extens
data
molecular
characteris
intestin
protist
necessari
pcrbase
diagnosi
detect
genet
variant
intestin
parasit
especi
eventu
aim
substitut
morphologybas
method
diagnost
pcr
often
base
amplif
small
subunit
ssu
rrna
gene
partli
due
fact
gene
present
highcopi
number
howev
data
strain
current
avail
ssu
rrna
gene
intestin
parasit
often
one
two
sequenc
avail
genbank
databas
process
collect
data
genet
characteris
protozoa
iodamoeba
entamoeba
coli
entamoeba
hartmanni
entamoeba
poleckilik
organ
isol
clinic
sampl
know
amount
divers
display
among
clinic
isol
parasit
help
us
gener
specif
sensit
primer
use
case
definit
diagnosi
establish
basi
microscopi
preliminari
result
show
genet
divers
within
entamoeba
coli
extens
less
four
genet
subtyp
uninucl
amoeb
cyst
isol
human
faec
also
obtain
genet
data
protozoan
genera
sequenc
conclus
futur
platform
diagnosi
intestin
protist
reli
pcr
comprehens
data
molecular
characteris
organ
need
design
evalu
valid
optimis
pcr
protocol
e
asadollahi
p
ilam
ir
liverpool
uk
object
resist
chloroquin
cq
plasmodium
falciparum
malaria
becom
major
health
concern
develop
world
resist
prompt
reexamin
pharmacolog
altern
antimalari
may
effect
resist
strain
amodiaquin
aq
antimalari
effect
mani
chloroquineresist
strain
p
falciparum
howev
clinic
use
aq
sever
restrict
associ
hepatotox
agranulocytosi
base
knowledg
metabol
basi
amodiaquin
toxic
aim
studi
examin
effect
replac
oh
function
amodiaquin
fluorin
success
fourstep
synthesi
new
seri
fluoro
analogu
design
appli
synthesi
array
analogu
malaria
parasit
maintain
continu
cultur
use
method
jensen
trager
antimalari
activ
assess
adapt
sensit
assay
desjardin
et
al
use
hypoxanthin
incorpor
assess
parasit
growth
chemistri
fluoro
seri
provid
target
compound
higher
overal
yield
initi
test
seri
analogu
carri
chloroquin
sensit
resist
strain
liverpool
school
tropic
appar
sever
analogu
potent
antimalari
activ
sensit
strain
parasit
data
indic
h
superior
pyrollidino
analogu
strain
examin
also
clear
ntert
butyl
analogu
potent
chloroquin
resist
strain
though
quit
activ
amodiaquin
aq
chloroquin
senstit
resist
parasit
conclus
summari
work
conduct
studi
identifi
sever
potent
backup
compound
clinic
candid
clear
fluoro
seri
sever
member
potent
activ
compar
amodiaquin
shown
h
slightli
less
potent
amodiaquin
chloroquin
clinic
candid
studi
metabol
pharmacokinet
h
necessari
almashhadani
r
r
vivanco
keenan
n
beech
j
wain
c
parri
liverpool
colindal
london
uk
object
nontyphoid
salmonella
nt
caus
gastroenter
lead
seriou
invas
ill
death
mani
case
nt
go
untreat
caus
mild
ill
seriou
case
treatment
requir
fluoroquinolon
often
drug
choic
isol
decreas
suscept
ciprofloxacin
dc
usual
associ
resist
nalidix
acid
na
increas
suggest
foreign
travel
risk
factor
acquisit
salmonella
enterica
isol
na
resist
dc
studi
aim
investig
link
foreign
travel
na
resistantdc
isol
liverpool
carbapenem
resist
acinetobact
repres
major
threat
antibiot
armamentarium
gener
class
b
blactamas
form
basi
phenotyp
class
blactamas
serin
enzym
either
monom
dimer
possess
uniqu
structur
motif
util
carbamyl
lysin
distinct
complex
hydrogenbond
network
creat
fix
blactam
substratebind
pocket
assist
bind
acyl
deacyl
result
substitut
acceler
blactam
use
mani
class
enzym
emerg
possess
function
structur
properti
confer
select
advantag
bacterium
hous
carbapenem
hydrolyz
blactamas
import
carbapenemas
acinetobact
includ
bla
bla
bla
bla
bla
notion
mind
purpos
review
molecular
epidemiolog
genet
major
class
serin
carbapenemas
present
acinetobact
spp
ii
analyz
amino
acid
chang
alter
substrat
specif
use
select
exampl
iii
highlight
chang
express
efflux
pump
outer
membran
protein
amplif
carbapenem
resist
crystal
structur
import
class
enzym
review
analyz
recent
decad
pseudomona
aeruginosa
emerg
major
threat
result
signific
mortal
associ
pneumonia
bacteraemia
evolv
resist
exhibit
pathogen
numer
antibacteri
sinc
time
appropri
therapi
need
sever
p
aeruginosa
infect
clinician
awar
risk
factor
associ
pathogen
multidrug
resist
still
debat
combin
monotherapi
institut
ps
aeruginosa
infect
use
combin
therapi
ps
aeruginosa
pneumonia
longadvoc
practic
potenti
increas
valu
new
horizon
diagnosi
bacteri
sepsi
combin
therapi
monotherapi
remain
controversi
howev
empir
combin
therapi
maxim
chanc
bacteri
coverag
especi
sever
infect
like
exert
lower
resist
select
pressur
upon
confirm
ps
aeruginosa
infect
treatment
given
accord
site
infect
pathophysiolog
patient
pharmacokineticpharmacodynam
profil
antimicrobi
antimicrobi
suscept
pattern
includ
mic
valu
strain
resist
antimicrobi
colistin
antimicrobi
advoc
choic
option
either
monoor
combin
therapi
inde
sinc
novel
antibiot
drug
develop
pipelin
multidrugresist
ps
aeruginosa
old
antibiot
polymyxin
ie
colistin
also
known
polymyxin
e
polymyxin
b
reemerg
last
resort
therapi
howev
current
clinic
use
colistin
larg
inform
inadequ
case
inaccur
pharmacokinet
pharmacodynam
data
rifampin
sulbactam
carbapenem
fosfomycin
possibl
option
combin
treatment
due
vitro
synergist
effect
among
carbapenem
doripenem
seem
possess
lower
potenti
resist
select
favour
pharmacokinet
profil
newer
antipseudomon
antibacteri
expect
avail
near
futur
among
experiment
polypeptid
ie
antipcrv
immunoglobulin
g
antibodi
may
provid
new
therapeut
approach
j
sevil
es
carbapenem
consid
drug
choic
treatment
seriou
infect
caus
esblproduc
enterobacteria
howev
altern
need
carbapenemresist
due
carbapenemas
mechan
increas
worldwid
treatment
uncompl
cystiti
due
esbl
produc
observ
studi
show
high
cure
rate
oral
fosfomycin
nitrofurantoin
amoxicillinclavulatan
suscept
isol
involv
mecillinam
stabl
esbl
also
potenti
option
patient
type
infect
includ
complic
urinari
tract
infect
option
limit
isol
may
show
low
mic
specif
cephalosporin
depend
type
esbl
produc
pkpd
data
suggest
infect
treat
cephalosporin
particularli
cefepim
use
appropri
dose
practic
recommend
empir
therapi
mic
predict
ad
aminoglycosid
standard
regimen
reason
option
select
patient
low
risk
renal
toxic
area
preval
aminoglycosid
resist
among
esblproduc
low
efficaci
combin
cephalosporin
blactamas
inhibitor
cefoperazonesulbactam
combin
cephalosporin
amoxicillinclavulatan
temocillin
studi
differ
clinic
set
howev
worldwid
spread
multidrug
resist
clone
e
coli
k
pneumonia
reduc
therapeut
option
carbapenem
tigecyclin
colistin
might
activ
older
drug
fosfomycin
probabl
combin
merit
investig
system
infect
new
drug
activ
organ
clearli
need
increas
preval
esbl
produc
enterobacteria
commun
hospit
threat
anymor
real
everyday
problem
h
athen
gr
resist
carbapenem
due
product
metalloblactamas
mbl
kpc
enzym
enterobacteriacea
increas
intern
public
health
problem
mdr
even
pdr
phenotyp
associ
carbapenem
resist
enterobacteriacea
strain
usual
harbor
mechan
resist
aminoglycosid
quinolon
well
nevertheless
strain
often
exhibit
lowlevel
resist
carbapenem
mic
remain
suscept
rang
render
therapeut
role
carbapenem
question
armamentarium
pdr
gramneg
microorgan
almost
exhaust
option
left
colistin
antibiot
introduc
tigecyclin
modifi
minocyclin
monotherapi
combin
therapi
colistin
often
use
recent
emerg
colistinresist
strain
klebsiella
pneumonia
limit
therapeut
option
even
accumul
evid
vivo
activ
tigecyclin
mdr
enterobacteriacea
low
level
drug
achiev
blood
indic
necess
higher
dose
case
bacteraemia
mbl
kpc
produc
enterobacteria
vitro
suscept
fosfomycin
clinic
experi
set
seriou
infect
carbapenemaseproduc
bacteria
still
limit
final
combin
regimen
often
use
empir
clinic
practic
although
scientif
evid
advantag
combin
usual
scarc
except
carbapenemsuscept
k
pneumonia
clinic
data
suggest
combin
meropenem
gentamicin
could
activ
vivo
case
meropenem
mic
mgml
emerg
carbapenemaseproduc
enterobacteriacea
highlight
end
antibiot
concentr
effort
need
preserv
wise
use
option
avail
meantim
intensifi
infect
control
measur
may
protect
hospit
patient
difficult
treat
pathogen
biomark
diagnosi
sepsi
provid
ad
valu
ambigu
clinic
sign
limit
current
microbi
techniqu
diagnosi
bacteri
infect
grade
sever
well
known
use
biomark
provid
novel
complementari
approach
diagnos
infect
estim
treatment
respons
outcom
patient
plethora
protein
specul
promis
marker
observ
studi
includ
creactiv
protein
variou
interleukin
chemokin
procalctionin
amongh
other
unfortun
infect
includ
sepsi
true
gold
standard
diagnosi
exist
thu
true
ad
valu
biomark
clinic
use
assess
intervent
studi
endpoint
safeti
antibiot
use
hospit
set
shown
procalcitonin
pct
multipl
random
control
interenvet
studi
sever
independ
group
similar
outcom
antibiot
exposur
could
reduc
prognost
assess
biomark
eg
adrenomedullin
demonstr
high
predict
potenti
estim
risk
mortal
short
long
term
advers
outcom
critic
apprais
advantag
limit
biomark
differ
clinic
situat
mandatori
discuss
current
data
use
pct
biomark
diagnosi
treatment
guidanc
prognost
assess
bacteri
infect
potenti
role
overal
assess
patient
sepsi
respiratori
tract
infect
import
precursor
c
amsterdam
nl
molecular
techniqu
gain
interest
rapid
diagnosi
sever
bacteri
infect
dnahybridis
probe
pcrbase
detect
use
rapid
identif
bacteria
eccmid
oral
present
first
signal
growth
convent
blood
cultur
pcrassay
also
use
direct
detect
pathogen
blood
pcr
aim
specif
pathogen
broadrang
case
pcr
follow
sequenc
pcr
product
identif
pcr
also
use
quantif
amount
bacteri
dna
blood
sever
studi
point
valu
bacteri
dna
load
bdl
blood
marker
sever
infect
shown
pneumococci
meningococci
particular
anecdot
evid
bdl
also
correl
sever
infect
staphylococc
infect
interpret
result
pcr
appli
directli
blood
sampl
need
studi
howev
sever
aspect
kinet
presenc
bacteri
dna
blood
infect
still
unknown
particular
must
awar
difficult
defin
best
gold
standard
bacteraemia
pcr
detect
dna
rather
live
pathogen
alway
risk
contamin
littl
known
yet
background
bacteri
dna
blood
sepsi
associ
mortal
rate
rang
repres
second
lead
caus
death
noncoronari
intens
care
unit
earli
diagnosi
sepsi
follow
prompt
appropri
treatment
improv
prognosi
septic
patient
suggest
nucleicacidbas
technolog
pcr
sensit
also
shorten
time
result
compar
convent
blood
cultur
techniqu
date
howev
littl
known
kinet
clinic
therapeut
relev
bacteri
dna
present
blood
patient
sepsi
time
cours
invas
blood
stream
infect
recent
introduct
standard
new
pcrbase
diagnost
assay
includ
test
provid
exact
quantit
measur
dna
therefor
may
open
window
opportun
better
understand
kinet
clinic
signific
microbi
dna
circul
blood
patient
blood
stream
infect
fact
potenti
influenc
bacteri
dna
sever
outcom
blood
stream
infect
underlin
find
recent
clinic
laboratori
studi
suggest
procalcitonin
plasma
level
sofa
score
significantli
higher
length
icu
hospit
stay
longer
surviv
clearli
decreas
subgroup
septic
patient
reveal
posit
find
pcr
test
blood
cultur
whether
better
insight
clinic
signific
dnaemia
inde
contribut
rapid
initi
bettertailor
therapi
improv
manag
septic
patient
conjunct
laboratori
marker
howev
await
evalu
laboratori
studi
intervent
clinic
trial
present
lectur
summaris
known
recent
studi
diagnost
clinic
signific
dnaemia
patient
sepsi
fever
common
symptom
critic
ill
patient
often
set
play
seri
investig
health
care
provid
establish
etiolog
recent
practic
guidelin
evalu
fever
icu
patient
recogn
kneejerk
respons
syndrom
absenc
care
clinic
evalu
lead
increas
cost
morbid
patient
addit
mani
diagnost
studi
uninform
nevertheless
noninfecti
caus
fever
often
diagnos
exclus
balanc
expens
invas
investig
old
fashion
clinic
acumen
need
appli
evalu
fever
icu
session
common
noninfecti
etiolog
fever
discuss
illustr
case
exampl
eg
gout
drug
fever
vascul
etc
addit
role
molecular
test
use
assist
determin
infecti
etiolog
fever
pcr
method
biomark
procalcitonin
review
joint
diseas
may
present
acut
chronic
time
monarticular
polyarticular
arthriti
aetiolog
agent
identifi
monarticular
infect
may
also
caus
polyarticular
infect
similarli
polyarticular
non
infecti
arthriti
may
appear
monarticular
mani
clinic
situat
extraarticular
manifest
may
differenti
infecti
non
infecti
arthriti
recent
develop
new
technolog
cultur
molecular
biolog
permit
recognis
viru
bacteria
joint
degen
inflammatori
cours
infecti
arthriti
reactiv
arthriti
rea
conceptu
ground
somewher
septic
arthriti
autoimmun
diseas
rheumatoid
arthriti
fact
arthriti
whippl
sapho
etc
recognis
infecti
arthriti
may
respond
antibiot
treatment
prompt
treat
number
patient
arthriti
unknown
aetiolog
antimicrobi
form
practic
point
view
answer
question
arthriti
real
infect
may
treat
cure
infect
three
aetiolog
involv
patient
acut
monarticular
arthriti
mechan
infect
microcrystallin
inflammatori
arthriti
may
also
present
monarticular
arthriti
besid
differ
non
infecti
diseas
produc
acut
arthriti
pseudosept
arthriti
tool
diagnosi
arthriti
limit
matter
fact
rheumatolog
pattern
diseas
particularli
import
joint
involv
sequenc
accompani
symptom
even
durat
diseas
definit
laboratori
marker
except
crystal
cultur
synovi
fluid
biochem
cytolog
valu
synovi
fluid
permit
classifi
arthriti
mechan
inflammatori
septic
particular
patient
margin
valu
critic
review
cytolog
synovi
fluid
evid
mainli
anecdot
report
specif
sensit
reliabl
topic
mani
medic
histori
epidemiolog
investig
clinic
examin
main
stone
diagnosi
detail
histori
physic
examin
may
rais
possibl
initi
unsuspect
system
local
non
infecti
diseas
hypothesi
infecti
origin
autoimmun
diseas
receiv
great
attent
recent
year
microbi
agent
virus
induc
autoimmun
diseas
varieti
mechan
exampl
protein
certain
infecti
agent
act
polyclon
activ
uniqu
lymphocyt
subset
virus
preferenti
infectdestroy
particular
cell
subset
lead
imbal
immun
respons
instanc
infecti
agent
upregul
cytokin
therebi
increas
select
express
molecul
major
histocompat
complex
mhc
glycoprotein
well
activ
costimulatori
molecul
sever
microbi
agent
found
encod
superantigen
select
activ
subset
cell
microb
also
direct
releas
cytokin
chemokin
act
growth
differenti
chemotact
factor
differ
th
popul
regul
express
mhc
class
class
ii
molecul
hand
healthi
immun
system
toler
molecul
bodi
compos
howev
one
find
among
major
antigen
recogn
wide
varieti
bacteri
viral
parasit
diseas
mani
belong
conserv
protein
famili
share
extens
sequenc
ident
conform
fit
host
molecul
name
molecular
mimicri
antigen
similar
either
molecul
linear
aminoacid
sequenc
conform
structur
antigen
infecti
agent
host
tissu
might
trigger
immun
respons
share
determin
result
toler
autoantigen
break
pathogenspecif
immun
respons
gener
crossreact
host
structur
caus
tissu
damag
diseas
present
case
syndrom
system
lupu
erythematosu
antiphospholipid
syndrom
among
other
review
clear
exampl
autoimmun
diseas
infecti
origin
postul
nasopharyng
colonis
pneumococci
frequent
contrast
pneumococc
pneumonia
invas
pneumococc
diseas
compar
infrequ
event
reflect
success
innat
adapt
host
respons
pneumococci
presenc
varieti
virul
factor
includ
polysaccharid
capsul
pneumolysin
challeng
host
respons
epitheli
cell
sens
microbi
product
releas
cytokin
respons
pneumococci
lower
respiratori
tract
solubl
factor
includ
complement
factor
activ
classic
altern
pathway
play
import
contribut
host
defenc
lung
alveolar
macrophag
play
critic
role
resid
phagocyt
lung
clear
bacteria
lung
orchestr
inflammatori
respons
resid
defenc
becom
compromis
inflammatori
respons
includ
recruit
neutrophil
becom
essenti
microbi
control
come
potenti
cost
compromis
lung
homeostasi
regul
process
also
requir
macrophag
compet
ensur
limit
inflammatori
respons
result
bacteri
clearanc
without
lung
injuri
evolut
pulmonari
infect
number
critic
transit
point
occur
specif
molecul
host
respons
critic
determin
infect
evolv
outcom
infect
infecti
inoculum
virul
pathogen
host
suscept
determin
posit
transit
rel
role
key
host
defenc
strategi
increas
recognit
role
tcell
bcell
dendrit
cell
pulmonari
respons
pneumococci
integr
variou
host
respons
pneumococci
case
repres
paradigm
provid
templat
success
host
respons
pathogen
pulmonari
bacteria
c
muzzi
covacci
r
rappuoli
v
masignani
barocchi
siena
pneumonia
part
normal
upper
respiratori
tract
flora
becom
pathogen
caus
varieti
diseas
rang
otiti
media
sinus
pneumonia
septicemia
mening
due
intim
relationship
human
host
pneumonia
evolv
seri
strategi
vari
genet
repertoir
evad
host
immun
respons
use
abil
recombin
dna
acquir
environ
pneumonia
strain
abl
renew
dispens
genom
ie
region
genom
share
isol
dispens
gene
frequent
acquir
lost
caus
loss
correl
phylogenet
histori
strain
presenc
gene
encod
protein
antigen
properti
consequ
organ
access
genet
repertoir
pangenom
larger
genom
compon
strain
speci
level
pangenom
pneumonia
grow
number
sequenc
strain
increas
due
influx
genet
materi
close
relat
speci
mode
growth
posit
pneumococc
speci
edg
open
close
pangenom
second
strategi
antigen
variat
shown
evolut
pili
long
filament
appendag
involv
adhes
host
cell
pili
encod
rlra
islet
kb
genom
region
consist
rlra
transcript
regul
rrga
rrgb
rrgc
code
lpxtg
protein
form
structur
pilu
srtb
srtc
srtd
code
sortas
enzym
catalyz
pilu
polymer
reaction
due
exposur
host
immun
respons
rrga
rrgb
posit
select
caus
increas
rate
fixat
new
allel
exist
three
distinct
clade
correl
mlst
design
strain
instead
rrgc
srtb
srtc
srtd
gene
code
protein
directli
expos
host
immun
system
posit
select
region
contain
gene
evid
homolog
recombin
major
recombin
hotspot
identifi
due
homogen
effect
recombin
gene
differ
major
structur
compon
pilu
well
conserv
sequenc
level
addit
piliat
strain
pneumococcu
associ
multidrug
resist
casset
may
provid
pneumonia
ad
fit
streptococcu
pneumonia
worldwid
lead
caus
morbid
mortal
due
respiratori
invas
diseas
estim
annual
least
one
million
children
year
age
die
infect
caus
pathogen
differ
capsular
serotyp
make
difficult
design
prevent
strategi
univers
pneumococc
coverag
polysaccharid
vaccin
market
effect
invas
pneumococc
bloodstream
infect
adult
unfortun
vaccin
prove
low
immunogen
children
due
tcell
independ
type
immuneprotect
new
conjug
vaccin
licens
usa
protect
well
invas
pneumococc
diseas
ipd
caus
vaccin
serotyp
also
infant
young
children
howev
within
year
follow
implement
addit
seriou
drop
vaccin
serotyp
diseas
signific
increas
ipd
caus
nonvaccin
serotyp
observ
impact
call
replac
diseas
total
incid
ipd
seem
vari
popul
countri
recent
two
extend
pneumococc
conjug
vaccin
approv
use
children
adult
cover
current
emerg
serotyp
present
follow
topic
address
like
caus
replac
diseas
vaccin
pressur
unmask
nonvaccin
serotyp
secular
trend
combin
expect
new
extend
conjug
vaccin
solv
issu
replac
diseas
expect
addit
shift
within
ipd
caus
serotyp
also
shift
diseas
caus
respiratori
bacteria
potenti
new
vaccin
candid
expect
vaccin
respect
impact
pneumococc
nonpneumococc
diseas
ventilatorassoci
tracheobronch
vat
intermedi
process
colon
lower
respiratori
tract
ventilatorassoci
pneumonia
vap
postmortem
studi
show
continuum
eccmid
oral
present
bronchiti
pneumonia
mechan
ventil
icu
patient
progress
colon
vat
case
vap
depend
quantiti
virul
bacteri
pathogen
host
lung
defens
vat
common
mechan
ventil
patient
incid
rang
icu
patient
definit
vat
matter
debat
group
defin
vat
use
follow
criteria
fever
recogniz
caus
purul
sputum
product
posit
cultur
respiratori
specimen
signific
threshold
radiograph
sign
new
pneumonia
portabl
chest
radiograph
inaccur
diagnos
new
infiltr
mechan
ventil
patient
therefor
differenti
vat
vap
could
difficult
task
icu
patient
vat
frequent
caus
gramneg
bacilli
especi
pseudomona
aeruginosa
although
sever
studi
investig
risk
factor
vap
evalu
risk
factor
vat
howev
risk
factor
infect
appear
similar
age
year
copd
prior
antimicrobi
treatment
surgeri
identifi
risk
factor
vat
tracheobronch
character
lower
respiratori
tract
inflamm
increas
sputum
product
factor
may
gener
wean
difficulti
result
longer
durat
mechan
ventil
larg
cohort
mechan
ventil
patient
vat
significantli
associ
longer
durat
mechan
ventil
icu
stay
benefici
effect
antimicrobi
therapi
recent
report
vat
patient
random
blind
placebocontrol
trial
aerosol
antibiot
significantli
reduc
incid
subsequ
vap
aerosol
antibiot
increas
wean
mechan
ventil
reduc
usag
system
antibiot
antibiot
resist
impact
system
antibiot
outcom
vat
patient
evalu
random
unblind
control
studi
antibiot
treatment
increas
mechan
ventil
free
day
reduc
incid
subsequ
vap
icumort
futur
studi
confirm
promis
result
determin
best
durat
antimicrobi
therapi
vat
patient
c
maastricht
nl
cytomegaloviru
cmv
human
herp
simplex
viru
hsv
belong
famili
herpesvirida
cmv
hsv
highli
preval
ubiquit
distribut
immunocompet
adult
host
cmv
hsv
infect
usual
benign
cours
case
herpesvirus
initi
infect
follow
lifelong
latent
infect
reactiv
occur
immunocompet
individu
asymptomat
viral
shed
may
detect
respiratori
materi
saliva
sputum
case
hsv
cmv
also
urin
case
cmv
viral
shed
patient
without
activ
viral
diseas
make
difficult
diagnos
activ
diseas
patient
especi
sinc
symptom
cmv
hsv
infect
exclud
typic
skin
lesion
often
nonspecif
immunocompromis
patient
cmv
lead
sever
diseas
vari
retin
pneumon
gener
cmv
diseas
occasion
hsv
may
caus
pneumonia
result
immunosuppress
high
mortal
howev
critic
ill
patient
admit
intens
care
unit
icu
consid
immunocompet
studi
perform
icu
patient
shown
patient
risk
sever
infect
cmv
hsv
case
cmv
result
previous
conduct
studi
point
toward
reactiv
latenc
like
explan
rather
primari
infect
icu
patient
recent
studi
suggest
activ
cmv
infect
quit
common
icu
patient
preval
depend
subgroup
patient
studi
furthermor
associ
presenc
cmv
infect
increas
mortal
critic
ill
patient
found
recent
year
interest
hsv
caus
microorgan
icu
patient
increas
especi
caus
pulmonari
infect
recent
report
detect
respiratori
sampl
icu
patient
consid
primarili
immunocompromis
studi
signific
advers
effect
shed
respiratori
tract
clinic
outcom
establish
two
studi
show
associ
high
load
hsv
present
respiratori
tract
increas
mortal
moment
clear
whether
associ
cmv
hsv
increas
mortal
due
microorgan
indic
deterior
physic
condit
patient
lead
reactiv
viru
concept
clinic
sepsi
cultur
neg
septic
patient
p
lausann
ch
despit
attempt
prevent
nosocomi
infect
ni
may
complic
stay
one
third
patient
requir
icu
manag
develop
sepsi
sever
consid
potenti
ni
prompt
initi
broadspectrum
antibiot
sourc
control
key
factor
favor
outcom
major
devicerel
systemat
workshop
perform
identifi
document
sourc
infect
may
allow
specif
measur
abscess
drainag
cathet
remov
guidelin
nowaday
also
includ
recommend
systemat
period
revalu
evolut
order
adapt
antibiot
therapeut
measur
absenc
posit
cultur
combin
clinic
evolut
biolog
paramet
may
contribut
safe
deescal
strategi
million
year
armsrac
shape
evolut
speci
across
planet
also
insid
human
bodi
innat
immun
system
constantli
evolv
differ
strategi
detect
destroy
intrus
microb
microb
evolv
herewith
strategi
microb
develop
avoid
circumv
immun
recognit
studi
evolut
model
organ
escherichia
coli
select
pressur
bacteri
kill
cell
macrophag
cell
line
raw
form
import
compon
innat
immun
system
approxim
gener
bacteri
line
evolv
presenc
macrophag
show
remark
polymorph
occur
control
rel
abund
new
morph
fluctuat
stochast
time
exhibit
mixtur
local
peak
short
period
appar
stabl
frequenc
distinct
genotyp
mark
morpholog
differ
clearli
seen
e
coli
form
coloni
fac
measur
furthermor
first
observ
morph
persist
better
insid
macrophag
slow
growth
rate
defici
metabol
characterist
scv
small
coloni
variant
sampl
patient
variou
recurr
persist
infect
morph
becam
resist
engulf
possibl
kill
phagocyt
show
mucoid
phenotyp
investig
longterm
consequ
biotic
interact
clearli
emerg
field
research
implic
appli
biomedicin
furthermor
abl
gener
predict
concern
natur
adapt
microorgan
multipl
infect
immun
system
dehn
j
vila
r
read
sheffield
uk
barcelona
es
object
previou
studi
suggest
fluoroquinolon
resist
may
associ
attenu
virul
may
reason
low
level
fluoroquinolon
resist
compar
nalidix
acid
resist
salmonella
clinic
isol
compar
intracellular
surviv
wildtyp
ciprofloxacin
mic
ug
fluoroquinoloneresist
ciprofloxacin
mic
ug
revert
ciprofloxacin
mic
ug
typhimurium
murin
macrophag
fluoroquinoloneresist
typhimurium
obtain
vitro
serial
passag
wildtyp
strain
increas
concentr
ciprofloxacin
wherea
revert
strain
obtain
passag
fluoroquinoloneresist
strain
antibioticfre
media
macrophag
seed
cell
per
well
left
adher
hour
control
well
fix
paraformaldehyd
prior
infect
well
block
bsa
minut
bacteri
cultur
grown
log
phase
dilut
infect
macrophag
moi
gentamicin
protect
assay
perform
viabl
count
perform
hour
result
fluoroquinoloneresist
typhimurium
show
significantli
decreas
overal
surviv
comparison
wildtyp
median
area
curv
auc
versu
statist
signific
level
experi
log
differ
bacteri
concentr
cfu
wildtyp
resist
strain
timepoint
signific
differ
wildtyp
revert
strain
revert
fluoroquinoloneresist
strain
determin
whether
differ
intracellular
replic
data
analys
percentag
bacteri
concentr
minut
infect
statist
signific
differ
group
p
conclus
fluoroquinoloneresist
typhimurium
show
decreas
surviv
murin
macrophag
work
need
identifi
gene
respons
chang
sinc
mutant
isogen
eccmid
oral
present
bind
activ
plasminogen
fusobacterium
necrophorum
p
n
friberg
h
jarva
p
mattila
r
soliymani
baumann
helsinki
fi
object
mani
bacteria
plasminogen
plg
receptor
plgr
surfac
bind
plgr
enhanc
activ
bound
plg
activ
enzym
plasmin
lead
protect
surfaceassoci
plasmin
physiolog
plasmin
inhibitor
surfaceassoci
plasmin
thought
play
pathogenet
role
variou
infect
work
studi
plg
bind
activ
fusobacterium
necrophorum
fnec
import
gramneg
rodshap
anaerob
caus
lemierr
syndrom
character
sepsi
intern
jugular
vein
thrombosi
preced
oropharyng
infect
method
plg
bind
monitor
incub
bacteria
isol
clinic
sampl
plg
alon
variou
combin
lysin
analog
epsilonaminocapro
acid
eaca
tissuetyp
plasminogen
activ
tpa
physiolog
plasmin
inhibitor
follow
count
bound
radioact
analyz
bound
plg
sdspage
autoradiographi
plg
activ
record
follow
breakdown
chromogen
substrat
variou
reagent
combin
tent
fusobacteri
plgr
identifi
mean
ligand
blot
bacteri
outer
membran
protein
plg
subsequ
malditof
analysi
result
fnec
n
bound
significantli
better
iodin
plg
f
nucleatum
n
bind
inhibit
eaca
lead
enhanc
activ
tpa
form
plasmin
protect
inhibit
addit
sdspage
analysi
bound
plasmin
reveal
trim
form
gluplasmin
slightli
shorter
lysform
enzym
ligand
blottingmalditof
analys
reveal
acylcoa
dehydrogenas
predomin
plg
binder
among
fusobacteri
outer
membran
protein
present
result
show
fnec
much
stronger
capac
bind
plg
f
nucleatum
inhibit
bind
eaca
indic
lysin
bind
site
ntermin
portion
plg
involv
bind
inabl
inhibit
form
plasmin
activ
emphas
receptor
associ
plasmin
trim
surfaceassoci
gluplasmin
lysform
speak
increas
affin
plasmin
plgr
acylcoa
dehydrogenas
strong
tent
plgr
fnec
data
indic
format
surfac
associ
plasmin
fnec
may
play
import
role
tissu
invas
escap
thrombi
g
mm
joainig
c
el
zechner
graz
object
klebsiella
oxytoca
shown
caus
agent
antibiot
associ
hemorrhag
coliti
aahc
diseas
occur
medic
treatment
penicillin
result
sudden
onset
bloodi
diarrhoea
abdomin
cramp
patholog
featur
mucos
haemorrhag
mucos
oedema
affect
ascend
colon
cecum
histolog
featur
aahc
resembl
toxininduc
coliti
cytotox
substanc
found
condit
cellfre
medium
bacteri
cultur
aim
identifi
gene
involv
cytotoxin
product
secret
identif
cytotox
relat
gene
allow
biochem
descript
toxin
provid
insight
effect
host
cell
human
epitheli
cell
line
use
measur
cytotox
klebsiella
product
qualit
quantit
via
mtt
viabil
assay
random
transposon
mutagenesi
creat
librari
randomli
insert
knock
mutant
aahc
patient
isol
k
oxytoca
mutant
librari
screen
loss
cytotox
transposon
insert
site
toxin
neg
mutant
identifi
isol
adjac
chromosom
dna
via
plasposon
rescu
protocol
follow
dna
sequenc
final
specif
delet
mutant
identifi
gene
gener
complement
cytotoxin
neg
phenotyp
perform
structur
regul
cytotoxin
product
gene
cytotoxin
chemic
natur
investig
cytotoxin
posit
neg
k
oxytoca
strain
screen
furthermor
distribut
gene
result
far
screen
mutant
librari
reveal
two
toxin
neg
mutant
insert
site
cluster
region
indic
operon
three
function
relat
put
gene
could
identifi
nonribosom
peptid
synthas
dahp
synthas
xaa
prolin
amino
peptidas
gene
involv
nonribosom
peptid
biosynthesi
conserv
klebsiella
speci
conclus
cluster
mutat
lead
cytotoxin
neg
phenotyp
suggest
nonribosom
biosynthesi
pathway
essenti
cytotoxin
product
substanc
famili
known
synthes
pathway
organ
includ
numer
fungal
bacteri
effector
substanc
includ
antibiot
cytostat
siderophor
c
silvacosta
j
melocristino
ramirez
lisbon
pt
object
chromosom
gene
speb
spef
encod
true
exotoxin
speb
cystein
proteas
spef
mitogen
factor
commonli
includ
exotoxin
gene
profil
group
streptococci
ga
implic
virul
aim
present
work
confirm
presenc
gene
ga
isol
characteris
detail
put
genom
delet
gene
spea
speb
spec
spef
speh
ssa
pcrscreen
total
ga
isol
invas
infect
pharyng
pcrneg
result
speb
spef
confirm
southern
blot
hybrid
probe
specif
gene
longrang
pcr
primer
specif
region
flank
put
delet
perform
exact
delet
breakpoint
determin
sequenc
absenc
speb
detect
four
isol
one
also
isol
neg
spef
latter
strain
isol
blood
sequenc
confirm
delet
bp
comparison
publish
genom
sequenc
strain
nucleotid
genbank
spebneg
isol
belong
emm
type
isol
pharyng
case
presenc
speb
spef
gene
characterist
ga
recov
human
infect
still
four
isol
spebneg
one
spefneg
isol
appar
highli
virul
spite
bp
delet
encompass
sever
gene
encod
protein
recogn
import
virul
speb
spef
transcript
regul
rgg
glycerol
dehydrogenas
well
four
orf
unidentifi
function
lipocalin
detriment
murin
pneumococc
pneumonia
j
sharif
b
doning
mesteri
k
stich
knapp
vienna
object
lipocalin
antibacteri
protein
known
interfer
bacteri
siderophoredepend
iron
acquisit
thu
mice
highli
suscept
infect
siderophoredepend
pathogen
e
coli
mycobacteria
although
siderophor
detect
streptococcu
pneumonia
infect
bacterium
induc
tremend
elev
level
biolog
role
find
remain
elus
therefor
attempt
investig
role
pneumococc
pneumonia
ageand
sexmatch
mice
inocul
intranas
streptococcu
pneumonia
sacrif
hour
infect
monitor
surviv
lung
homogen
plate
agar
plate
bacteri
count
cytokin
detect
embed
paraffin
histolog
analysi
result
observ
significantli
kc
bronchoalveolar
lavag
mice
hour
infect
result
significantli
increas
neutrophil
influx
hour
lead
improv
bacteri
clearanc
hour
consist
observ
found
decreas
cytokin
level
reduc
lung
inflamm
mice
later
timepoint
infect
final
mice
display
signific
surviv
advantag
wild
type
anim
conclus
detriment
murin
pneumococc
pneumonia
postul
lipocalin
prevent
earli
induct
inflamm
upon
pneumonia
infect
thu
impair
clearanc
bacteria
surviv
hofer
grandgirard
trachsel
sl
bern
ch
background
bacteri
mening
bm
lead
learn
deficit
survivor
histomorpholog
correl
deficit
includ
apoptosi
neurogen
cell
hippocampu
brain
structur
involv
learn
object
use
vitro
system
hippocamp
neuron
differenti
identifi
trigger
molecular
mechan
apoptosi
ii
investig
whether
differenti
stage
neurogenesi
determin
vulner
apoptosi
method
stemand
neuron
progenitorcel
isol
postnat
rat
hippocampu
dissoci
cell
driven
neuron
differenti
addit
bdnf
cell
challeng
differ
stimuli
characterist
bm
growth
factor
depriv
gfd
omiss
bdnf
egf
fgf
h
applic
tnfa
h
exposur
live
bacteria
streptococcu
pneumonia
togeth
penicillin
streptomycin
caus
bacteriolysi
h
differenti
stage
document
immunoassay
nestin
stem
cell
doublecortin
immatur
neuron
neuron
neuron
differenti
vitro
document
shift
predomin
stain
pattern
nestin
doublecortin
figur
caspas
depend
independ
apoptosi
immunoassay
activ
annexinv
respect
result
depend
apoptosi
observ
gfd
cell
tnfa
less
bacteria
mix
cell
popul
contrast
apoptosi
identifi
annexinv
stain
induc
bacteria
lesser
extent
gfd
tnfa
vulner
apoptosi
peak
stem
cell
immatur
neuron
specif
suscept
depend
apoptosi
induc
gfd
tnfa
respect
figur
conclus
novel
vitro
system
hippocamp
neuron
differenti
gfd
tnfa
induc
caspas
depend
apoptosi
bacteria
induc
caspas
independ
apoptosi
stem
cell
immatur
neuron
specif
vulner
undergo
apoptosi
paradigm
bm
result
suggest
hippocamp
injuri
bm
includ
apoptosi
stem
cell
compromis
regen
potenti
hippocampu
may
contribut
persist
neurolog
deficit
bm
object
streptococcu
sui
type
import
swine
human
pathogen
respons
septicaemia
mening
demonstr
brain
infect
mice
sui
microglia
express
increas
level
differ
proinflammatori
gene
expand
knowledg
interact
sui
microglia
evalu
signal
pathway
underli
suisinduc
proinflammatori
event
method
mous
microglia
line
infect
virul
wild
type
wt
strain
sui
panel
mutant
alter
capsul
cpsmutant
cell
wall
level
phagocytosi
quantifi
antibiot
protect
assay
cell
supernat
use
measur
proinflammatori
cytokin
elisa
nitric
oxid
griess
reaction
analysi
cell
lysat
evalu
inflammationassoci
intracellular
signal
pathway
carri
western
blot
use
specif
antibodi
ino
ppkc
ptyr
mitogenactiv
protein
kinas
mapk
member
pjnk
perk
specif
inhibitor
mapk
use
confirm
particip
cytokin
product
involv
inflammatori
transcript
factor
nfkb
monitor
emsa
result
phagocytosi
cytokin
studi
show
cp
relev
virul
factor
modul
bacteri
interact
microglia
cp
help
bacteria
resist
phagocytosi
regul
inflammatori
respons
hide
proinflammatori
compon
bacteri
cell
wall
sui
induc
ino
express
product
microglia
cell
infect
cpsmutant
show
stronger
phosphoryl
profil
pkc
tyr
mapk
likewis
pharmacolog
inhibit
mapk
abrog
tnfa
product
infect
cell
final
suisinduc
nfkb
transloc
faster
cell
stimul
cpsmutant
suggest
bacteri
cell
wall
compon
potent
induc
nfkb
conclus
data
help
better
understand
mechan
underli
sui
induct
inflamm
brain
time
would
use
design
effici
antiinflammatori
strategi
mening
asp
limit
specif
clinic
area
hospit
could
consid
hospitalwid
program
asp
work
year
frequent
principl
abx
stewardship
implement
program
abx
streamlin
deescal
intraven
po
switch
present
survey
follow
monitor
strateg
abx
respond
state
physician
could
initi
prescrib
antimicrobi
includ
formulari
frequent
activ
carri
set
spanish
asp
abx
restrict
follow
confer
therapeut
audit
feedback
tafb
ask
antimicrobi
close
monitor
carbapenem
linezolid
fluoroquinolon
major
respond
highli
pleas
task
efficaci
activ
set
thought
tafb
consid
highli
efficaci
automat
remind
antimicrobi
durat
therapi
conclus
minor
survey
hospit
spain
ongo
asp
larg
geograph
variat
observ
asp
implement
last
year
tafb
perceiv
use
intervent
set
asp
carbapenem
linezolid
fluoriquinolon
consid
abx
suitabl
monitor
intervent
polici
amt
base
develop
agre
upon
prophylact
therapeut
antimicrobi
regimen
regular
educ
activ
microbiolog
pharmaceut
monitor
significantli
improv
appropri
antimicrobi
prescript
highrisk
set
also
econom
cost
antimicrobi
acquisit
efficaci
effici
restrict
antibiot
polici
mrsa
intens
care
unit
n
r
aschbach
b
moser
harbarth
p
mian
p
bonnabri
l
pagani
geneva
ch
bolzano
object
determin
efficaci
effici
restrict
antibiot
polici
incid
methicillinresist
staphylococcu
aureu
mrsa
gener
intens
care
unit
icu
tertiari
care
hospit
itali
method
base
updat
microbiolog
report
clinic
pharmacolog
paramet
dedic
antimicrobi
manag
team
pursu
appropri
approach
antimicrobi
prophylaxi
empir
therapi
icu
either
withdraw
ampicillinsulbactam
prophylaxi
target
vancomycin
van
therapi
whenev
indic
use
intervent
timeseri
analysi
first
evalu
efficaci
van
restrict
consumpt
combin
model
transfer
function
model
use
antibiot
final
assess
effici
incid
clinic
isol
mrsa
april
decemb
atcddd
classif
use
refer
normal
per
patientday
pd
result
intervent
model
demonstr
restrict
antibiot
polici
yield
statist
signific
decreas
pd
novemb
six
month
later
van
decreas
pd
five
month
restrict
mrsa
incid
significantli
decreas
case
final
model
explain
incid
mrsa
time
show
convers
increas
pd
antibiot
increas
incid
mrsa
isol
current
level
ie
ceftriaxon
signific
impact
lag
levofloxacin
time
conclus
studi
show
model
antibiot
use
either
drive
appropri
empir
target
antimicrobi
therapi
inform
polici
maker
neg
advers
effect
certain
antibiot
agent
select
mrsa
may
ultim
control
prevent
misus
antimicrobi
restrict
sever
broadspectrum
antimicrobi
might
posit
impact
mrsa
even
casemix
huge
inhomogen
patient
gener
icu
may
neg
affect
overal
fit
model
escherichia
coli
use
populationbas
data
larg
hospit
surround
commun
n
b
huttner
muscionico
j
salomon
p
bonnabri
j
j
schrenzel
harbarth
geneva
ch
alicant
es
object
determin
tempor
relationship
antibiot
use
incid
antibioticresist
escherichia
coli
inpati
outpati
set
swiss
canton
geneva
tempor
effect
resist
commun
isol
outpati
use
ciprofloxacin
immedi
time
lag
month
moxifloxacin
time
lag
month
observ
explain
varianc
time
incid
cefepim
resist
e
coli
surrog
marker
esbl
correl
ciprofloxacin
use
inpati
lag
month
outpati
lag
month
set
use
ceftriaxon
lag
month
piperacillin
tazobactam
lag
month
cefepim
month
hospit
conclus
result
support
effort
reduc
prescript
select
antimicrobi
drug
class
fluoroquinolon
reduct
resist
e
coli
includ
esbl
show
ad
valu
time
seri
analysi
better
understand
interact
commun
hospit
antibiot
prescrib
reduct
ciprofloxacin
use
univers
hospit
correl
increas
suscept
quinolon
blactam
antibiot
gramneg
organ
j
g
millar
e
smyth
r
mcmullan
belfast
uk
object
antibiot
polici
revis
implement
institut
univers
hospit
belfast
juli
purpos
substitut
ceftriaxon
ciprofloxacin
blactam
antibiot
aim
studi
investig
whether
follow
polici
chang
chang
usag
piperacillintazobactam
piptazo
aztreonam
ceftriaxon
ciprofloxacin
meropenem
base
defin
daili
dose
ddd
prescrib
shift
proport
gramneg
organ
suscept
antibiot
signific
relationship
suscept
usag
antibiot
method
first
isol
gramneg
organ
recov
blood
cultur
sputum
urin
hospitalis
adult
januari
august
includ
proport
isol
report
suscept
polici
chang
compar
c
test
ddd
compar
use
independ
ttest
associ
ddd
prescript
suscept
test
use
pearson
correl
linear
regress
result
ciprofloxacin
use
decreas
p
aztreonam
use
increas
p
follow
polici
revis
chang
meropenem
ceftriaxon
piptazo
use
isol
evalu
proport
suscept
ciprofloxacin
p
aztreonam
p
piptazo
p
increas
signific
invers
linear
associ
ciprofloxacin
use
suscept
detect
p
correl
p
furthermor
piptazo
aztreonam
meropenem
suscept
invers
correl
ciprofloxacin
use
univari
piptazo
r
p
aztreonam
r
p
meropenem
r
p
linear
relationship
appar
piptazo
p
aztreonam
p
meropenem
p
surprisingli
signific
posit
linear
associ
aztreonam
use
suscept
r
p
conclus
data
suggest
antibiot
polici
revis
success
reduc
ciprofloxacin
use
correl
increas
ciprofloxacin
suscept
among
gramneg
organ
furthermor
also
associ
increas
suscept
blactam
antibiot
spite
increas
use
aztreonam
therefor
reduc
quinolon
exposur
within
popul
appear
exert
favour
effect
quinolon
blactam
suscept
gramneg
organ
conclus
implement
fluoroquinolon
ban
prove
challeng
reward
reduct
case
cdi
fluoroquinolon
resist
e
coli
intervent
may
use
adjunct
measur
manag
outbreak
infect
due
clostridium
difficil
ribotyp
concern
increas
use
broad
spectrum
agent
meropenem
effort
requir
limit
use
agent
particularli
context
recent
emerg
carbapenemas
produc
enterobacteriacea
lack
new
antigramneg
agent
publish
studi
provid
accur
estim
associ
antibiot
exposur
acquisit
antibioticresist
bacteria
cataldo
g
de
ang
cipriani
r
cauda
e
rome
object
antibiot
stewardship
usual
includ
multifacet
approach
combat
spread
antibiot
resist
bacteria
arb
healthcar
set
numer
paper
demonstr
prior
antimicrobi
drug
exposur
strong
risk
factor
infect
due
arb
howev
associ
antibiot
therapi
acquisit
arb
still
unclear
often
confound
scarc
data
antibiot
usag
object
defin
major
limit
avail
evid
explor
sourc
heterogen
method
two
metaanalys
perform
determin
whether
antibiot
exposur
risk
factor
isol
arb
target
bacteria
methicillinresist
staphylococcu
aureu
mrsa
carbapenemsresist
acinetobact
baumannii
crab
test
calcul
assess
whether
result
vari
might
expect
play
chanc
subgroup
analysi
perform
stratifi
sampl
frame
inclus
definit
case
subject
control
studi
design
geograph
area
studi
presenc
adjust
covari
length
time
antibiot
exposur
detect
signific
heterogen
consid
result
seventyeight
studi
relat
mrsa
studi
crab
consid
elig
inclus
studi
cohort
casecontrol
preval
survey
patient
taken
antibiot
risk
increas
ci
ci
fold
acquir
mrsa
crab
respect
significantli
heterogen
detect
studi
design
definit
control
sampl
frame
inclus
endem
epidem
set
adjust
covari
regress
analysi
reveal
heterogen
link
length
time
antibiot
exposur
detect
isol
select
control
group
sampl
frame
inclus
conclus
analysi
confirm
qualiti
evid
avail
associ
antibiot
therapi
acquisit
antibioticresist
bacteria
poor
specif
guidelin
focus
methodolog
issu
address
epidemiolog
antibioticresist
infect
urgent
need
diverg
intent
use
local
antibiot
guidelin
theori
plan
behaviour
survey
p
b
schreur
w
peeterman
k
de
witt
g
laekeman
leuven
brussel
background
order
improv
antimicrobi
practic
correctli
identifi
antibiot
guidelin
barrier
assess
rel
import
import
factor
theori
plan
behaviour
tpb
permit
assess
use
alreadi
evalu
antibiot
use
accord
theori
intent
drive
guidelin
use
fuell
three
factor
attitud
subject
norm
sn
perceiv
social
pressur
regard
guidelin
perceiv
behaviour
control
pbc
guidelin
use
tbpbase
questionnair
want
studi
guidelin
use
affect
hospit
method
base
earlier
observ
questionnair
construct
modifi
account
habit
strength
pilot
test
survey
distribut
among
physician
major
teach
hospit
result
contact
physician
complet
questionnair
receiv
correct
respons
rate
use
multivari
analysi
habit
strength
b
p
pbc
b
p
signific
determin
overal
intent
moder
effect
respond
posit
staff
member
vs
resid
found
staff
member
intent
influenc
habit
strength
b
p
resid
intent
pbc
b
p
factor
signific
look
specif
issu
educ
antibiot
guidelin
rate
unsatisfactori
conclus
diverg
origin
stipul
differ
approach
improv
staff
member
experienc
high
influenc
previou
routin
habit
prefer
intervent
group
educ
focus
chang
prior
antibiot
practic
caus
remind
resid
intent
guid
mainli
extern
influenc
amount
selfconfid
make
feedback
conveni
guidelin
format
thorough
guidelin
familiar
suitabl
refer
result
potenti
particip
respond
four
nonrespond
withdrew
offici
indic
panel
use
research
n
assay
offer
n
major
dataset
gener
pfge
n
remaind
gener
aflp
n
spa
type
n
seventythre
percent
particip
type
sampl
correctli
pfge
result
obtain
spatyp
amplifi
fragment
length
polymorph
aflp
found
less
discrimin
obtain
pfge
discuss
present
first
eqa
programm
genotyp
mrsa
pfge
implement
particip
laboratori
howev
protocol
prove
suboptim
result
inferior
resolut
higher
lower
fragment
region
suggest
assay
optimis
requir
lack
resolut
evid
close
relat
mrsa
strain
panel
result
gener
use
aflp
spatyp
show
less
discriminatori
power
compar
pfge
particip
report
rang
criteria
determin
genotyp
subtyp
figur
thu
allow
rapid
accur
discrimin
investig
serotyp
conclus
hrm
analysi
new
singlestep
closedtub
screen
method
fast
mutat
detect
therefor
use
discrimin
even
genet
close
relat
sampl
hrm
analysi
potenti
complement
classic
serotyp
salmonella
isol
due
discriminatori
power
simplic
antifung
therapi
microscop
fungu
mous
man
symposium
support
gilead
anim
model
help
predict
host
respons
fungal
infect
antifung
treatment
choos
therapi
basi
efficaci
safeti
clinic
outcom
invas
fungal
infect
involv
complex
interplay
infect
organ
antifung
treatment
host
immun
respons
factor
host
neutropen
statu
well
known
influenc
outcom
may
particular
relev
antifung
treatment
fungistat
rather
fungicid
immun
respons
involv
far
neutrophil
alon
cytokin
chang
may
correl
clinic
respons
clinic
failur
symposium
faculti
show
chang
vitro
may
correl
respons
vivo
anim
model
therefor
predict
respons
human
host
mrsa
molecular
epidemiolog
molecular
screen
symposium
support
roch
molecular
diagnost
differenti
human
epidem
anim
associ
mrsa
strain
lightcycl
melt
curv
analysi
u
regensburg
de
object
number
realtim
pcr
assay
direct
detect
mrsa
clinic
specimen
target
sccmecorfx
junction
aureu
genom
respect
implic
screen
test
perform
admiss
patient
risk
mrsa
infect
assay
rapid
sensit
possibl
select
effici
primer
probe
complic
known
sequenc
divers
among
variou
type
sccmec
cassett
consequ
primer
probe
design
cover
common
sccmec
type
encount
clinic
mrsa
isol
consid
enorm
divers
sccmec
sequenc
ration
primer
select
best
compromis
coverag
mani
sccmec
variant
possibl
loos
analyt
sensit
due
primer
multiplex
problem
therefor
incus
rate
may
differ
among
variou
pcr
assay
concept
method
three
commerci
pcr
test
target
sccmecorfx
junction
evalu
analyt
sensit
timetoresult
perform
cover
animalassoci
mrsa
strain
clonal
complex
next
human
epidem
mrsa
strain
result
except
mrsa
strain
harbor
uncommon
sccmec
element
investig
human
epidem
animalassoci
mrsa
strain
detect
roch
lightcycl
mrsa
advanc
test
latter
strain
present
differ
tmvalu
melt
curv
analysi
dna
sequenc
reveal
singlenucleotid
polymorph
snp
within
aureu
orfx
region
characterist
mrsa
strain
obvious
cover
proprietari
sensor
hybrid
probe
assay
mrsa
strain
cover
lightcycl
mrsa
advanc
test
also
test
posit
bd
geneohm
mrsa
cepheid
xpert
mrsa
test
either
realtim
pcr
test
option
perform
tmanalysi
view
melt
curv
conclus
practic
applic
newli
identifi
snp
present
use
commerci
realtim
pcr
test
direct
detect
simultan
identif
animalassoci
mrsa
strain
investig
mrsa
strain
harbor
least
one
novel
snp
sccmecorfx
junction
repres
characterist
tm
subsequ
melt
curv
analysi
sinc
tmshift
observ
non
mrsa
strain
yet
may
serv
molecular
marker
presenc
mrsa
cc
antibacteri
suscept
test
implic
resist
surveil
treatment
problem
low
level
resist
quinolon
bacteri
resist
quinolon
relat
decreas
permeabl
activ
efflux
drug
modif
target
modif
target
protect
recent
studi
indic
certain
gene
reca
recc
tolc
fi
ruvc
xsea
xseb
also
contribut
intrins
resist
e
coli
quinolon
microbiolog
clinic
aspect
low
level
quinolon
resist
often
studi
enterobacteria
organ
singl
gyra
mutat
caus
resist
nalidix
acid
mic
fluoroquinolon
low
mcgml
still
higher
mic
mcgml
wildtyp
isol
mechan
favour
appear
addit
mutat
gyra
topoisomeraseencod
gene
final
result
high
level
resist
target
protect
qnr
protein
often
encod
plasmid
gene
decreas
permeabl
porin
modif
activ
efflux
chromosom
particularli
rnd
transport
plasmid
qepa
protein
oqxab
origin
also
determin
low
level
quinolon
resist
aac
ibcr
enzym
modifi
quinolon
piperazinyl
substitu
vitro
vivo
data
suggest
addit
lowlevel
mechan
may
also
repres
initi
step
acquisit
increas
resist
low
level
resist
mechan
may
difficult
detect
translat
mic
current
eucast
clsi
breakpoint
interestingli
plasmidmedi
mechan
may
suffici
compromis
activ
nalidix
acid
result
decreas
suscept
lowlevel
fluoroquinolon
resist
absenc
nalidix
acid
resist
contrast
usual
consequ
mutat
topoisomeras
gene
quinolon
efficaci
relat
cmaxcmi
auc
cmi
paramet
small
variat
even
dilut
due
lowlevel
resist
mechan
may
contribut
therapeut
failur
anim
model
clinic
data
suggest
poor
outcom
patient
sever
infect
caus
salmonella
klebsiella
presum
enterobacteria
low
level
fluoroquinolon
resist
reason
would
import
know
actual
mic
quinolon
clinic
isol
obtain
addit
inform
quinolon
resist
mechan
allow
better
knowledg
risk
factor
acquir
low
level
resist
strain
better
definit
actual
therapeut
relev
organ
emerg
methicillinresist
staphylococcu
aureu
mrsa
strain
complic
treatment
aureu
infect
vancomycin
current
cornerston
treatment
bacteraemia
infecti
endocard
ie
due
pathogen
evid
link
vancomycin
minimum
inhibitori
concentr
mic
high
failur
rate
vancomycin
led
suscept
breakpoint
consid
mic
howev
vancomycin
treatment
failur
uncommon
even
mrsa
strain
fulli
suscept
mic
studi
describ
reduct
vancomycin
efficaci
mrsa
strain
high
mic
within
suscept
rang
present
deal
differ
method
determin
vancomycin
mic
discuss
implic
understand
relationship
vancomycin
mic
vancomycin
efficaci
ibcr
gene
found
isol
respect
qnr
mostli
present
klebsiella
pneumonia
aac
ibcr
found
exclus
escherichia
coli
qepa
found
gene
local
plasmid
could
transform
transconjug
acceptor
strain
mic
fluoroquinolon
acceptor
strain
indic
increas
resist
due
plasmidmedi
mechan
howev
highlevel
resist
fluoroquinolon
wildtyp
strain
due
addit
presenc
topoisomeras
mutat
strain
present
esbl
pmqr
ampc
detect
isol
enterobact
spp
proteu
mirabili
carbapenemas
found
isol
e
aerogen
e
coli
k
pneumonia
carbapenemas
subsequ
genotyp
character
imp
vim
oxa
kpc
cmi
sme
type
conclus
emerg
resist
mechan
found
esblproduc
strain
pmqr
frequent
genotyp
assay
implement
phenotyp
test
ampc
carbapenemas
method
avail
date
detect
pmqr
henc
phenotyp
genotyp
method
employ
ration
direct
pharmacolog
treatment
screen
specif
pcr
sequenc
analysi
fingerprint
type
method
use
compar
isol
other
k
pneumonia
isol
found
hospit
result
k
pneumonia
isol
blood
cultur
patient
leukemia
santa
maria
hospit
lisbon
mic
imipenem
aztreonam
extendedspectrum
cephalosporin
mgl
resist
phenotyp
unchang
edta
inhibit
zone
imipenem
aztreonam
extendedspectrum
cephalosporin
increas
boron
acid
k
pneumonia
produc
restrict
blactamas
carbapenemas
gene
part
plasmid
amplif
observ
pcr
detect
transposas
resolvas
put
insert
sequenc
element
locat
upstream
blakpc
gene
suggest
blakpc
gene
k
pneumonia
includ
differ
genet
environ
like
fingerprint
analysi
reveal
genotyp
detect
hospit
previous
also
sequenc
type
detect
other
k
pneumonia
kpcproduc
strain
describ
worldwid
conclus
first
report
k
pneumonia
clinic
isol
portug
find
alert
medic
author
implement
stringent
method
detect
spread
control
emerg
kpc
carbapenemas
characterist
multiresist
bacteria
actual
diffus
centr
region
franc
healthcar
institut
n
van
der
valentindomeli
charbonni
gra
la
ligeon
n
guichard
n
girard
r
quentin
rhc
studi
group
tour
fr
object
epidemiolog
studi
involv
teach
hospit
gener
hospit
local
hospit
privat
clinic
rehabilitationcar
center
psychiatr
clinic
nurs
home
nh
townclin
laboratori
outpati
document
diffus
multiresist
bacteria
mrb
region
million
unhabit
method
day
mrb
isol
diagnost
clinic
sampl
document
strain
central
identif
control
antibiot
suscept
test
perform
standard
procedur
genet
divers
strain
studi
pfge
urin
urin
sampl
superfici
pu
pu
respiratori
tract
respiratori
tract
sampl
deep
pu
blood
one
intraven
devic
mrb
belong
speci
aureu
e
coli
predomin
follow
e
cloaca
p
aeruginosa
k
pneumonia
baumannii
vancomycinresist
e
faecali
e
faecium
recov
divers
highest
healthcar
institut
hci
contrast
aureu
predomin
nh
e
coli
among
outpati
mrsa
strain
nonmultiresist
usual
name
camrsa
esblproduc
e
coli
strain
ctxm
mrsa
esblproduc
e
coli
strain
mostli
resist
fluoroquinolon
respect
genet
divers
distinct
clone
classic
spread
hci
wide
spread
hci
nh
outpati
respons
rare
outbreak
nh
e
cloaca
k
pneumonia
p
mirabili
baumannii
involv
outbreak
hci
associ
lower
genet
divers
conclus
mrd
unfrequ
diffus
larg
especi
recent
mrsa
esblproduc
e
coli
clone
preval
highest
hci
mdr
diffus
hci
especi
nh
suggest
effect
alert
system
detect
emerg
andor
epidem
phenomenon
involv
mdr
survey
hci
nh
townclin
laboratori
object
examin
differ
antibiot
suscept
gram
neg
bacteria
antibiot
consumpt
tertiari
hospit
within
year
oper
method
clinic
sampl
inpati
identif
suscept
test
use
wider
semiautom
system
clsi
breakpoint
antibiot
consumpt
express
defin
daili
dose
ddd
per
patientday
object
metalloblactamas
power
resist
mechan
gener
insensit
virtual
blactam
antibiot
recent
epidem
emerg
resist
mechan
klebsiella
spp
e
coli
enterobact
cloaca
citrobact
freundii
providencia
rettgeri
geograph
distant
area
india
uk
major
caus
concern
project
initi
determin
genet
vehicl
respons
rapid
emerg
dissemin
mbl
enter
organ
method
speci
identif
antibiot
suscept
profil
harbour
enter
isol
collect
chenai
south
india
haryana
north
india
perform
use
phoenix
machin
isol
type
puls
field
gel
electrophoresi
digest
plasmid
visual
ethidium
bromid
stain
follow
pfge
partial
digest
plug
plasmid
carri
identifi
probe
gel
use
label
ac
rep
probe
transconjug
select
follow
mat
macconkey
plate
contain
azid
mgl
meropenem
plasmid
analysi
subset
transconjug
perform
replic
type
pfge
subsequ
probe
ac
plasmid
analysi
perform
use
set
primer
design
amplifi
section
backbon
ac
plasmid
dna
probe
ac
probe
result
isol
north
india
klebsiella
pneumonia
carri
ac
plasmid
size
howev
south
india
isol
variou
enter
speci
gave
numer
differ
puls
field
gel
restrict
type
furthermor
plasmid
found
isol
south
mani
differ
size
rang
size
probe
indic
plasmid
carri
rep
ac
type
test
found
carri
f
plasmid
transconjug
select
strain
except
small
plasmid
north
india
transconjug
gave
plasmid
mostli
size
exampl
found
size
chang
follow
transconjug
includ
increas
decreas
size
pcr
transconjug
parent
indic
differ
ac
plasmid
backbon
conclus
emerg
enter
organ
india
link
mostli
ac
plasmid
type
vari
size
rang
object
e
coli
frequent
caus
bacteraemia
uk
increas
antimicrobi
resist
could
sever
compromis
current
therapeut
approach
object
atyp
mycobacteria
caus
diseas
healthi
immunocompromis
individu
rare
caus
dissemin
infect
nevertheless
infect
immunocompromis
patient
atyp
mycobacteria
describ
result
report
case
man
diffus
larg
bcell
lymphoma
dlbcl
stadium
iii
e
b
stomach
proxim
duodenum
axillari
inguin
cervic
lymph
node
six
cycl
rchop
one
cycl
rdhap
chemotherapi
receiv
via
central
venou
cathet
cvc
develop
leucopenia
anemia
blood
cultur
reveal
mycobacterium
fortuitum
admiss
hospit
sever
day
later
blood
sampl
reveal
leucocytosi
cellslitr
low
hemoglobin
level
gdl
thrombocytosi
plateletslitr
creactiv
protein
level
mgl
patient
fever
blood
cultur
taken
simultan
peripher
via
cvc
reveal
mycobacterium
conceptionens
mycobacterium
fortuitum
group
cvc
remov
routin
cultur
neg
mycobacteria
sustain
bacteraemia
ten
day
underli
immunocompromiss
antibiot
treatment
clarithromycin
mg
twice
daili
amikacin
mgkg
daili
done
two
week
accord
guidelin
american
thorac
societi
at
repeat
blood
cultur
therapi
steril
conclus
literatur
descript
invas
infect
rapidli
grow
mycobacterium
fortuitum
set
underli
immunocompromis
diseas
treat
bloodstream
infect
advoc
durat
two
week
remov
cathet
review
literatur
necess
antibiot
treatment
assess
underli
risk
factor
infect
assess
treatment
given
incid
side
effect
treatment
cure
relaps
rate
method
retrospect
studi
examin
pulmonari
ntm
infect
south
london
hospit
case
identifi
microbiolog
databas
case
note
record
inclus
criteria
cultur
posit
mycobacterium
kansasii
mk
mycobacterium
avium
intracellular
mai
mycobacterium
xenopi
mx
mycobacterium
malmoens
mm
year
old
hiv
neg
meet
at
american
thorac
societi
clinic
criteria
radiolog
report
made
radiologist
statist
analys
made
spss
use
test
mann
whitney
u
appropri
result
patient
identifi
ntm
isol
met
inclus
criteria
male
median
age
year
predomin
predispos
factor
smoke
alcohol
copd
radiolog
cavit
pulmonari
infiltr
common
find
patient
treat
treat
die
predomin
organ
mk
case
mk
infect
cure
rate
relaps
rate
year
follow
period
treatment
cours
differ
british
thorac
societi
bt
guidelin
patient
receiv
tripl
therapi
rifampicin
ethambutol
usual
clarithromycin
ciprofloxacin
month
side
effect
common
occur
treat
infect
statist
signific
predictor
poor
outcom
low
pretreat
weight
absenc
fever
conclus
kansasii
predomin
ntm
organ
london
optim
treatment
regimen
unclear
studi
mani
patient
treat
agent
counterpoint
bt
guidelin
howev
ad
third
agent
treatment
regimen
mk
appear
reduc
relaps
rate
increas
risk
side
effect
object
may
septemb
patient
refer
infecti
diseas
outpati
clinic
skin
lesion
suppur
lymphaden
perman
makeup
eyebrow
present
clinic
microbiolog
characterist
patient
result
outbreak
investig
method
one
patient
least
lymph
node
fine
needl
aspir
wherea
skin
biopsi
eyebrow
perform
case
microscop
examin
mycobacteria
cultur
broadrang
mycobacteri
pcr
rrna
perform
diagnosi
first
case
establish
use
broadrang
mycobacterium
pcr
pcr
posit
haemophilum
special
cultur
perform
notif
public
health
author
investig
start
possibl
contamin
materi
examin
mycobacteria
result
patient
present
inflammatori
lesion
eyebrow
associ
ipsilater
lymphaden
locat
within
parotid
gland
lesion
appear
week
perman
makeup
eyebrow
fine
needl
aspir
skin
biopsi
eyebrow
posit
mycobacteria
case
respect
microscop
examin
show
acidfast
bacilli
case
wherea
broadrang
pcr
posit
haemophilum
case
cultur
posit
patient
day
median
day
microorgan
identifi
haemophilum
patient
treat
variou
combin
ciprofloxacin
clarithromycin
either
rifampin
rifabutin
parotidectomi
local
eyebrow
excis
partial
neck
dissect
perform
case
three
patient
complet
remiss
follow
surgic
intervent
one
patient
partial
remiss
two
month
conserv
treatment
remain
patient
stabl
week
antibiot
therapi
still
ongo
outbreak
investig
show
makeup
procedur
perform
tattoo
artist
pcr
makeup
ink
posit
sampl
haemophilum
cultur
still
neg
week
report
first
haemophilum
outbreak
perman
makeup
due
contamin
makeup
ink
pcr
analysi
mycobacteri
rrna
effect
tool
earli
diagnosi
appropri
select
cultur
method
optim
manag
infect
requir
studi
protect
studi
immun
mice
intraperiton
infect
gb
result
dna
sampl
gb
strain
test
pcr
hybrid
found
carri
cspa
gene
two
portion
scpb
two
portion
cspa
encod
helic
region
cspa
amplifi
clone
result
protein
mm
kda
kda
kda
kda
respect
success
express
e
coli
follow
purif
ni
sepharos
polypeptid
studi
gener
humor
immun
respons
mice
rabbit
antisera
examin
opson
abil
gb
strain
six
differ
serotyp
employ
mous
periton
macrophag
data
demonstr
signific
opson
effect
immun
sera
control
mice
preliminari
immun
polypeptid
studi
develop
gb
infect
result
obviou
gb
clearanc
spleen
mice
immun
comparison
control
group
determin
contrast
antibodi
found
possess
neither
opson
abil
protect
activ
mention
experi
conclus
dna
gb
strain
compris
cspa
gene
high
helix
structur
display
immunogen
protect
properti
allow
propos
vaccin
compon
gb
object
extraintestin
pathogen
e
coli
expec
frequent
caus
agent
sepsi
neonat
mening
urinari
tract
infect
lead
signific
mortal
morbid
human
well
livestock
big
burden
healthcar
provid
fast
rise
antibiot
resist
rate
among
clinic
expec
isol
prevent
vaccin
pathogen
e
coli
greatli
desir
method
base
genom
analysi
data
vivo
transcript
studi
select
target
virul
factor
express
cours
infect
iron
acquisit
system
immunogen
region
well
unknown
three
dimension
structur
protein
analyz
silico
mhci
mhcii
epitop
well
proteasom
cleveag
site
also
taken
account
base
data
two
synthet
modular
vaccin
protein
design
bear
eight
epitop
rich
subfrag
fulli
synthet
gene
construct
optim
regard
sequenc
codon
bia
use
evalu
two
applic
rout
mous
model
first
use
purifi
vaccin
protein
intranas
applic
second
use
novel
salmonella
base
bacteri
antigen
deliveri
system
simpli
administ
oral
transloc
vaccin
directli
cytoplasm
immun
cell
vivo
tcellular
respons
greatli
enhanc
result
specif
immun
respons
evalu
ifng
elispot
flow
cytometri
subclass
sensit
antibodi
elisa
intranas
immun
mice
demonstr
massiv
increas
specif
serum
igg
well
vagin
fluid
iga
antibodi
recombin
vaccin
protein
well
purifi
full
length
virul
factor
expec
expans
vaccin
specif
ifng
secret
tcell
could
proven
immun
rout
challeng
model
periton
signific
reduct
bacteri
load
could
achiev
immun
mice
demonstr
first
success
combin
tcell
vaccin
expec
mous
model
combin
tcell
antibodi
stimul
vaccin
contain
multipl
epitop
effect
expec
mous
evalu
need
elucid
potenti
use
human
sinc
vaccin
strategi
toxoplasmosi
mainli
use
dna
vaccin
purifi
recombin
protein
show
variabl
protect
vaccin
candid
antigen
almost
alway
select
randomli
target
tachyzoit
form
invad
host
cell
abruptli
immedi
emb
protect
parasitophor
vacuol
keep
away
host
immun
respons
current
substanti
evid
gondii
oocyst
contain
sporozoit
caus
water
relat
outbreak
classif
gondii
oocyst
categori
b
bioterror
agent
water
safeti
threat
demand
protect
vaccin
toxoplasmosi
increas
present
studi
aim
gener
first
time
dna
vaccin
contain
sporozoit
specif
surfac
antigen
sporosag
block
sporozoit
releas
oocyst
intestin
increas
efficaci
vaccin
antigen
respons
induc
antiapoptot
bclxl
gene
insert
dual
express
dna
vaccin
method
construct
dual
express
dna
vaccin
sporosag
insert
cmv
promot
antiapoptot
protein
bclxl
insert
frame
egfp
ire
vitro
transfect
cell
perform
show
express
sporosag
bclxl
function
bclxl
demonstr
flow
cytometri
humor
cellular
immun
respons
ifng
analyz
sera
spleen
cell
vaccin
balbc
mice
western
blot
flow
cytometri
use
purifi
recombin
sporosag
protein
figur
western
blot
fluoresc
microscopi
analys
transfect
cell
show
sporosag
bclxl
express
analys
ration
bclxl
express
imped
apoptot
cell
death
analysi
sera
obtain
vaccin
mice
show
antisporosag
antibodi
respons
compar
control
cellular
immun
respons
analys
show
increas
ifng
respons
compar
control
indic
protect
toxoplasmosi
assess
new
dna
vaccin
candid
urinari
tract
infect
j
fallah
hoseini
moghaddam
najafi
n
khoramabadi
mahdavi
tehran
zanjan
ir
object
urinari
tract
infect
uti
one
common
infecti
diseas
major
agent
uti
uropathogen
escherichia
coli
upec
time
affin
attach
vagin
urinari
tract
mucosa
tissu
upec
intracellular
propag
invas
bladder
epitheli
cell
therefor
cellular
immun
respons
import
case
research
genet
construct
induc
cellular
immun
system
design
immun
respons
immun
mice
evalu
materi
method
chromosom
dna
extract
e
coli
posit
type
pili
strain
fimh
gene
amplifi
use
templat
pcr
pcr
product
insert
pbluescript
clone
vector
sequenc
fimh
gene
sub
clone
pvax
eukaryot
express
vector
recombin
vector
sequenc
cell
line
transfect
complex
pvaxfimh
exgen
poli
cation
polym
three
group
balbc
mice
immun
recombin
dna
construct
first
group
inject
intramuscularli
im
two
dose
mg
everi
inject
two
week
purifi
pvaxfimh
second
group
inject
amount
pvax
vector
third
group
inject
pb
neg
control
mice
challeng
one
week
follow
second
inject
uropathogen
escherichia
coli
strain
moreov
lymphocyt
isol
spleen
immun
mice
cultur
cytokin
assay
result
sequenc
e
coli
fimh
gene
research
show
ident
fimh
sequenc
report
genbank
express
fimh
gene
transfect
confirm
rtpcr
result
challeng
show
time
reduct
e
coli
colon
bladder
tissu
first
group
mice
addit
ifng
titer
got
rise
first
group
compress
other
group
discuss
fimh
gene
littl
variat
among
type
pili
posit
strain
less
variat
amino
acid
sequenc
henc
detect
ident
e
coli
fimh
sequenc
other
express
fimh
pvaxfimh
cassett
confirm
rtpcr
consequ
induct
cellular
immun
respons
show
increas
infg
titrat
immun
mice
dna
vaccin
potenti
candid
limit
recurr
urinari
tract
infect
postexposur
treatment
doubl
intramuscular
dose
convent
regimen
aluminiumadjuv
tetanu
toxoid
w
jaijaroensup
p
khawplod
u
thisyakorn
v
sitprija
bangkok
th
hivinfect
patient
low
lymphocyt
poor
nab
respons
convent
preand
postexposur
rabi
vaccin
previou
report
reveal
hivinfect
patient
count
ml
respond
well
convent
intramuscular
im
postexposur
vaccin
multiplesit
intraderm
id
vaccin
conduct
prospect
studi
nab
respons
doubl
im
dose
im
regimen
essen
aluminiumadjuv
tetanu
toxoid
tt
aid
person
fifteen
aid
patient
age
rang
year
without
activ
opportunist
infect
present
possibl
proven
rabi
exposur
enrol
four
patient
sever
exposur
categori
iii
patient
histori
aidsrel
condit
opportunist
infect
count
ml
patient
receiv
antiretrovir
therapi
patient
given
postexposur
rabi
prophylaxi
receiv
doubl
dose
im
regimen
purifi
vero
cell
rabi
vaccin
doubl
im
dose
vaccin
essenim
regimen
one
two
rabi
vaccin
day
dissolv
dose
aluminiumadjuv
tt
blood
sampl
obtain
day
vaccin
rabi
nab
count
determin
patient
vaccin
blood
drawn
determin
hivrna
level
day
vaccin
seriou
advers
reaction
among
patient
treat
death
result
rabi
next
year
report
seven
aid
patient
count
rang
ml
poor
even
undetect
nab
respons
eight
aid
patient
higher
count
ml
good
nab
respons
previou
studi
also
observ
hivrna
level
increas
significantli
rabi
vaccin
conclus
present
cleans
wound
vigor
wound
inject
immunoglobulin
determin
nab
respons
aid
patient
low
cd
lymphocyt
count
postexposur
rabi
vaccin
import
postexposur
measur
offer
aid
moder
sever
rabiesexpos
patient
patient
stratifi
group
accord
count
primari
pcv
administ
group
cellsml
group
cellsml
group
cellsml
group
cellsml
patient
given
diari
record
discomfort
vaccin
statist
analys
perform
stata
statist
softwar
result
hivinfect
patient
vaccin
pcv
studi
period
patient
receiv
two
dose
patient
one
dose
first
dose
vaccin
patient
return
oneweek
diari
record
side
effect
assess
among
hivinfect
patient
patient
report
discomfort
vaccin
includ
inject
site
sore
pain
red
swell
fever
headach
fatigu
cough
rash
rhinorrhea
sneez
insomnia
none
patient
report
sever
advers
event
prompt
medic
attent
factor
found
associ
occurr
side
effect
high
nadir
count
p
vaccin
associ
factor
inject
site
sore
common
side
effect
vaccin
includ
high
nadir
count
p
vaccin
high
hiv
viral
load
vaccin
p
none
patient
receiv
two
dose
pcv
report
aggrav
discomfort
second
dose
vaccin
conclus
conclud
vaccin
pcv
among
hivinfect
patient
gener
safe
high
nadir
count
vaccin
associ
increas
risk
inject
side
reaction
children
mostli
colon
vaccinerel
nonvaccin
strain
improv
overal
antibiot
suscept
introduct
vaccin
psdp
isol
mainli
recruit
among
inappropri
prescript
threaten
sustain
vaccinerel
benefit
combin
vaccineand
antibioticdriven
select
pressur
object
evalu
distribut
pilu
islet
among
streptococcu
pneumonia
recov
invas
infect
vaccin
avail
method
two
piluslik
structur
recent
recogn
pneumococci
implic
virul
suggest
potenti
vaccin
target
howev
piluslik
structur
univers
distribut
among
pneumococc
strain
previous
demonstr
carri
clonal
properti
pneumonia
invas
strain
carri
rlra
islet
furthermor
piliat
strain
express
vaccin
serotyp
similar
find
report
islet
shown
present
conveni
sampl
strain
posit
clonal
complex
associ
serotyp
introduct
conjug
vaccin
result
chang
serotyp
frequenc
also
affect
pili
preval
evalu
effect
determin
presenc
among
collect
invas
isol
recov
children
introduct
result
analyz
term
pilu
islet
associ
antibiot
resist
serotyp
pulsedfield
gel
electrophoret
profil
pfge
multilocu
sequenc
type
result
overal
strain
present
one
pilu
islet
observ
previou
studi
serotyp
distribut
analysi
show
high
correspond
serotyp
presenc
type
pili
wallac
coeffici
w
associ
even
higher
consid
pili
pfge
cluster
w
rlra
islet
identifi
strain
express
serotyp
islet
found
present
pneumococc
strain
identifi
mainli
among
serotyp
conclus
decreas
presenc
rlra
islet
among
invas
pneumococc
strain
observ
avail
chang
associ
decreas
vaccin
serotyp
sinc
major
strain
carri
express
vaccin
serotyp
contrast
islet
preval
due
predomin
serotyp
sinc
strain
carri
pili
present
serotyp
includ
either
current
futur
conjug
vaccin
formul
potenti
use
vaccin
would
offer
limit
addit
benefit
object
survey
incid
demograph
clinic
microbiolog
characterist
clostridium
difficil
infect
cdi
hospit
europ
organis
network
laboratori
capabl
isol
c
difficil
strain
european
countri
novemb
hospit
per
countri
depend
popul
size
test
stool
sampl
patient
age
year
suspect
cdi
develop
diarrhoea
day
hospit
admiss
cdi
defin
posit
enzym
immunoassay
c
difficil
toxin
andor
b
posit
cytotox
test
posit
cultur
toxigen
strain
hospit
collect
detail
clinic
data
first
cdi
case
sent
stool
isol
c
difficil
pcrribotyp
character
toxin
toxin
b
binari
toxin
gene
month
followup
clinic
data
collect
result
cdi
incid
vari
across
hospit
mean
per
patientday
per
hospit
rang
detail
inform
obtain
patient
isol
patient
avail
character
sixtytwo
differ
pcr
ribotyp
found
among
preval
preval
pcr
ribotyp
patient
previous
identifi
risk
profil
elderli
patient
comorbid
recent
antibiot
use
followup
patient
die
death
cdi
play
role
multivari
analysi
age
yr
use
macrolid
infect
pcr
ribotyp
significantli
associ
death
cdi
contribut
ceftazidim
use
recurr
cdi
inclus
significantli
associ
recurr
followup
conclus
paneuropean
hospitalbas
studi
incid
healthcareassoci
cdi
vari
wide
hospit
overal
attribut
mortal
high
domin
pcr
ribotyp
wherea
associ
complic
diseas
cours
data
emphasis
import
multicountri
surveil
inde
pcr
ribotyp
preval
caus
cdi
europ
ac
cdipati
report
cdi
incid
case
per
pd
case
per
admiss
origin
case
healthcareassoci
ha
acquir
report
hcf
communityassoci
ca
unknown
origin
uo
among
cdipati
diagnos
hcf
activ
follow
month
sever
case
die
cdi
rltc
cdipati
report
cdi
incid
case
per
pd
origin
case
ha
acquir
report
hcf
ca
uo
among
cdipati
diagnos
hcf
activ
follow
month
sever
case
die
cdi
last
c
difficil
strain
sent
hcf
nrc
characteris
type
underway
conclus
preliminari
result
survey
confirm
cdi
incid
franc
much
lower
report
european
countri
suggest
cdi
adequ
control
french
hcf
howev
high
proport
ca
case
report
ac
ward
suggest
need
studi
final
result
survey
present
april
recent
studi
conduct
canada
unit
state
sweden
point
clostridium
difficil
spore
present
retail
ground
meat
thu
suggest
meat
could
act
food
sourc
clostridium
difficil
human
infect
object
aim
pilot
studi
estim
occurr
clostridium
difficil
minc
beef
pork
retail
northeastern
itali
crosssect
studi
perform
februarymarch
retail
outlet
randomli
sampl
provinc
northeastern
itali
among
provinc
retail
sampl
size
proport
resid
popul
sampl
retail
one
laboratori
sampl
minc
beef
one
pork
randomli
collect
sampl
microbiolog
process
use
clostridium
difficil
select
medium
cefoxitin
cycloserin
fructos
broth
ad
taurocol
day
incub
broth
cultur
plate
blood
agar
base
hors
blood
red
cell
ad
vv
test
pcr
detect
clostridium
difficil
dna
accord
pender
presenc
toxin
b
broth
cultur
evalu
techlab
cdiff
quik
chek
complet
kit
techlab
posit
control
meat
experiment
infect
clostridium
difficil
spore
carri
simultan
batch
experiment
sampl
total
pork
beef
sampl
analyz
sampl
neg
clostridium
difficil
microbiolog
pcr
analysi
search
toxin
b
gave
neg
result
well
conclus
although
public
health
relev
clostridium
difficil
contamin
food
yet
clarifi
preliminari
result
prompt
consid
ground
beef
pork
repres
risk
factor
human
infect
northeast
itali
find
support
von
abercron
found
low
preval
clostridium
difficil
contamin
ground
meet
sweden
differ
rodriguezpalacio
wees
canada
songer
unit
state
report
respect
preval
clostridium
difficil
contamin
ground
meat
appar
conflict
result
may
due
differ
preval
clostridium
difficil
fat
calf
swine
primari
product
differ
hygien
slaughterhous
retail
outlet
hypothesi
investig
overal
logist
regress
model
length
stay
transfer
anoth
nh
hospit
number
differ
antibiot
number
day
quinolon
antibiot
degre
comorbid
number
day
nitroimidazol
antibiot
identifi
risk
factor
see
figur
reduct
odd
cdi
therapi
interest
find
subgroup
analysi
three
main
strain
associ
length
hospit
stay
transfer
anoth
nh
hospit
associ
antibiot
use
especi
quinolon
ribotyp
associ
cephalosporin
use
ppi
therapi
risk
factor
ribotyp
ribotyp
highest
observ
rate
mortal
morbid
signific
differ
mortal
morbid
detect
differ
ribotyp
discuss
studi
find
differ
mortal
morbid
differ
strain
clostridium
difficil
find
differ
risk
factor
ribotyp
unexpect
associ
therapi
reduct
odd
cdad
observ
studi
limit
diagnosi
clostridium
difficil
associ
diseas
base
toxin
detect
may
sensit
specif
detail
present
multipl
logist
regress
model
ribotyp
object
diagnosi
clostridium
difficil
c
difficil
associ
diarrhoea
usual
base
detect
faecal
toxin
ab
rather
stool
cultur
therefor
studi
correl
incid
c
difficil
antibiot
consumpt
limit
toxic
strain
past
aim
ecolog
studi
analys
associ
unitspecif
antibiot
consumpt
incid
toxigen
nontoxigen
c
difficil
hospitalis
patient
method
unit
specif
antibiot
consumpt
data
incid
c
difficil
unit
year
analys
univers
hospit
basel
switzerland
stool
sampl
test
toxin
ab
simultan
cultur
second
step
posit
cultur
test
toxin
product
order
analys
specif
antibiot
unit
specif
length
stay
antibiot
show
signific
associ
univari
analysi
enter
multipl
linear
regress
model
result
year
total
first
isol
toxin
produc
c
difficil
first
isol
c
difficil
detect
incid
c
difficil
overal
toxin
produc
c
difficil
per
patient
day
respect
correl
figur
highli
signific
analys
p
higher
correl
result
c
difficil
strain
includ
model
r
vs
r
multivari
analysi
explain
varianc
incid
c
difficil
piperacillintazobactam
trimethoprimsulfamethoxazol
aminoglycosid
found
statist
signific
risk
factor
show
first
time
correl
antibiot
consumpt
c
difficil
incid
rate
significantli
improv
detect
limit
toxin
produc
strain
overal
antibiot
pressur
risk
factor
previous
underestim
due
restrict
toxin
produc
strain
result
underlin
import
overal
pressur
antibiot
explain
major
varianc
rather
import
singl
group
antimicrobi
agent
quinolon
therefor
intervent
reduc
overal
antibiot
consumpt
might
success
control
c
difficil
incid
intervent
focus
certain
group
antibiot
figur
correl
unitspecif
antibiot
consumpt
incid
c
difficil
conclus
impair
immun
function
high
comorbid
burden
advanc
age
presenc
infect
seen
risk
factor
hohcfa
cdi
antibiot
therapi
known
play
central
role
pathogenesi
cdi
observ
tigecyclin
exposur
protect
effect
unexpect
addit
research
need
better
understand
differenti
risk
benefit
variou
broad
spectrum
antibiot
among
patient
risk
hohcfa
cdi
multivari
analysi
adjust
age
sex
geograph
region
rel
risk
ci
conclus
ident
mortal
seen
patient
cd
strain
possess
binari
toxin
irrespect
pcr
ribotyp
cd
mortal
patient
cd
b
strain
significantli
lower
among
patient
cd
higher
among
unselect
patient
result
suggest
binari
toxin
either
marker
virul
cd
strain
contribut
directli
virul
strain
furthermor
data
confirm
criteria
use
danish
cd
surveil
programm
ensur
molecular
characteris
genotyp
toxin
profil
pcr
ribotyp
virul
strain
enabl
detect
emerg
hyper
virul
strain
background
suggest
treatment
lower
respiratori
tract
infect
lrti
broad
spectrum
antibiot
newer
fluoroquinolon
particular
contribut
select
clostridium
difficil
c
diff
studi
preval
c
diff
carriag
select
c
diff
develop
c
diff
infect
cdi
patient
pt
hospit
treat
lrti
compar
differ
treatment
regim
method
pt
receiv
antibiot
treatment
lrti
one
univers
medic
center
affili
teach
hospit
prospect
follow
day
care
monitor
develop
diarrhoea
patient
stool
sampl
collect
admiss
day
day
discontinu
antibiot
day
cultur
c
diff
use
select
plate
cultur
isol
character
toxin
product
type
pcr
ribotyp
cdi
defin
presenc
diarrhoea
posit
faec
toxin
test
result
pt
includ
pt
treat
moxifloxacin
blactam
monotherapi
blactammacrolid
combin
therapi
endem
rate
cdi
particip
hospit
pt
year
total
studi
period
c
diff
cultur
n
pt
isol
toxin
posit
admiss
baselin
preval
c
diff
carriag
n
one
patient
mild
cdi
persist
posit
cultur
c
diff
studi
period
overal
acquisit
rate
c
diff
carriag
antibiot
treatment
lrti
popul
n
acquisit
rate
c
diff
carriership
n
moxifloxacin
n
blactam
n
blactammacrolid
treat
pt
p
ns
test
faec
toxin
product
neg
pt
acquir
c
diff
acquir
cdi
relaps
previou
cdi
occur
studi
period
risk
factor
c
diff
carriership
time
intraven
antibiot
treatment
day
ci
hospit
past
month
ci
conclus
set
low
endem
rate
acquisit
rate
c
diff
antibiot
treatment
lrti
lead
cdi
moxifloxacin
associ
increas
acquisit
rate
c
diff
compar
antibiot
class
prescrib
lrti
l
j
mcewen
n
henderson
nathwani
g
phillip
brown
j
coia
dunde
glasgow
uk
object
descript
outbreak
clostridium
difficil
infect
cdi
affect
nine
patient
vascular
surgeri
ward
week
period
caus
high
level
clindamycin
resist
pcr
ribotyp
clindamycin
mic
mgl
method
c
difficil
outbreak
suspect
basi
three
case
within
day
departur
normal
pattern
case
cdi
defin
patient
diarrhoea
posit
c
difficil
toxin
neg
enter
pathogen
cultur
sent
scottish
refer
laboratori
ssscdrl
pcr
ribotyp
antibiot
suscept
test
pcr
detect
ermb
result
ward
bed
side
room
outbreak
involv
patient
two
diagnos
post
discharg
mean
age
patient
year
rang
year
eight
patient
male
signific
underli
medic
disord
receiv
clindamycin
ciprofloxacin
accord
approv
long
stand
antibiot
polici
unit
none
case
sever
complic
c
difficil
nine
case
type
pcr
ribotyp
show
high
level
resist
clindamycin
suggest
cross
transmiss
ward
five
isol
test
pcr
presenc
ermb
gene
amplif
detect
strain
rare
isol
outwith
ward
outbreak
control
success
closur
ward
termin
clean
use
hypochlorit
solut
reinforc
infect
control
precaut
especi
hand
wash
stop
use
ciprofloxacin
clindamycin
introduct
new
antibiot
polici
new
case
c
difficil
day
sinc
last
outbreak
case
diagnos
conclus
report
demonstr
outbreak
cdi
caus
c
difficil
pcr
ribotyp
outbreak
caus
unusu
strain
display
high
level
clindamycin
resist
mediat
ermb
belong
pcr
ribotyp
outbreak
like
associ
use
clindamycin
cross
infect
spore
environ
report
highlight
implement
strict
infect
control
precaut
antimicrobi
stewardship
enhanc
environment
clean
key
compon
manag
outbreak
success
interestingli
number
mrsa
acquisit
also
drop
dramat
intervent
r
palmer
k
woodrow
n
harper
jagadeesan
blackpool
uk
background
clindamycin
cd
wide
report
literatur
associ
high
risk
c
difficil
infect
cdi
highdos
cd
daili
defin
dose
ddd
data
use
varieti
clinic
indic
steadili
increas
last
blackpool
victoria
hospit
larg
district
hospit
clostridium
difficil
infect
contain
programm
ccdcp
introduc
aim
reduc
avoid
cdi
associ
morbid
mortal
cost
increas
qualiti
care
patient
safeti
rate
cdi
trust
declin
sinc
introduct
ccdcp
real
time
monitor
multidisciplinari
audit
multicentr
region
health
protect
agenc
led
nest
casecontrol
studi
cdi
rootcaus
analysi
everi
case
janoct
find
incl
data
use
cd
use
inform
fine
tune
program
azithromycin
new
horizon
symposium
support
teva
azithromycin
treatment
chronic
bacteri
prostat
prostat
inflammatori
condit
prostat
present
urethr
symptom
prostat
symptom
sexual
dysfunct
diagnos
clinic
symptom
sign
microscopi
express
prostat
secret
ep
cultur
ep
segment
urin
sampl
prostat
chronic
symptom
present
least
month
part
sever
scientif
research
project
prospect
investig
prostat
syndrom
outpati
depart
urogenit
infect
sexual
transmit
diseas
dr
fran
mihaljev
univers
hospit
infecti
diseas
zagreb
croatia
sinc
march
still
ongo
examin
patient
year
age
symptom
chronic
prostat
evid
lower
genitourinari
tract
abnorm
azithromycin
fulfil
criteria
treatment
chronic
prostat
sexual
transmit
infect
high
efficaci
common
bacteri
agent
urogenit
sexual
transmit
infect
accept
toxic
toler
simpl
oral
use
excel
penetr
chronic
inflammatori
chang
prostat
capsul
achiev
high
concentr
prostat
tissu
slowli
elimin
week
anti
inflammatori
immunomodulatori
effect
activ
bacteri
biofilm
total
patient
chronic
prostat
caus
chlamydia
trachomati
treat
azithromycin
total
dose
g
week
erad
chlamydia
trachomati
achiev
patient
clinic
cure
statist
signific
differ
three
dosag
regimen
total
patient
chronic
prostatit
caus
ureaplasma
urealyticum
treat
azithromycin
total
dose
g
week
erad
ureaplasma
urealyticum
clinic
cure
conclus
azithromycin
effect
safe
antimicrobi
drug
treatment
chronic
prostat
caus
chlamydia
trachomati
ureaplasma
urealyticum
recommend
total
dose
g
po
week
administ
day
weekli
dose
mg
po
per
day
result
recent
publish
clinic
studi
treatment
chronic
bacteri
prostat
combin
therapi
ciprofloxacin
azithromycin
impress
also
limit
posit
experi
azithromycin
new
horizon
symposium
support
teva
acut
infecti
gastroenterocol
common
diseas
worldwid
case
gastroenterocol
requir
antimicrobi
treatment
consid
selflimit
mild
diseas
short
durat
howev
antibiot
therapi
indic
sever
case
hivposit
immunocompromis
patient
also
receiv
antimicrobi
treatment
case
antibiot
could
decreas
durat
diseas
enabl
faster
recoveri
shorten
carrier
state
azithromycin
prove
effect
treatment
acut
infecti
gastroenterocol
two
studi
involv
us
militari
personnel
thailand
indic
singl
azithromycin
dose
g
regimen
mgday
compar
superior
ciprofloxacin
levofloxacin
empir
treatment
acut
diarrhea
efficaci
azithromycin
treatment
travel
diarrhea
infant
children
also
suggest
campylobact
enterocol
frequent
form
acut
bacteri
diarrhea
affect
human
particularli
children
young
adult
evalu
efficaci
toler
singl
oral
azithromycin
treatment
campylobact
enterocol
children
year
age
administ
earli
cours
diseas
compar
standard
erythromycin
regimen
antibiot
studi
suggest
singl
azithromycin
mgkg
administ
earli
cours
campylobact
enterocol
children
year
age
effect
erad
pathogen
acceler
clinic
cure
attain
clinic
superior
earli
commenc
erythromycin
regimen
respiratori
tract
infect
rti
continu
major
caus
morbid
mortal
worldwid
lower
respiratori
tract
infect
lrti
includ
cap
rank
third
list
lead
caus
death
worldwid
pathogen
pneumonia
h
influenza
catarrhali
atyp
pathogen
still
remain
preval
one
independ
countri
tradit
blactamas
modern
macrolid
respiratori
fluoroqinolon
adult
drug
choic
therapi
rti
antimicrobi
resist
among
pathogen
continu
major
challeng
physician
countri
total
pneumonia
citi
central
northwestern
southern
privolgsk
ural
siberian
fareastern
region
russia
studi
blactam
retain
compar
high
vitro
activ
pneumonia
nonsuscept
penicillin
amoxicillinclavulan
ceftriaxon
cefotaxim
proport
multiresist
pneumonia
exceed
studi
period
ampicillin
resist
haemophilu
influenza
resist
amoxicillinclavulan
resist
azithromycin
wass
found
moraxella
catarrhali
seem
low
epidemiolog
import
russia
isol
rare
case
patient
otiti
media
acut
exacerb
chronic
bronchiti
virtual
strain
blactamas
produc
retain
suscept
blactamblactamas
inhibitor
conclus
three
class
antimicrobi
retain
place
treatment
rti
azithromycin
twenti
year
extens
use
still
one
prescrib
antibiot
treatment
bacteri
respiratori
tract
infect
multidrug
resist
mdr
report
worldwid
clinic
consequ
mdr
still
remain
controversi
suporti
studi
design
evalu
efficaci
azithromycin
therapi
treatment
respiratori
tract
infect
adult
children
compar
result
earli
clinic
trial
suporti
studi
multicent
prospect
noncompar
phase
iv
studi
includ
patient
bacteri
upper
lower
respiratori
tract
infect
three
countri
center
particip
studi
outpati
includ
studi
trial
includ
patient
acut
pharyng
sinus
otiti
media
well
patient
acut
exacerb
chronic
bronchiti
mild
moder
commun
acquir
pneumonia
azithromycin
administ
oral
clinic
effect
assess
third
fourth
visit
dynam
clinic
score
assess
throughout
studi
present
result
effect
safeti
azithromycin
obtain
studi
nontyp
haemophilu
influenza
nthi
common
commens
human
respiratori
tract
mucosa
fastidi
gramneg
coccobacillu
resid
exclus
human
host
date
nthi
infect
accept
larg
opportunist
occur
particularli
case
host
immun
statu
physiolog
barrier
compromis
exampl
acut
exacerb
chronic
obstruct
pulmonari
diseas
adult
otiti
media
om
young
children
howev
increas
evid
despit
absenc
polysaccharid
capsul
nthi
caus
signific
invas
diseas
well
mucos
respiratori
infect
subject
without
predispos
risk
factor
develop
develop
countri
nthi
may
caus
septicaemia
mening
children
preval
least
equal
due
singl
major
streptococcu
pneumonia
serotyp
develop
countri
especi
post
h
influenza
vaccin
era
difficult
estim
current
diseas
burden
although
countri
suggest
increas
number
case
invas
diseas
report
literatur
matern
genitourinari
tract
infect
identifi
sourc
highli
fatal
earli
onset
neonat
nthi
septicaemia
signific
mucos
infect
known
caus
nthi
om
sinus
conjunct
approxim
onethird
bacteri
isol
om
sinus
nthi
era
proportion
increas
frequenc
recoveri
nthi
mucos
isol
demonstr
children
adult
unit
state
furthermor
sever
line
evid
suggest
nthi
may
also
play
import
role
paediatr
commun
acquir
lower
respiratori
infect
especi
children
recurr
persist
bronchiti
pneumonia
studi
warrant
understand
public
health
import
nthi
pathogen
review
suggest
nthi
caus
invas
diseas
underestim
import
invas
diseas
burden
nthi
appear
commonli
respons
mucos
respiratori
infect
previous
recogn
guidelin
treatment
respiratori
tract
infect
rti
may
need
reevalu
consid
increas
import
nontyp
haemophilu
influenza
nthi
report
compar
preval
bacteri
pathogen
acut
otiti
media
acut
bacteri
sinus
children
prior
introduct
conjug
pneumococc
vaccin
show
replac
streptococcu
pneumonia
vaccin
type
nonvaccin
type
also
show
increas
preval
nthi
recent
report
confirm
nthi
associ
recurr
protract
morbid
sign
blactamasedepend
blactam
resist
nthi
replac
nonblactamasedepend
resist
mechan
may
render
use
current
firstlin
treatment
antibiot
amoxyclavulan
acid
secondgener
cephalosporin
ineffect
worldwid
blactamas
product
account
major
h
influenza
ampicillin
resist
mutat
penicillinbind
protein
anoth
blactam
resist
mechan
h
influenza
strain
call
blactamaseneg
ampicillinresist
blnar
blnar
strain
less
suscept
ampicillin
also
amoxyclavulan
secondor
thirdgener
cephalosporin
blnar
strain
rare
increas
minimum
inhibitori
concentr
mic
limit
make
use
aminopenicillin
high
dose
still
warrant
situat
chang
notabl
exampl
blnar
strain
increas
significantli
japan
similarli
european
countri
spain
franc
increas
preval
blnar
also
seen
strain
increas
mic
valu
make
treatment
aminopenicillin
secondor
thirdgener
cephalosporin
ineffect
increas
blnar
strain
might
challeng
current
guidelin
treatment
rti
advoc
use
amoxyclavulan
secondgener
cephalosporin
firstlin
treatment
option
base
observ
effect
possibl
clinic
implic
new
vaccin
explor
order
monitor
impact
hib
vaccin
epidemiolog
invas
haemophilu
influenza
diseas
intern
collabor
eccmid
oral
present
establish
countri
respond
provid
nation
surveil
data
invas
h
countri
incorpor
hib
conjug
vaccin
infant
immun
schedul
routin
serotyp
clinic
h
influenza
isol
total
h
influenza
infect
report
due
hib
nontyp
h
influenza
nthi
found
incid
nthi
almost
twice
hib
versu
per
case
hib
nthi
infect
common
infant
elderli
moreov
incid
nthi
much
higher
hib
first
month
life
versu
per
case
infect
like
occur
first
week
life
suggest
vertic
acquir
infect
overal
howev
median
age
diseas
higher
nthi
infect
hib
year
versu
year
p
nthi
infect
also
associ
higher
case
fatal
ratio
cfr
versu
p
particularli
among
infant
versu
p
higher
proport
nthi
infect
among
women
childbear
age
addit
onethird
report
mening
case
due
nthi
cfr
hib
nthi
mening
similar
euibi
data
versu
england
wale
cfr
much
higher
nthi
mening
versu
reason
unclear
conclus
need
continu
largescal
clinicoepidemiolog
surveil
collect
data
clinic
present
nthi
risk
factor
manag
nthiattribut
death
refer
frequenc
divers
seriou
fungal
infect
increas
sever
immunocompromis
patient
particularli
vulner
infect
mould
yeast
candida
aspergillu
speci
predomin
pathogen
candida
bloodstream
infect
associ
high
morbid
mortal
neutropen
nonneutropen
critic
ill
patient
risk
factor
associ
divers
includ
exposur
broad
spectrum
antimicrobi
agent
mucos
colon
indwel
vascular
cathet
surgeri
cancer
chemotherapi
differ
geograph
epidemiolog
emerg
particular
regard
shift
toward
nonalbican
speci
shift
correl
routin
fluconazol
administr
aspergillu
spp
caus
wide
spectrum
diseas
human
includ
allergi
superfici
infect
invas
diseas
invas
aspergillosi
emerg
lead
caus
morbid
mortal
immunocompromis
patient
import
speci
aspergillu
fumigatu
follow
aspergillu
flavu
contemporan
infect
rare
mold
rise
zygomyzet
trichosporon
fusarium
alternaria
pseudallescheria
dematiac
fungi
recogn
frequent
emerg
organ
multifactori
relat
intens
immunosuppress
prolong
surviv
patient
select
pressur
broad
spectrum
antifung
agent
use
prophylaxi
therapi
among
rare
mould
infect
zygomycet
commonli
encount
appear
associ
use
voriconazol
aspergillu
terreu
speci
resist
amphotericin
b
less
frequent
ustu
lentulu
note
increasingli
caus
invas
aspergillosi
tertiari
care
centr
scedosporium
innat
resist
mani
antifung
agent
emerg
major
caus
dissemin
infect
follow
infect
due
fusarium
speci
dematiac
brownblack
fungi
often
associ
chronic
localis
infect
increasingli
report
caus
dissemin
infect
immunosuppress
host
watch
surveil
rapid
detect
diseas
adequ
treatment
effect
control
measur
highli
warrant
optim
manag
difficult
treat
fungal
infect
impact
commens
flora
health
diseas
adult
bodi
harbour
approxim
ten
time
microbi
cell
human
cell
genom
microbiom
endow
us
physiolog
capac
strongli
influenc
wellb
howev
microbiom
larg
unexplor
great
need
increas
understand
interact
human
microbi
genom
sequenc
human
genom
constitut
start
point
understand
human
biolog
global
scale
yet
today
grow
agreement
human
health
diseas
understood
without
consid
microbi
commun
human
microbiom
project
launch
number
intern
consortium
start
effort
explor
role
human
microbiota
health
diseas
mani
line
evid
suggest
role
commens
transient
microb
statu
human
health
well
risk
contract
certain
diseas
last
year
molecular
microbiolog
revolution
landscap
microbiolog
continu
provid
new
solut
microb
identif
character
nextgener
sequenc
open
new
area
research
peopl
field
intestin
skin
oral
caviti
microbiom
highthroughput
sequenc
platform
access
hope
also
help
increas
understand
hostbacteria
interact
immun
matur
mechan
behind
chronic
diseas
develop
interdisciplinari
approach
must
taken
compris
medic
epidemiolog
comput
biotechnolog
expertis
focus
understand
human
microbi
commun
effect
human
health
applic
differ
omic
method
comput
system
biolog
method
uniqu
biobank
requir
order
map
human
microbiom
well
human
cellular
machineri
interact
esblproduc
e
coli
commun
big
threat
outpati
set
e
coli
ctxm
enzym
global
preval
esbl
produc
often
isol
urin
patient
attend
gener
practic
data
assess
accur
extent
commun
burden
preval
esbl
produc
faec
healthi
peopl
typic
europ
recent
multicentr
studi
nonhospit
patient
infect
one
third
esbl
produc
mainli
e
coli
recent
health
care
contact
benami
et
al
clin
infect
di
uk
esblproduc
e
coli
caus
c
case
bacteraemia
pa
may
estim
caus
c
urinari
tract
infect
pa
mani
belong
globallydissemin
uropathogen
clone
esbl
though
equal
common
clone
belfast
citi
clone
present
faec
nurs
home
resid
esbl
associ
incfii
multiresist
plasmid
belfast
encod
plasmid
plasmid
readili
lost
even
absenc
antibiot
select
pressur
sinc
encod
multipl
addict
system
henc
esbl
produc
may
serv
longterm
commun
reservoir
resist
gene
foreign
travel
may
also
associ
gut
colon
esblproduc
isol
esbl
present
often
reflect
type
preval
countri
visit
food
remain
underexplor
potenti
sourc
esblproduc
e
coli
raw
chicken
sampl
uk
ctxm
group
esbl
found
meat
import
south
america
type
account
esbl
clinic
infect
current
data
suggest
wide
presenc
esbl
foodstuff
may
found
e
coli
anim
strain
usual
distinct
domin
human
clinic
type
esbl
produc
often
multiresist
carbapenem
drug
choic
seriou
infect
resist
may
emerg
strain
reduc
permeabl
observ
uk
nurs
home
resid
recent
hospit
carbapenem
exposur
carbapenemaseproduc
e
coli
rare
although
isol
metallocarbapenemas
addit
acquir
ampc
enzym
give
caus
concern
lest
becom
preval
tradit
enzym
follow
commun
set
chang
epidemiolog
alter
manag
prevent
strategi
sinc
escherichia
coli
produc
ctxm
enzym
especi
emerg
worldwid
import
caus
communityonset
urinari
tract
uti
blood
stream
infect
due
extendedspectrum
blactamas
esbl
produc
bacteria
molecular
epidemiolog
studi
suggest
sudden
worldwid
increas
e
coli
mostli
due
singl
clone
name
foreign
travel
highrisk
area
indian
subcontin
might
play
part
role
spread
clone
across
differ
contin
carbapenem
wide
regard
drug
choic
treatment
sever
infect
due
esblproduc
enterobacteriacea
empir
antibiot
coverag
resist
organ
consid
commun
patient
present
sepsi
involv
urinari
tract
especi
patient
certain
risk
factor
recent
antibiot
use
resid
longterm
care
facil
recent
hospit
male
older
year
recent
travel
highrisk
area
failur
initi
appropri
antibiot
therapi
start
appear
respons
higher
patient
mortal
studi
differ
part
world
show
percent
popul
commun
rectal
colon
esblproduc
enterobacteriacea
larg
scale
introduct
bacteria
hospit
set
yet
demonstr
howev
higher
rate
colon
esblproduc
enterobacteriacea
present
household
contact
patient
infect
caus
esblproduc
enterobacteriacea
resid
nurs
home
longterm
care
center
prevent
spread
bacteria
manag
infect
caus
esblproduc
e
coli
commun
remain
difficult
controversi
issu
integr
diagnost
platform
versu
standalon
microbiolog
laboratori
integr
diagnost
platform
clinic
microbiolog
subject
rapid
evolut
due
need
rapid
complex
diagnost
increas
difficulti
recruit
train
personnel
well
medic
technic
level
need
proven
costeffici
increas
overhead
cost
associ
qualiti
control
side
new
opportun
follow
introduct
new
techniqu
pcr
malditof
particular
avail
autom
inocul
plate
read
system
replac
manual
labour
reaction
challeng
differ
rang
outsourc
nonhospit
base
special
microbiolog
lab
variou
form
cooper
smaller
lab
cooper
exist
central
part
almost
activ
central
hospitalbas
lab
network
divis
labor
collabor
lab
solut
share
one
factor
increas
size
seek
increas
costeffici
facilit
introduct
new
special
expens
techniqu
outsourc
often
reject
risk
reduc
microbiolog
pure
analyt
activ
littl
microbiologistdepend
addedvalu
concentr
smaller
microbiolog
lab
one
central
lab
network
may
alway
possibl
practic
reason
increas
distanc
clinic
microbiologist
microbiolog
test
solut
assur
suffici
lab
size
even
mediums
hospit
without
need
collabor
lab
outsourc
integr
microbiolog
lab
patholog
lab
clinic
chemistri
clinic
hematolog
kind
integr
combin
economi
scale
conserv
microbiolog
activ
within
hospit
thu
close
link
microbiolog
infecti
diseas
infect
control
specialist
integr
laboratori
simplest
form
exist
share
machin
lab
space
also
lead
integr
diagnost
activ
accord
common
workflow
exampl
integr
unit
molecular
test
perform
nucleic
acid
base
test
microbiolog
hematolog
also
human
genet
forens
medicin
integr
lab
demand
new
way
organ
lab
activ
essenti
integr
lab
separ
medic
technic
expertis
medic
organiz
respons
follow
allogen
stem
cell
transplant
patient
profound
prolong
immunosuppress
sever
hla
mismatch
transplant
requir
extens
cell
deplet
prevent
graftversushost
diseas
recipi
cord
blood
transplant
contain
memori
tlymphocyt
consequ
high
morbid
mortal
infect
diseas
relaps
develop
two
approach
repopul
immun
system
follow
transplant
reduc
type
risk
first
approach
isol
viral
fungal
antigen
reactiv
lymphocyt
donor
blood
expand
ex
vivo
infus
stem
cell
recipi
gener
lymphocyt
specif
common
virus
epsteinbarr
viru
cytomegaloviru
adenoviru
engin
expand
effici
vivo
prove
effect
prevent
treat
seriou
viru
ill
target
patient
popul
extend
approach
treatment
fungal
diseas
second
approach
remov
alloreact
cell
donor
pbm
infus
deplet
cell
produc
broad
immun
reconstitut
safeti
measur
prevent
gvhd
infus
cell
incorpor
new
suicid
gene
compos
modifi
caspas
activ
small
molecul
drug
earli
clinic
result
show
high
safeti
efficaci
approach
also
develop
tumorspecif
cytotox
lymphocyt
use
nativ
chimer
receptor
direct
tumor
associ
antigen
express
chimer
receptor
viru
specif
lymphocyt
thu
gain
benefit
antivir
antitumor
respons
infus
tcell
approach
appear
extrem
cost
effect
high
margin
safeti
hepat
e
viru
hev
infect
consid
emerg
infecti
diseas
industri
countri
hev
genotyp
eccmid
oral
present
wide
distribut
anim
grow
evid
hepat
e
zoonot
diseas
transmit
directli
indirectli
anim
human
shown
recent
hev
lead
chronic
infect
solidorgan
transplant
recipi
liver
fibrosi
progress
popul
rapid
lead
liver
cirrhosi
within
year
infect
virolog
tool
crucial
diagnosi
also
determin
incid
hev
infect
solidorgan
transplant
recipi
although
sensit
eia
test
detect
antihev
antibodi
among
immunocompromis
patient
may
poor
perform
antihev
igm
assay
appear
use
identifi
recent
hev
infect
howev
detect
hev
rna
blood
stool
pcr
remain
gold
standard
prospect
cohort
solid
organ
transplant
recipi
acut
hepat
e
develop
chronic
infect
two
main
hev
genotyp
identifi
sequenc
region
genotyp
concentr
hev
rna
plasma
acut
phase
patient
clear
viru
similar
develop
chronic
infect
contrast
acut
phase
aminotransferas
activ
higher
patient
clear
viru
possibl
reduct
immunosuppress
drug
target
tcell
chronic
infect
patient
must
consid
firstlin
therapeut
option
order
obtain
hev
rna
clearanc
recent
data
also
indic
pegyl
interferon
ribavirin
induc
biochem
virolog
respons
select
popul
conclus
hev
infect
must
consid
differenti
diagnosi
hepat
solidorgan
transplant
patient
improv
inform
prophylact
measur
need
reduc
risk
viru
transmiss
chronic
liver
diseas
screen
procedur
signific
impact
incid
densiti
methicillinresist
staphylococcu
aureu
german
intens
care
unit
f
schwab
c
geffer
behnk
p
gastmeier
giessen
berlin
de
object
evalu
incid
densiti
id
methicillinresist
staphylococcu
aureu
mrsa
screen
control
measur
intens
care
unit
icu
particip
german
nosocomi
infect
surveil
system
kiss
method
surveil
modul
multidrugresist
bacteria
icu
mdrkiss
collect
data
mrsa
case
particip
icu
aim
provid
nation
refer
tool
monitor
evalu
infect
control
manag
median
id
mrsa
case
per
patientday
pd
interquartil
rang
iqr
calcul
mrsa
case
subcategori
import
icuacquir
case
pool
data
icu
refer
comparison
local
mrsa
id
detail
questionnair
regard
icu
structur
microbiolog
diagnost
mrsa
screen
procedur
mrsa
control
measur
infect
control
educ
implement
surveil
sent
particip
icu
associ
questionnair
result
high
mrsa
id
percentil
evalu
logist
regress
analysi
result
icu
patient
pd
submit
data
mrsa
case
complet
questionnair
median
mrsa
id
icu
iqr
iqr
iqr
per
pd
case
import
icuacquir
case
respect
routin
screen
mrsa
perform
icu
convent
mrsa
detect
method
use
icu
pcrbase
screen
icu
method
icu
relev
screen
procedur
control
measur
shown
tabl
variabl
deriv
questionnair
variabl
gener
admiss
screen
patient
odd
ratio
p
screen
admit
patient
regular
interv
odd
ratio
p
independ
associ
high
mrsa
id
conclus
consider
differ
exist
mrsa
incid
densiti
screen
control
measur
german
icu
mrsa
screen
procedur
import
impact
mrsa
incid
densiti
icu
decid
perform
gener
admiss
screen
probabl
realiz
mrsa
problem
object
screen
methicillinresist
staphylococcu
aureu
mrsa
becam
mandatori
uk
elect
day
case
admiss
april
mandatori
emerg
admiss
april
data
assess
effect
strategi
individu
hospit
level
lack
analyz
screen
programm
data
determin
number
need
test
nnt
detect
colonis
patient
across
rang
clinic
specialti
develop
risk
assess
strategi
mrsa
screen
method
mrsa
screen
nose
groin
perform
use
chromogen
agar
addit
site
wound
cathet
includ
present
hospit
mrsa
screen
data
resolv
prospect
individu
patient
level
oppos
commonli
util
approxim
use
match
censu
admiss
data
screen
data
map
patient
administr
system
databas
contain
relev
special
code
mismatch
screen
result
exist
individu
patient
investig
weekli
includ
identif
patient
specif
categori
exclud
screen
screen
effici
specialti
fed
back
weekli
clinic
team
drive
improv
perform
rate
mrsa
posit
nnt
detect
posit
patient
determin
specialti
result
month
octob
laboratori
perform
mrsa
swab
individu
cost
euro
screen
effici
elect
admiss
improv
emerg
admiss
overal
hospit
admiss
mrsa
posit
mrsa
posit
emerg
elect
day
case
case
respect
highest
mrsa
posit
rate
seen
emerg
case
hepatolog
intervent
radiolog
vascular
surgeri
elect
vascular
surgeri
patient
mrsa
posit
lowest
mrsa
posit
rate
day
case
orthopaed
patient
screen
without
detect
singl
posit
patient
nnt
detect
posit
rang
depend
clinic
special
admiss
type
conclus
accur
data
result
mrsa
screen
use
assess
risk
individu
patient
admiss
cost
effect
screen
specif
patient
group
enhanc
effici
screen
process
respect
neither
level
trend
cheng
rate
significantli
reduc
respect
kept
level
sinc
signific
chang
rate
bacteraemia
due
methicllinsuscept
aureu
result
explain
chang
casemix
antibiot
consumpt
segment
regress
model
shown
tabl
eccmid
oral
present
expect
valu
perfect
inform
paramet
high
conclus
microbi
resist
decolonis
agent
decolonis
strategi
costeffect
particularli
decolonis
mrsa
posit
admiss
identifi
pcr
screen
model
allow
uncertainti
decis
make
quantifi
highlight
paramet
inform
need
ensur
costeffect
decis
case
probabl
progress
colonis
infect
decolonis
undecolonis
patient
futur
highthroughput
microbiolog
laboratori
believ
massspectrometri
malditof
mass
spectrometri
revolut
identif
pathogen
clinic
laboratori
manag
bacteri
infect
identif
pathogen
follow
growth
remain
essenti
propos
soon
possibl
appropri
treatment
avail
antibiot
suscept
strategi
common
pathogen
requir
gram
stain
result
simpl
test
determin
oxidas
catalas
activ
appropri
phenotyp
test
use
commerci
identif
kit
andor
autom
system
new
proteom
strategi
progress
chang
strategi
identifi
bacteri
fungal
speci
grown
plate
within
minut
matrix
assist
laser
desorpt
ionis
timeofflight
mass
spectrometri
malditofm
intact
bacteria
yield
reproduc
spectrum
depend
upon
strain
speci
use
whole
viabl
bacteria
describ
applic
malditofm
identif
bacteri
pathogen
isol
routin
clinic
microbiolog
laboratori
aim
primari
isol
bacterium
grown
onto
plate
identifi
spectral
print
malditof
spectrum
use
recogn
genu
speci
malditofm
perform
use
bacteria
obtain
one
isol
coloni
clinic
relev
bacteri
speci
select
speci
one
sever
refer
strain
select
establish
spectral
print
strain
peak
conserv
spectra
isol
coloni
rel
intens
retain
thu
lead
set
select
peak
per
strain
group
pathogen
databas
valid
use
set
isol
identifi
use
mostli
rna
sequenc
use
strategi
identifi
bacteri
speci
clinic
microbiolog
laboratori
present
object
method
give
overview
climat
chang
europ
region
exampl
knowledg
influenc
preval
parasit
infect
use
review
literatur
northern
part
europ
arctic
three
time
higher
temperatur
rest
world
due
climat
chang
lot
learn
happen
circumpolar
area
adapt
strategi
parasit
infect
leishmania
opistorchi
echinococcosi
multiloculari
alveolari
expand
along
giardia
intestinali
exampl
impact
differ
region
conclus
given
dynami
complex
climatesensit
infecti
diseas
particularli
transmit
mosquito
rodent
europ
need
develop
sustain
surveil
earli
warn
system
region
focu
accord
unit
nation
world
popul
elderli
surpass
children
age
year
health
resourc
shift
popul
growth
thu
measur
reduc
health
cost
prevent
care
prudent
ill
foodborn
pathogen
avoid
technolog
use
maxim
safeti
food
water
popul
educ
selfcar
medic
therapi
advanc
earli
diagnosi
treatment
sinc
selfcar
strategi
requir
alter
usual
cultur
habitu
behavior
educ
effort
limit
success
elderli
difficult
teach
elderli
handl
food
safe
consequ
failur
heed
profession
advic
medic
person
elderli
bodi
begin
senesc
suscept
opportunist
infect
increas
age
immun
system
primari
reason
suscept
foodborn
pathogen
elderli
natur
senesc
immun
exacerb
immun
insuffici
chronic
diseas
pharmacolog
therapi
common
popul
immun
insuffici
associ
malnutrit
becom
caus
factor
physic
mental
capac
age
individu
deterior
poor
hygien
failur
handl
store
food
safe
inabl
distinguish
safe
taint
food
may
consequ
diminish
mental
gener
health
group
hous
failur
care
staff
heed
food
handl
guidanc
could
affect
health
multipl
resid
due
widespread
exposur
immun
insuffici
yet
accept
wellmean
advic
chang
poor
health
habit
limit
due
lack
trust
efficaci
inform
inform
contrari
cultur
tradit
practic
failur
recogn
accept
declin
physiolog
mental
health
challeng
health
profession
provid
food
safeti
guidanc
recogn
social
health
mental
barrier
control
abil
individu
act
advic
goal
foodborn
ill
world
realiti
prevent
care
longer
possibl
palli
care
must
take
place
analysi
bacteri
protein
profil
obtain
matrixassist
laser
desorpt
ioniz
timeofflight
malditof
mass
spectrometri
ms
emerg
past
year
new
method
accur
identif
bacteri
isol
malditodm
protein
profil
achiev
within
muinut
thu
speed
identif
cheap
technolog
includ
decreas
cost
mass
spectromet
protein
profil
issu
identif
reproduc
robust
new
gener
mass
spectromet
smaller
machin
easili
implant
within
laboratori
paramet
make
malditof
ms
technolog
introduc
modern
microbiolog
laboratori
includ
pointofcar
laboratori
databas
crucial
part
process
compris
bacteri
speci
routin
encount
microbiolog
laboratori
despit
fact
gramposit
organ
remain
malditof
resist
part
underli
taxonom
weak
part
databas
weak
malditof
definit
first
line
method
routin
identif
bacteri
isol
centuri
push
biochem
profil
even
gram
stain
laboratori
toward
museum
bacteriolog
rapid
identif
type
listeria
speci
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
listeria
monocytogen
foodborn
pathogen
caus
agent
human
listeriosi
opportunist
infect
primarili
infect
pregnant
women
immunolog
compromis
individu
rapid
accur
discrimin
listeria
strain
essenti
appropri
therapeut
manag
time
intervent
infect
control
rapid
method
involv
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
malditof
ms
show
promis
identif
listeria
speci
type
even
allow
differenti
level
clonal
lineag
among
pathogen
strain
l
monocytogen
present
total
strain
differ
listeria
speci
serotyp
well
clinic
isol
analyz
method
compar
pulsedfield
gel
electrophoresi
analysi
listeria
strain
compris
l
monocytogen
strain
isol
foodborn
epidem
sporad
case
isol
repres
differ
serotyp
number
listeria
strain
whose
genom
complet
sequenc
follow
short
inactivationextract
procedur
cell
materi
bacteri
coloni
deposit
sampl
target
dri
overlaid
matrix
necessari
maldi
process
analyz
malditof
ms
techniqu
examin
chemistri
major
protein
yield
profil
spectra
consist
seri
peak
characterist
fingerprint
mainli
deriv
ribosom
protein
specimen
prepar
minut
plate
liquid
cultur
spectrum
obtain
within
minut
mass
spectra
deriv
listeria
isol
show
characterist
peak
conserv
speci
lineag
level
malditof
ms
fingerprint
may
potenti
listeria
identif
subtyp
may
improv
infect
control
measur
microbi
classif
identif
today
base
larg
upon
compar
rrna
sequenc
analysi
howev
desir
retain
polyphas
approach
microorgan
far
divers
unequivoc
delin
singl
method
proteom
form
sdspage
mlee
ief
profil
long
histori
applic
shown
excel
congruenc
genom
method
dnadna
reassoci
arriv
maldim
esim
made
studi
proteom
access
within
less
decad
platform
avail
clinic
applic
thu
develop
intact
cell
malditof
mass
spectrometri
infect
elderli
new
concept
approach
matur
uptak
diagnost
laboratori
increas
steadili
extens
databas
eg
anagnostec
ms
spectra
neglig
sampl
prepar
rapid
analysi
main
reason
success
peptidesprotein
present
ms
spectra
either
surfaceassoci
intracellular
ribosom
protein
consequ
present
littl
inform
obtain
use
sole
approach
gain
inform
antibiot
resist
pattern
indepth
analysi
involv
lcmsm
method
requir
use
approach
new
inform
antibiot
resist
mechan
becom
appar
provid
excel
tool
elucid
complex
mechan
genom
analysi
alon
provid
solut
identif
clinic
yeast
import
task
mycolog
laboratori
especi
view
rise
number
patient
respect
opportunist
mycos
reliabl
speci
identif
use
first
guidanc
initi
appropri
antifung
therapi
conclus
malditof
ms
fingerprint
turn
promiss
tool
reliabl
rapid
handson
time
min
identif
clincal
yeast
low
cost
consum
per
identif
approch
much
hamper
influenc
morpholog
fungu
cultur
condit
e
g
cultur
media
minor
chang
incub
temperatur
compar
msbase
identif
hyphomycet
techniqu
facilit
high
put
object
identif
yeast
use
qualitycheck
databas
epidemiolog
data
show
hivinfect
popul
age
mainli
result
prolong
surviv
due
potent
antiretrovir
regimen
success
control
viral
replic
thu
prevent
aidsrel
event
also
late
diagnosi
hiv
infect
older
patient
specif
guidelin
develop
clinic
manag
older
hivinfect
patient
clinician
must
take
account
sever
factor
peculiar
popul
like
presenc
comorbid
pharmacokinet
characterist
elderli
possibl
higher
incid
drugrel
toxic
differ
respons
antiretrovir
therapi
older
hivinfect
popul
morbid
mortal
still
remain
high
consequ
increas
risk
nonaid
relat
condit
compar
agematch
hivseroneg
subject
condit
includ
cancer
neurocognit
disord
cardiovascular
liver
kidney
bone
diseas
mani
factor
contribut
non
aidsrel
comorbid
relat
popul
characterist
eg
higher
preval
tradit
healthrel
risk
factor
like
diabet
hypertens
hyperlipidemia
smoke
antiretrovir
drug
eg
associ
long
term
exposur
proteas
inhibitor
higher
risk
cardiovascular
diseas
tenofovir
exposur
renal
bone
dysfunct
hivinfect
eg
associ
agerel
event
low
cell
count
higher
level
inflamm
marker
found
hivposit
patient
pharmacokinet
characterist
elderli
peculiar
possibl
modif
drug
absorpt
distribut
hepat
renal
clearanc
result
high
interindividu
pharmacokinet
variabl
moreov
interact
antiretrovir
drug
frequent
prescrib
non
hivrel
comorbid
contribut
variabl
consequ
plasma
drug
level
drop
effect
concentr
promot
treatment
failur
becom
high
result
toxic
mani
data
show
despit
high
rate
virolog
suppress
usual
attribut
high
adher
therapi
older
patient
significantli
slower
cell
count
reconstitut
younger
subject
caus
find
could
due
sever
factor
like
late
diagnosi
treatment
hiv
infect
one
hand
thymic
involut
immunosenesc
age
hand
mani
studi
indic
suboptim
cell
increas
associ
higher
risk
non
aidsassoci
morbid
mortal
cancer
heart
liver
diseas
patient
popul
conclus
preval
older
hivinfect
patient
increasingli
grow
addit
research
need
fulli
understand
factor
contribut
peculiar
evolut
hiv
infect
associ
comorbid
age
group
order
optim
clinic
care
popul
advanc
health
care
conduc
develop
countri
age
popul
longterm
care
facil
ltcf
institut
provid
heath
care
peopl
unabl
manag
commun
resid
elder
multipl
comorbid
resid
stay
ltcf
month
year
henc
comfort
digniti
social
import
issu
order
control
cost
mani
postacut
patient
use
stay
acut
care
hospit
long
time
current
transfer
ltcf
situat
led
necess
invas
devic
urinari
vascular
cathet
feed
tube
fact
increas
incid
nosocomi
infect
one
observ
hospit
sever
signific
differ
point
hospit
ltcf
notabl
nursepati
ratio
avail
microbiolog
cultur
laboratori
diagnost
equip
site
access
costli
antibiot
addit
ltcf
infect
control
staff
lack
nosocomi
infect
surveil
program
also
antibiot
polici
strategi
gener
rate
colon
multiresist
bacteria
resid
ltcf
higher
observ
hospit
patient
exampl
studi
shown
rate
methicillin
resist
staphylococcu
aureu
mrsa
carriag
among
ltcf
resid
reach
hospit
gener
although
possibl
detect
outbreak
mrsa
infect
ltcf
sporad
relat
pressur
ulcer
gener
less
seriou
seen
hospit
preval
multidrug
resist
gramneg
mdrgnb
bacteria
also
high
among
ltcf
resid
particularli
among
faecal
incontin
antibiot
exposur
mdrgnb
frequent
eccmid
oral
present
recov
environment
sampl
common
area
provid
opportun
persontoperson
transmiss
clostridium
difficil
continu
increas
problem
ltcf
common
caus
nonepidem
acut
diarrheal
ill
ltcf
outbreak
also
recogn
particularli
relat
antimicrobi
consumpt
conclus
ltcf
act
reservoir
multiresist
bacteria
caus
sporad
infect
well
indol
outbreak
multilevel
approach
includ
antimicrobi
polici
prevent
transmiss
measur
need
limit
impact
problem
herp
zoster
shingl
caus
reactiv
varicella
zoster
viru
character
acut
pain
rash
patient
experi
prolong
pain
postherpet
neuralgia
rare
case
last
year
debilit
incid
sever
zoster
increas
age
treatment
option
zoster
post
herpet
neuralgia
limit
costli
shingl
vaccin
licens
europ
unit
state
follow
complet
shingl
prevent
studi
random
control
trial
healthi
adult
vaccin
decreas
incid
sever
zoster
median
year
primari
efficaci
measur
burden
ill
score
combin
incid
durat
sever
pain
vaccin
decreas
burden
ill
effect
vari
age
efficaci
prevent
acut
zoster
declin
age
vaccin
minim
efficaci
past
age
year
vaccin
reduc
incid
postherpet
neuralgia
age
achiev
prevent
acut
zoster
among
patient
age
year
attenu
diseas
patient
age
year
side
effect
mild
seriou
advers
event
common
vaccin
group
percent
vs
percent
p
debat
use
vaccin
revolv
around
effect
costeffect
vaccin
expens
per
dose
publish
analys
found
increment
costeffect
ratio
rang
per
qualityadjust
life
year
vaccin
appear
costeffect
among
incid
diseas
age
group
high
vaccin
recipi
still
abl
mount
satisfactori
immun
respons
despit
recommend
center
diseas
control
adult
age
year
receiv
shingl
vaccin
uptak
us
slow
barrier
vaccin
includ
difficulti
vaccin
storag
variabl
insur
coverag
compet
prioriti
primari
care
doctor
sinc
licensur
cost
vaccin
increas
moreov
studi
willingnesstopay
suggest
current
vaccin
price
accept
patient
conclus
shingl
vaccin
appear
effect
reduc
morbid
cost
high
univers
vaccin
age
year
may
current
repres
good
valu
object
make
genet
screen
tuberculosi
tb
isol
suitabl
lowincom
countri
well
endem
countri
high
prevalenceincid
drugresist
tb
emerg
epidem
drugresist
tb
call
rapid
diagnosi
earli
detect
drug
resist
allow
immedi
appropri
treatment
patient
could
therebi
reduc
spread
multidrugresist
mdr
extens
drug
resist
tb
xdrtb
recent
develop
mtbspecif
multiplex
assay
base
multiplex
ligationdepend
probe
amplif
mlpa
method
allow
simultan
detect
multipl
dispers
dr
mutat
genotypespecif
mutat
mycobacterium
tuberculosi
mtb
genom
prove
highli
specif
current
readout
mlpa
done
capillari
electrophoresi
method
expens
timeconsum
therefor
difficult
implement
sustain
lowincom
countri
recent
develop
biotechnolog
rais
opportun
transfer
assay
liquid
array
current
mlpaprob
modifi
compat
system
cover
increas
preval
mdrand
xdrtb
isol
target
reveal
resist
sever
import
secondlin
drug
eg
fluoroquinolon
includ
mlpa
assay
well
addit
genotyp
marker
newli
includ
mlpaprob
specif
target
snp
allow
detect
preval
secondlin
drug
resist
mutat
delin
mtb
complex
member
genotyp
abil
mlpa
assay
addit
increas
discoveri
new
genotyp
marker
explos
snp
discoveri
next
year
data
high
throughput
sequenc
project
becom
avail
method
allow
inform
snp
rapidli
detect
becom
increasingli
valuabl
furthermor
feel
new
analysi
method
mlpa
specif
ad
valu
lowincom
countri
high
endem
drtb
liquid
array
allow
multiparamet
test
could
provid
standard
platform
sever
diagnost
screen
test
tradit
perform
sever
differ
method
therefor
mlpa
combin
detect
system
bring
molecular
type
mtb
clinic
isol
closer
patient
current
feasibl
applic
rapid
detect
system
tuberculosi
complex
rifampicin
resist
xpert
mtbrif
decontamin
respiratori
specimen
nonrespiratori
specimen
cultur
l
deforg
jm
le
glaunec
n
launay
r
vergn
minaret
marzouk
n
p
legrand
creteil
maurensscopont
fr
object
genexpert
cepheid
autom
realtim
pcr
system
easi
use
suitabl
emerg
use
principl
xpert
mtbrif
test
run
genexpert
detect
tuberculosi
complex
mutat
gene
rpob
caus
resist
rifampicin
done
directli
minimum
ml
respiratori
sampl
min
treatment
sampl
stage
sampl
prepar
pcr
take
place
within
instrument
restrict
use
led
us
valid
system
variou
type
sampl
method
respiratori
sampl
decontamin
naclnaoh
ml
decontamin
product
ad
ml
lysi
buffer
provid
xpert
product
nonrespiratori
nondecontamin
sampl
csf
pleural
liquid
biopsi
sampl
volum
sometim
low
case
distil
water
ad
ml
addit
lysi
buffer
solid
cultur
one
coloni
resuspend
ml
distil
water
liquid
cultur
ml
medium
centrifug
prior
addit
lysi
buffer
fifteen
decontamin
respiratori
sampl
ppd
nonpulmonari
sampl
object
although
leprosi
treat
multidrug
therapi
sinc
resist
firstlin
drug
dapson
rifampicin
describ
year
resist
secondlin
drug
fluoroquinolon
describ
sinc
sinc
mycobacterium
lepra
grow
vitro
suscept
test
one
year
experi
mous
footpad
rare
done
molecular
method
thu
necessari
detect
antibiot
resist
leprosi
far
hous
method
requir
sequenc
aim
provid
commerci
base
molecular
test
abl
detect
antibiot
resist
leprosi
method
lepra
strain
contain
biopsi
skin
sampl
studi
resist
dapson
rifampicin
ofloxacin
refer
drug
suscept
method
mous
footpad
method
dna
extract
region
involv
resist
three
drug
rpob
gene
rifampicin
gyra
gene
ofloxacin
gene
dapson
resist
amplifi
sequenc
new
dna
strip
test
genotyp
lepraedr
appli
blindli
result
compar
obtain
genotyp
method
pcr
sequenc
phenotyp
refer
method
mous
footpad
result
among
lepra
strain
resist
rifampicin
resist
dapson
resist
ofloxacin
resist
isol
pcr
sequenc
concord
mous
footpad
test
mutat
number
system
lepra
genom
rpob
gyra
result
obtain
genotyp
lepraedr
test
concord
two
refer
method
suscept
strain
two
discord
mous
footpad
test
pcr
sequenc
pcrsequenc
show
one
strain
silent
mutat
codon
rpob
second
strain
serin
cystein
substitut
codon
associ
rifampicin
resist
genotyp
lepra
dr
show
wildtyp
pattern
rpob
two
isol
object
mycobacterium
avium
subsp
paratuberculosi
map
known
etiolog
agent
paratuberculosi
john
diseas
rumin
crohn
diseas
inflammatori
gastrointestin
tract
diseas
human
present
similar
symptom
patholog
chang
gut
john
diseas
cattl
therefor
suggest
map
could
one
etiolog
factor
diseas
aim
present
studi
develop
mapspecif
realtim
pcr
assay
provid
addit
possibl
detect
viabl
map
method
realtim
pcr
assay
base
amplif
specif
target
design
includ
intern
amplif
control
identifi
fals
neg
result
detect
limit
establish
artifici
contamin
raw
milk
sampl
optim
assay
appli
natur
contamin
raw
milk
sampl
potenti
realtim
pcr
assay
detect
viabl
map
explor
assess
express
target
raw
milk
sampl
inocul
dubo
broth
method
show
inclus
exclus
test
map
strain
nonmap
mycobacteria
raw
milk
microflora
strain
detect
limit
artifici
contamin
raw
milk
map
cellsml
milk
survey
natur
contamin
sampl
obtain
dairi
herd
known
histori
paratuberculosi
premilk
main
milk
sampl
test
posit
realtim
pcrderiv
mapspecif
bacteri
cell
equival
bce
rang
ml
major
sampl
less
one
bce
per
ml
milk
express
chosen
target
detect
artifici
contamin
raw
milk
well
inocul
dubo
broth
thu
confirm
realtim
pcr
assay
potenti
detect
viabl
map
cell
object
object
studi
determin
whether
activ
cytomegaloviru
cmv
specif
cellmedi
respons
preemptiv
therapi
control
replic
episod
without
valganciclovir
administr
solid
organ
transplant
sot
patient
high
risk
cmv
infect
method
sot
recipi
high
risk
cmv
infect
seroneg
receiv
seroposit
graft
follow
month
transplant
cmv
viral
load
vl
determin
realtim
pcr
cmvspecif
immun
respons
character
flow
cytometri
detect
cell
express
secret
ifng
preemptiv
treatment
administ
vl
reach
copiesml
cmvspecif
immun
respons
detect
treatment
administ
patient
close
monitor
result
eleven
patient
median
age
year
includ
week
transplant
patient
experienc
cmv
replic
episod
rang
copiesml
resolv
administr
valganciclovir
week
posttransplant
cmvspecif
immun
respons
detect
patient
replic
episod
detect
control
host
immun
system
without
administr
treatment
vl
rang
copiesml
furthermor
although
number
posit
pcr
result
similar
acquisit
immun
vl
level
significantli
lower
p
immun
median
valu
copiesml
copiesml
respect
week
week
replic
episod
copiesml
new
replic
episod
detect
week
analysi
immun
respons
demonstr
secret
cell
significantli
earlier
ifng
vs
week
posttranspl
p
adit
ifng
secret
cell
significantli
earlier
cell
vs
week
posttranspl
p
conclus
preemptiv
therapi
promot
acquisit
earli
immun
respons
transplant
sot
patient
high
risk
cmv
infect
demonstr
immun
respons
elicit
preemptiv
therapi
confer
immun
later
cmv
replic
event
object
human
activ
mostli
variant
b
common
liver
transplant
reactiv
asymptomat
symptom
enceph
hepat
graft
dysfunct
describ
clinic
experi
antivir
therapi
limit
base
vitro
studi
current
antivir
drug
effect
cytomegaloviru
cmv
also
activ
howev
ganciclovir
less
effect
aim
studi
investig
effici
antivir
prophylaxi
given
cmvseroneg
risk
patient
receiv
graft
seroposit
donor
prevent
reactiv
method
consecut
adult
liver
transplant
patient
belong
cmv
high
risk
group
receiv
valganciclovir
ganciclovir
prophylaxi
month
transplant
patient
frequent
monitor
cmv
realtim
quantit
pcr
reactiv
demonstr
antigenemia
test
pbmc
use
indirect
immunoperoxidas
stain
monoclon
antibodi
intragraft
infect
demonstr
liver
biopsi
use
antibodi
immunostain
result
antivir
prophylaxi
breakthrough
cmv
infect
record
contrari
antigenemia
detect
patient
appear
mean
day
rang
day
transplant
reactiv
caus
three
case
antigen
also
detect
transplant
associ
graft
dysfunct
conclus
reactiv
common
antivir
prophylaxi
liver
transplant
least
three
case
also
transplant
infect
valganciclovirganciclovir
prophylaxi
prevent
infect
adult
liver
transplant
patient
result
eleven
renal
transplant
adult
recipi
identifi
calicivirida
infect
includ
nov
spv
given
induct
immunosuppress
therapi
relay
tripl
mainten
therapi
median
time
transplant
symptom
diagnosi
month
rang
day
rang
respect
patient
protract
diarrhea
requir
hospit
iv
rehydr
vomit
fever
present
patient
respect
one
experienc
weight
loss
averag
loss
kg
present
acut
renal
failur
patienttopati
nosocomi
transmiss
like
two
patient
share
hospit
room
variant
identifi
other
communityacquirednoroviru
infect
one
context
famili
outbreak
nov
genotyp
found
variant
patient
respect
diarrhea
last
week
median
durat
day
rang
strikingli
diarrhea
resolv
mycophenol
taper
withdraw
patient
respect
patient
surviv
none
experienc
relaps
diarrhea
median
followup
month
rang
conclus
nov
like
underestim
caus
sever
chronic
diarrhea
renal
transplant
recipi
may
delay
effect
therapeut
intervent
mostli
consist
reduc
immunosuppress
prospect
studi
warrant
assess
correl
immunosuppress
regimen
resolut
diarrhea
viru
clearanc
p
b
dussol
berland
p
de
micco
marseil
fr
object
anellovirida
famili
compos
multipl
viral
speci
belong
prototyp
tt
viru
biolog
implic
host
health
intrigu
viral
famili
still
matter
debat
order
better
understand
evolut
anellovirida
strain
immunocompromis
host
perform
molecular
analysi
serial
blood
biopsi
sampl
kidney
transplant
recipi
method
viral
dna
extract
plasma
sampl
use
high
pure
viral
nucleic
acid
kit
roch
biopsi
tissu
sampl
predigest
use
proteinas
k
nucleic
acid
extract
use
approach
roll
circl
amplif
rca
use
dna
polymeras
perform
extract
materi
order
optimis
detect
viral
dna
anellovirida
detect
perform
use
highli
conserv
pcr
system
amplifi
product
clone
sequenc
submit
phylogenet
analys
result
evolut
viral
strain
detect
blood
sampl
bimod
prior
kidney
transplant
day
genet
divers
exhibit
anellovirida
sequenc
moder
hand
multipl
variant
detect
end
followup
regard
biopsi
sampl
although
first
sampl
pcr
neg
anellovirida
sequenc
identifi
second
sampl
interestingli
sequenc
ident
nearli
ident
cluster
sequenc
identifi
blood
patient
transplant
studi
suggest
transplant
abl
colon
anellovirida
strain
identifi
previous
blood
correspond
patient
confirm
also
major
chang
anellovirida
dynam
occur
blood
patient
undergo
immunosuppress
treatment
precis
analysi
biolog
molecular
data
collect
studi
expos
five
nine
patient
develop
elpt
diagnos
liver
biopsi
immunohistochemistri
patient
elev
liver
enzym
time
baselin
patient
atyp
lymphocyt
time
diagnosi
elpt
monocytosi
two
patient
clinic
mononucleosislik
asymptomat
time
diagnosi
elpt
viral
load
genomesml
patient
number
elpt
present
two
event
ad
diagnosi
acut
cellular
reject
biopsi
second
event
elpt
high
viral
load
conclus
viral
load
genomesml
accompani
elev
liver
enzym
valu
four
time
normal
level
relat
develop
elpt
object
varicellazost
viru
vzv
infect
may
caus
signific
morbid
mortal
immunocompromis
patient
vzv
vaccin
induc
humor
cellular
immun
howev
clear
correl
igg
antibodi
titer
protect
infect
antibodi
protect
function
concentr
affin
chemic
bind
strength
avid
measur
function
affin
suggest
studi
vaccin
efficaci
incorpor
analysi
avid
sinc
high
avid
marker
memori
prime
present
studi
design
order
answer
question
whether
solid
organ
transplant
sot
recipi
lower
vzv
igg
antibodi
avid
despit
protect
igg
antibodi
level
vaccin
method
serum
sampl
sot
recipi
evalu
igg
antibodi
level
vzv
igg
antibodi
avid
twentyeight
patient
includ
studi
liver
transplant
heart
transplant
kidney
transplant
receiv
singl
dose
varivax
aventi
pasteur
lyon
franc
prior
transplant
control
group
consist
healthi
children
clinic
serolog
confirm
varicella
infect
wildviru
contact
varicella
vaccin
singl
dose
varivax
result
median
igg
antibodi
level
uml
wildviru
infect
control
uml
vaccin
control
uml
sot
recipi
median
rel
avid
index
rai
wildviru
infect
control
vaccin
control
transplant
recipi
p
compar
wildviru
infect
control
p
compar
vaccin
control
conclus
conclus
igg
antibodi
avid
sot
recipi
may
serv
substitut
marker
evalu
humor
immun
vzv
particular
import
clinic
set
exposur
vzv
consid
vzvspecif
immunglobulin
andor
acyclovir
treatment
order
prevent
clinic
relev
reinfect
varicellacaus
complic
result
exposur
vzv
transplant
howev
role
humor
protect
vzv
evalu
longterm
followup
sinc
also
cellular
immun
may
play
crucial
role
defenc
viral
infect
gramposit
organ
frequent
aetiolog
agent
overal
gramneg
organ
primari
aetiolog
agent
earli
postop
period
week
week
one
postolt
bsi
due
gramneg
organ
abdomin
sourc
gramposit
organ
predomin
first
postop
week
caus
bsi
crude
mortal
bsi
highest
earli
postop
period
among
gramposit
isol
vancomycinresist
enterococci
methicillinresist
staphylococcu
aureu
isol
among
gramneg
isol
esbl
ampc
produc
overal
incid
bsi
transplant
centr
decreas
two
time
period
period
olt
perform
incid
bsi
per
patient
transplant
gramposit
organ
frequent
caus
agent
period
conclus
bsi
remain
major
concern
olt
recipi
understand
aetiolog
bsi
postolt
import
empir
antibiot
choic
event
infecti
complic
postsurgeri
attempt
reduc
incid
bsi
postolt
plan
target
iv
catheterrel
sepsi
centr
object
evalu
quantit
real
time
pcr
plasma
sampl
monitor
activ
cmv
infect
allogen
stem
cell
transplant
allosct
patient
tri
new
strategi
initi
cmv
preemptiv
therapi
studi
plasma
sampl
obtain
cmv
infect
episod
allo
sct
patient
januari
februari
receiv
one
cours
preemptiv
therapi
upon
posit
ag
andor
tnaipcr
result
develop
cmv
endorgan
diseas
coliti
neumon
patient
monitor
poststc
antigenemia
cinapool
argen
ag
convent
quantit
pcr
coba
amplicor
cmv
automat
extract
coba
ampliprep
tnai
kit
roch
tnaipcr
posit
sampl
defin
ag
pmn
andor
tnaipcr
copiesmlal
sampl
retrospect
test
use
real
time
pcr
affigen
cmv
trender
automat
dna
extract
nuclisen
easymag
rtpcr
data
lower
copiesml
consid
neg
episod
defin
period
first
posit
sampl
antigenemia
andor
tnaipcr
first
neg
sampl
techniqu
invas
candida
infect
occur
mani
differ
patient
popul
critic
care
wide
acknowledg
import
predispos
factor
third
candidaemia
episod
occur
icu
chiefli
icu
patient
expos
mani
risk
factor
includ
compromis
natur
barrier
infect
candida
colonis
alter
normal
flora
presenc
debilit
diseas
immunosuppress
particularli
neutropenia
invas
candida
infect
also
occur
outsid
icu
cardin
risk
factor
present
varieti
patient
type
includ
patient
undergo
major
abdomin
surgeri
bone
marrow
solidorgan
transplant
patient
patient
undergo
cancer
chemotherapi
although
risk
factor
invas
candida
infect
well
characteris
definit
diagnosi
remain
problemat
due
long
lead
time
associ
blood
cultur
histopatholog
target
treatment
ie
select
antifung
agent
tailor
particular
candida
speci
known
antifung
suscept
rare
possibl
initi
consequ
preemptiv
empir
strategi
make
use
limit
inform
avail
guid
treatment
decis
commonli
employ
patient
invas
candida
infect
often
sever
ill
prior
develop
fungal
infect
therefor
rapid
initi
therapi
vital
risk
mortal
increas
significantli
delay
treatment
howev
also
import
consid
care
choic
agent
differ
exist
microbiolog
clinic
efficaci
mani
case
invas
candida
infect
caus
speci
potenti
resist
older
antifung
particularli
fluconazol
therefor
caus
agent
unknown
suspect
fluconazoleresist
speci
ie
c
glabrata
c
krusei
broadspectrum
antifung
agent
select
firstlin
recent
guidelin
recommend
echinocandin
best
overal
choic
differ
also
exist
echinocandin
particularli
regard
suitabl
use
certain
patient
popul
therefor
care
assess
individu
case
optim
basi
select
therapi
micafungin
evalu
extens
clinic
trial
programm
date
administ
patient
worldwid
recognis
treatment
option
intravascular
cathet
indispens
current
medic
practic
howev
provid
surfac
microbi
colonis
biofilm
format
predispos
patient
bacteraemia
common
caus
pathogen
coagulaseneg
staphylococci
staphylococcu
aureu
adher
properti
import
pathogenesi
catheterrel
infect
preval
multidrugresist
pathogen
need
rapidli
effect
empir
therapi
avoid
complic
improv
outcom
alter
pharmacokinet
septic
patient
make
bacteraemia
signific
clinic
challeng
infecti
diseas
societi
america
idsa
recent
publish
updat
guidelin
manag
catheterrel
bacteraemia
cathet
remov
prompt
system
antibiot
therapi
central
complic
uncompl
bacteraemia
manag
idsa
guidelin
highlight
ongo
clinic
challeng
recent
antibiot
help
address
exampl
clinic
evid
reduc
mrsa
suscept
vancomycin
prompt
idsa
recommend
daptomycin
institut
vancomycin
mic
mgml
common
bacteraemia
caus
vancomycinresist
enterococci
also
increas
concern
therapeut
option
limit
recent
novel
antibiot
may
help
case
haemodialysi
patient
particular
risk
factor
catheterassoci
bacteraemia
cathet
remov
may
pose
logist
problem
howev
failur
delay
remov
increas
risk
haematogen
spread
compar
cathet
retent
remov
aureusinfect
cathet
associ
rapid
respons
therapi
andor
higher
cure
rate
furthermor
success
rate
cathet
salvag
use
adjunct
antibiot
lock
therapi
lower
gramposit
pathogen
aureu
enterococci
staphylococcu
epidermidi
gramneg
infect
idsa
provid
dosag
recommend
daptomycin
linezolid
dialysi
patient
present
discuss
topic
clinic
challeng
manag
catheterrel
bacteraemia
daptomycin
licens
europ
treatment
complic
skin
soft
tissu
infect
cssti
aureu
rightsid
infect
endocard
rie
aureu
bacteraemia
associ
cssti
rie
patient
gramposit
noncatheterrel
bacteraemia
high
risk
septic
metastas
particularli
bone
joint
especi
prosthes
present
epidur
space
intervertebr
disc
cardiac
valv
present
noncatheterrel
bacteraemia
includ
primari
bloodstream
infect
bsi
bacteraemia
secondari
infect
site
acquir
either
commun
nosocomi
set
heterogen
may
requir
diagnosi
treatment
infect
foci
beyond
blood
domin
pathogen
nosocomi
communityacquir
bacteraemia
staphylococcu
aureu
aureu
bacteraemia
associ
high
frequenc
complic
includ
infect
endocard
ie
mortal
significantli
wors
patient
primari
secondari
bsi
compar
catheterrel
bacteraemia
also
infect
mrsa
vs
mssa
furthermor
inappropri
empir
treatment
patient
gramposit
bacteraemia
increas
mortal
risk
treatment
guidelin
bacteraemia
primarili
base
specif
infect
foci
ie
catheterrel
infect
empir
treatment
bacteraemia
take
account
like
pathogen
local
suscept
pattern
addit
present
symptom
patient
gener
heath
statu
medic
histori
includ
risk
factor
mdr
involv
comorbid
eg
renal
impair
concomit
medic
infect
focu
vascular
cathet
manag
also
address
risk
complic
particularli
relat
aureu
need
patient
receiv
prolong
therapi
potenti
initi
hospit
treatment
follow
continu
antimicrobi
therapi
postdischarg
daptomycin
one
antibiot
efficaci
safeti
treatment
aureu
bacteraemia
includ
associ
ie
rapid
bactericid
activ
includ
biofilm
stationari
phase
bacteria
potenti
outpati
treatment
oncedaili
intraven
inject
characterist
daptomycin
may
use
noncatheterrel
bacteraemia
daptomycin
licens
europ
treatment
complic
skin
soft
tissu
infect
cssti
aureu
rightsid
infect
endocard
rie
aureu
bacteraemia
associ
cssti
rie
prosthet
joint
infect
pji
osteomyel
ost
difficult
erad
remain
ongo
challeng
treat
physician
recent
prosthet
surgeri
usual
approach
either
twostag
exchang
separ
long
interv
week
lifelong
antibiot
suppress
therapi
first
approach
associ
prolong
hospitalis
risk
secondari
complic
second
low
probabl
success
antimicrobi
effect
slowgrow
stationari
growthphas
adher
microorgan
need
erad
biofilm
infect
present
discuss
novel
treatment
concept
impact
longterm
outcom
also
recent
updat
treatment
guidelin
pji
ost
choic
retain
remov
implant
depend
patient
profil
specif
group
implant
infect
cure
earli
debrid
longterm
treatment
antibiot
good
biofilm
activ
antimicrobi
type
dose
durat
therapi
discuss
potenti
newer
antibiot
daptomycin
may
prove
valuabl
option
implantassoci
methicillinresist
staphylococc
enterococc
infect
treatment
protocol
phase
ii
studi
daptomycin
without
rifampin
pji
ost
review
well
use
higher
dose
daptomycin
common
pitfal
reason
treatment
failur
outlin
empir
antibiot
therapi
administ
microbiolog
diagnost
confirm
difficult
antibiot
administ
drain
wound
overli
implant
addit
risk
develop
antimicrobi
resist
high
particularli
rifampin
therefor
rifampin
avoid
contact
bodi
surfac
implant
eg
open
wound
wound
dehisc
fistula
vacuumassist
closur
foam
drainag
common
mistak
insuffici
durat
andor
dose
antibiot
switch
intraven
oral
agent
insuffici
bioavail
inact
biofilm
daptomycin
licens
europ
treatment
complic
skin
soft
tissu
infect
cssti
dose
mgkg
od
staphylococcu
aureu
rightsid
infect
endocard
rie
aureu
bacteraemia
associ
cssti
rie
dose
mgkg
od
recent
year
wit
dramat
shift
preval
natur
antibiot
resist
key
chang
includ
rise
countri
subsequ
declin
mrsa
also
ii
rise
quinolon
cephalosporin
resist
enterobacteriacea
particularli
e
coli
klebsiella
spp
ctxm
esbl
increasingli
domin
sourc
cephalosporin
resist
iii
prolifer
baumannii
oxa
carbapenemas
iv
loss
fluoroquinolon
gonorrhoea
resist
rate
high
china
treatment
shift
predic
problem
exert
select
pressur
favour
spread
yet
resist
greatest
concern
hospit
medicin
emerg
enterobacteriacea
acquir
carbapenemas
includ
imp
vim
ndm
metallotyp
class
enzym
kpc
class
enzym
present
enterobacteriacea
enzym
prolifer
differ
part
world
ndm
india
turkey
vim
greec
kpc
us
stabil
distribut
unpredict
view
migrat
medic
tourism
gener
imp
vim
ndm
enzym
spread
plasmid
whilst
accumul
k
pneumonia
isol
kpc
enzym
larg
involv
dissemin
clone
loss
carbapenem
enterobacteriacea
would
public
health
catastroph
view
lack
altern
therapi
infect
due
multiresist
gramneg
bacteria
shift
greater
concern
present
receiv
eros
antigonococc
activ
cephalosporin
owe
chang
pbp
porin
efflux
increasingli
common
see
n
gonorrhoea
isol
cefixim
ceftriaxon
mic
mgl
repres
edg
treatabl
lack
conveni
alter
therapi
futur
risk
harder
predict
potenti
includ
transfer
resist
new
antigramposit
agent
notabl
mani
soil
streptomycet
degrad
daptomycin
organ
sourc
sever
resist
gene
spread
mobil
dna
clinic
pathogen
say
goe
predict
hard
especi
concern
futur
two
thing
certain
neither
evolut
resist
surpris
stop
yet
use
antibiot
hospit
set
shape
cultur
behaviour
aspect
well
clinic
situat
microbiolog
consider
understand
determin
antibiot
prescript
critic
explain
current
pattern
devis
program
reduc
inappropri
use
physician
behaviour
explain
factor
lack
inform
market
campaign
increas
use
newer
product
fear
advers
outcom
ineffect
prescript
studi
antibiot
use
pattern
consist
demonstr
frequent
inappropri
prescrib
low
adher
antibiot
prescript
abp
guidelin
factor
like
increas
emerg
resist
organ
behaviour
aspect
antibiot
prescript
remain
larg
unknown
explor
belief
percept
associ
measur
knowledg
abp
two
french
univers
hospit
physician
charg
abp
inpati
hospit
ward
ask
particip
volunt
complet
meet
less
hour
case
vignett
present
infecti
situat
explor
aspect
whether
hospit
need
initi
choic
ab
reevalu
day
treatment
durat
ii
selfreport
questionnair
collect
data
belief
percept
regard
abp
global
score
given
combin
answer
vignett
logist
regress
identifi
variabl
independ
associ
answer
case
vignett
median
global
score
elig
physician
agre
particip
senior
junior
physician
compris
medic
physician
surgeon
anesthesiologistsintensivist
ai
er
physician
median
global
score
iqr
multivari
analysi
surgeon
aor
ci
p
ai
perceiv
inappropri
abp
riski
patient
selfpercept
abil
compli
abp
guidelin
significantli
associ
measur
knowledg
median
score
particip
rate
reason
high
suggest
awar
abp
hospit
case
vignett
simpl
method
measur
knowledg
regard
abp
identifi
surgeon
job
profil
enhanc
educ
individu
level
strengthen
percept
risk
inappropri
abp
selfabl
compli
guidelin
may
contribut
better
practic
abp
studi
need
better
delin
factor
help
shape
physician
behaviour
antibiot
prescrib
lower
respiratori
tract
infect
lrti
account
almost
burden
morbid
mortal
western
lrti
compris
continuum
differ
sever
infect
rang
typic
self
limit
acut
bronchiti
sever
acut
exacerb
chronic
pulmonari
diseas
aecopd
lifethreaten
bacteri
communityacquir
pneumonia
cap
clinic
sign
symptom
tradit
laboratori
paramet
unreli
distinguish
viral
bacteri
lrti
consequ
lrti
treat
antibiot
despit
mainli
viral
origin
lead
ultim
emerg
bacteri
resist
limit
antibiot
overus
rapid
accur
differenti
clinic
relev
bacteri
lrti
caus
key
novel
approach
estim
probabl
bacteri
origin
lrti
measur
serum
procalcitonin
pct
level
pct
increas
rapidli
upon
infect
hour
decreas
upon
recoveri
pct
correl
sever
prognost
implic
kinet
make
good
marker
assess
effect
treatment
prerequisit
safe
guidanc
antibiot
therapi
pct
level
use
guid
antibiot
therapi
individu
patient
surrog
biomark
antibiot
stewardship
base
pct
cut
rang
success
implement
patient
lrti
differ
clinic
set
therebi
initi
continu
antibiot
less
discourag
ugl
ugl
encourag
ugl
ugl
figur
pct
valu
increas
antibiot
therapi
initi
repeat
pct
measur
recommend
antibiot
discontinu
use
cutoff
rang
clinic
algorithm
prospect
test
differ
intervent
trial
emerg
room
intens
care
unit
primari
care
recent
concept
extern
valid
larg
swiss
nationwid
multi
centr
trial
includ
patient
overal
pctguid
antibiot
stewardship
reduc
antibiot
prescript
rate
patient
acut
bronchiti
aecopd
cap
reduc
initi
prescript
rate
importantli
shorten
durat
antibiot
therapi
similar
outcom
patient
sever
similarli
pct
guidanc
safe
reduc
antibiot
exposur
primari
care
patient
upper
lower
therebi
pct
guidanc
significantli
reduc
antibioticrel
side
effect
especi
diarrhoea
nausea
septic
syndrom
far
heterogen
complex
reduc
singl
cutoff
surrog
marker
biomark
must
alway
evalu
context
care
clinic
microbiolog
assess
kinet
biomark
particular
diagnost
prognost
interest
repeat
measur
alway
perform
especi
antibiot
withheld
emerg
bacteri
resist
antimicrobi
agent
call
effici
effort
reduc
unnecessari
use
antimicrobi
agent
selflimit
nonbacteri
diseas
embed
clinic
algorithm
pctguid
antibiot
stewardship
offer
great
potenti
safe
markedli
reduc
antibiot
exposur
antibioticassoci
side
effect
sinc
escherichia
coli
produc
ctxm
enzym
especi
emerg
worldwid
import
caus
communityassoci
urinari
tract
uti
blood
stream
infect
due
extendedspectrum
blactamas
esbl
produc
bacteria
molecular
epidemiolog
studi
suggest
sudden
worldwid
increas
multiresist
ctxmproduc
e
coli
especi
mostli
due
singl
clone
name
foreign
travel
highrisk
area
indian
subcontin
might
play
part
role
spread
clone
across
differ
contin
clone
produc
ctxm
esbl
ie
often
also
associ
incfii
multiresist
plasmid
certain
virul
factor
malx
ompt
usp
communityassoci
acquisit
infect
due
enterobacteria
plasmidmedi
ampc
blactamas
rel
recent
phenomenon
describ
uk
canada
usa
spread
clone
commun
set
describ
enterobacteria
produc
plasmidmedi
ampc
blactamas
empir
antibiot
coverag
resist
organ
consid
commun
patient
present
sepsi
involv
urinari
tract
especi
patient
certain
risk
factor
recent
antibiot
use
resid
longterm
care
facil
recent
hospit
male
older
year
recent
travel
highrisk
area
emerg
public
health
threat
ignor
possibl
medic
commun
may
forc
near
futur
use
carbapenem
first
choic
empir
treatment
seriou
infect
associ
urinari
tract
infect
origin
commun
multidisciplinari
approach
current
appli
studi
acquisit
spread
antimicrobi
resist
clinicallyrelev
bacteri
pathogen
establish
surveil
implement
molecular
character
strain
genotyp
identif
resist
gene
type
virulotyp
analysi
replicon
type
circul
plasmid
multilocu
sequenc
type
also
use
document
intern
occurr
success
healthcareassoci
communityacquir
clone
mani
clone
often
resist
multipl
antibiot
multidrug
resist
often
encod
extrachromosom
element
call
plasmid
plasmid
evolv
integr
part
bacteri
genom
provid
resist
gene
easili
exchang
among
bacteria
differ
origin
sourc
natur
process
conjug
occurr
particular
epidem
plasmid
seem
tightli
link
posit
select
exert
antimicrobi
use
increment
preval
compar
observ
bacteri
popul
preselect
antimicrobi
resist
mani
question
remain
unansw
mechan
drive
success
dissemin
specif
plasmid
type
bacteri
clone
howev
recognit
success
clone
plasmid
essenti
first
step
may
lead
eventu
design
intervent
strategi
prevent
spread
class
blactamas
common
plasmidencod
blactamas
gramneg
bacteria
enzym
effici
hydrolyz
pencillin
mani
cephalosporin
effect
catalyst
extendedspectrum
cephalosporin
thu
provid
resist
drug
howev
variant
hydrolyz
extend
spectrum
cephalosporin
evolv
clinic
isol
last
two
decad
limit
treatment
option
evolv
enzym
term
extendedspectrum
blactamas
esbl
contain
one
five
amino
acid
substitut
result
increas
catalyt
effici
enzym
hydrolysi
extend
spectrum
cephalosporin
sitedirect
random
mutagenesi
studi
reveal
amino
acid
substitut
commonli
found
evolv
variant
increas
catalyt
effici
hydrolysi
extend
spectrum
cephalosporin
case
stabil
evolv
enzym
evolut
high
level
resist
involv
process
mutat
chang
activ
site
increas
catalysi
often
decreas
protein
stabil
turn
lead
acquisit
secondari
mutat
increas
vivo
half
life
enzym
interact
amino
acid
substitut
result
impact
evolut
esbl
activ
discuss
ampc
blactamas
highli
effici
hydrolysi
mani
cephalosporin
howev
exhibit
lower
activ
toward
extendedspectrum
cephalosporin
nevertheless
ampc
mediat
resist
extendedspectrum
cephalosporin
occur
due
high
level
enzym
product
mutat
enzym
result
increas
hydrolysi
drug
sever
amino
acid
substitut
well
small
insert
delet
ampc
enzym
report
increas
resist
extend
spectrum
cephalosporin
associ
increas
hydrolysi
antibiot
mutat
chang
occur
region
vicin
activ
site
may
act
increas
access
bulki
oxyiminocephalosporin
addit
random
mutagenesi
experi
reveal
posit
amino
acid
substitut
alter
substrat
specif
enzym
impact
amino
acid
substitut
evolut
extend
spectrum
cephalosporin
hydrolysi
ampc
enzym
discuss
lung
easili
affect
inhal
aerosol
mycobacteria
far
frequent
site
human
mycobacteriosi
hivneg
patient
diseas
undistinguish
tuberculosi
character
slow
progress
manifest
rang
absenc
symptom
cavitari
diseas
xray
may
reveal
fibrosi
upper
lobe
cavit
nodular
parenchym
opac
pleural
thicken
affect
elderli
patient
predispos
pulmonari
condit
eg
silicosi
obstruct
pulmonari
diseas
pneumoconiosi
previou
tuberculosi
bronchiectasi
cancer
symptom
includ
cough
fever
weight
loss
weak
respiratori
insuffici
ntm
frequent
respons
diseas
belong
mycobacterium
avium
complex
europ
infect
caus
mycobacterium
xenopi
particularli
northern
countri
caus
mycobacterium
malmoens
also
quit
frequent
wherea
usa
infect
caus
mycobacterium
kansasii
preval
aid
patient
radiograph
pictur
often
normal
may
reveal
mediastin
hilar
adenopathi
progress
diseas
rapid
frequent
symptom
cough
fever
weight
loss
patient
usual
lymphocyt
count
lower
recent
year
widespread
use
highli
activ
antiretrovir
treatment
dramat
reduc
frequenc
mycobacteri
diseas
includ
pulmonari
one
hivposit
patient
recent
pulmonari
infect
due
ntm
increasingli
report
patient
cystic
fibrosi
high
risk
contamin
sputum
environment
mycobacteria
estim
less
isol
ntm
respiratori
tract
clinic
relev
strict
observ
criteria
american
thorac
societi
essenti
correct
diagnosi
clinic
diagnosi
difficult
even
experienc
health
profession
henc
import
microbiolog
confirm
four
laboratori
test
current
use
direct
smear
exud
ulcer
lesion
situ
fine
needl
aspir
fna
nonulcer
lesion
biopsi
specimen
vitro
cultiv
ulceran
exud
fna
biopsi
gelbas
quantit
realtim
pcr
target
histopatholog
examin
import
bu
diagnosi
differenti
diagnosi
numer
infecti
noninfecti
diseas
neoplasm
diagnos
among
clinic
suspect
case
bu
tropic
phageden
ulcer
common
diagnost
problem
option
therapi
bu
surgeri
antibiot
combin
antibiot
therapi
form
gain
accept
world
health
organ
recommend
contraind
directli
observ
use
least
cours
oral
rifampin
streptomycin
intramuscular
inject
antibiot
treatment
may
also
combin
surgeri
antibiot
regimen
especi
administ
complet
oral
evalu
sever
zn
posit
lesion
larg
ulcer
dissemin
form
receiv
specif
antibiotherapi
surgic
treat
without
delay
avoid
deterior
lesion
possibl
bone
dissemin
object
mesotherapi
increas
use
techniqu
involv
subcutan
inject
minut
quantiti
variou
medic
drug
cosmet
rheumat
purpos
practic
alreadi
report
relat
infect
risk
januari
gener
practition
notifi
health
author
region
centr
infect
control
cluster
subcutan
infect
due
nontuberculosi
mycobacteria
ntm
follow
mesotherapi
epidemiolog
investig
perform
describ
outbreak
identifi
sourc
mechan
contamin
determin
risk
factor
method
case
definit
base
typic
clinic
subcutan
lesion
associ
posit
specimen
ntm
assess
practic
studi
perform
determin
potenti
risk
factor
test
compar
epidemiolog
studi
data
collect
includ
schedul
outpati
visit
localis
inject
type
inject
product
case
skin
affect
lymph
node
underw
violac
chang
discharg
purul
materi
week
total
resolut
achiev
within
month
patient
within
month
remaind
complic
observ
year
followup
skincolor
flat
scar
region
drainag
note
conclus
optim
therapi
condit
still
controversi
nevertheless
seem
antibiot
effect
treat
immunocompet
children
random
control
trial
examin
surgic
excis
versu
spontan
heal
warrant
v
j
sokolova
l
seng
duong
bratislava
trnava
sk
reason
antimalari
prophylaxi
failur
includ
poor
adher
antimalari
agent
ii
malabsorpt
antimalari
drug
iii
interact
medic
iv
advers
reaction
lead
treatment
interrupt
v
underdos
patient
vi
vitro
resist
case
clinic
failur
standbi
treatment
recommend
health
infrastructur
avail
commonli
use
antimalari
prophylaxi
travel
includ
mefloquin
atovaquonproguanil
prophylaxi
failur
therapi
artemisin
base
combin
drug
act
indic
special
condit
exist
ipt
intermitt
prevent
treatment
pregnant
women
endem
area
children
long
term
travelersresid
prophylaxi
hyperendem
area
usual
ineffect
eccmid
oral
present
within
past
year
virtual
malariaendem
countri
offici
adopt
artemisininbas
combin
therapi
act
first
second
line
therapi
treatment
p
falciparum
malaria
artemisinin
becom
essenti
class
antimalari
impact
compar
chloroquin
mid
centuri
spread
artemisinin
resist
could
therefor
devast
impact
malaria
control
effort
throughout
malariaendem
world
current
situat
lose
singl
class
antimalari
drug
resist
may
sever
impact
abil
mani
countri
treat
falciparum
malaria
concept
artemisinin
resist
contenti
one
mani
year
author
suggest
unlik
aris
first
place
howev
recent
data
indic
first
case
genuin
artemisinin
resist
alreadi
emerg
western
cambodia
may
alreadi
lose
artemisinin
select
part
world
data
show
individu
parasit
isol
resist
high
dose
artemisinin
prolong
parasit
clearanc
time
reduc
vitro
drug
respons
indic
phenomenon
yet
limit
rel
small
proport
parasit
isol
probabl
also
rel
small
area
southeast
asia
start
spread
resist
artemisinin
deriv
current
essenti
antimalari
drug
could
well
devast
event
histori
malaria
control
centuri
artemisininresist
malaria
new
emerg
diseas
requir
new
treatment
control
strategi
limit
impact
spread
resist
rest
malariaendem
world
microbi
colon
respiratori
tract
alway
predict
nasti
outcom
pneumocysti
pneumonia
long
recogn
caus
morbid
mortal
immunocompromis
popul
particularli
human
immunodefici
viru
hiv
infect
pneumocysti
colon
defin
detect
organ
dna
without
sign
symptom
pneumonia
sensit
molecular
techniqu
polymeras
chain
reaction
frequent
util
identifi
colon
accumul
evid
suggest
colon
pneumocysti
may
import
clinic
phenomenon
clinic
signific
colon
yet
fulli
understood
may
import
sever
reason
colon
person
may
risk
develop
pneumocysti
pneumonia
even
colon
individu
develop
pneumocysti
pneumonia
might
transmit
organ
other
exposur
pneumocystiscolon
anim
lead
colon
normal
anim
develop
clinic
diseas
immunosuppress
anim
colon
person
receiv
longterm
antipneumocysti
prophylaxi
may
also
lead
develop
mutat
associ
drug
resist
furthermor
pneumocysti
may
play
role
progress
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
presenc
pneumocysti
lung
even
low
level
seen
colon
produc
inflammatori
chang
similar
seen
copd
increas
number
neutrophil
cytotox
lymphocyt
colon
pneumocysti
demonstr
hivinfect
subject
hivinfect
smoker
particularli
suscept
pneumocysti
colon
regardless
cell
count
use
pneumocysti
prophylaxi
pneumocysti
colon
also
increas
nonhivinfect
patient
copd
directli
relat
sever
diseas
model
pneumocysti
colon
mice
smoke
exposur
nonhuman
primat
infect
hivsimian
immunodefici
viru
chimera
demonstr
develop
copdlik
chang
studi
suggest
treatment
prevent
pneumocysti
colon
atrisk
popul
may
novel
therapi
copd
epsteinbarr
viru
human
herpesviru
known
infect
effici
drive
activ
prolifer
rest
b
cell
vitro
achiev
express
nine
latent
protein
howev
vivo
ebv
persist
benign
dormant
state
rest
memori
b
cell
link
two
observ
vivo
ebv
use
latent
protein
activ
newli
infect
cell
lymphoid
tissu
cell
differenti
germin
center
becom
rest
memori
cell
viru
infect
cell
mimic
normal
process
wherebi
antigen
activ
b
cell
becom
long
term
memori
cell
stage
process
ebv
use
differ
combin
latent
protein
stage
infect
cell
unabl
progress
rest
memori
state
risk
becom
tumor
express
pattern
latent
protein
characterist
particular
stage
infect
thu
ebv
associ
sever
human
malign
includ
burkitt
lymphoma
hodgkin
diseas
immunoblast
lymphoma
nasopharyng
carcinoma
gastric
carcinoma
tumor
express
differ
pattern
latent
protein
reflect
origin
specif
stage
viral
life
cycl
recent
shown
ebv
also
latent
infect
cell
mirna
thought
play
critic
regulatori
function
normal
malign
cell
role
ebv
mirna
remain
unclear
also
unknown
express
tumor
specif
pattern
like
latent
protein
present
discuss
mechan
ebv
establish
persist
infect
memori
b
cell
includ
recent
evid
ebv
usurp
germin
center
process
gain
access
memori
b
cell
compart
detail
model
ebv
persist
explain
origin
ebv
associ
tumor
especi
lymphoma
demonstr
tumor
specif
express
profil
mirna
possibl
function
signific
express
pattern
polyomavirus
induc
tumor
natur
host
test
anim
tumorigenesi
virus
effect
number
differ
mechan
depend
specif
viru
studi
simian
viru
shown
viru
target
key
cellular
regulatori
protein
particular
tumor
suppressor
prb
stimul
cell
prolifer
block
cell
death
laboratori
use
combin
genet
proteom
gene
express
array
transgen
knockout
mice
understand
action
protein
cellular
target
lead
tumorigenesi
talk
review
research
present
model
transform
tumorigenesi
sharif
k
stich
biaggio
b
doning
mesteri
knapp
vienna
object
pantonvalentin
leukocidin
pvl
posit
staphylococcu
aureu
emerg
pathogen
associ
highli
lethal
necrot
pneumonia
pvl
bicompon
bbarrel
poreform
toxin
shown
caus
cell
death
neutrophil
howev
precis
mechan
lead
necrot
pneumonia
fulli
understood
role
pvl
herein
controversi
therefor
aim
investig
mechan
pvl
might
contribut
develop
sever
lung
inflamm
method
recombin
pvl
gener
cytotox
properti
verifi
patch
clamp
fac
inflammatori
potenti
pvl
test
alveolar
macrophag
use
mciroarray
profil
pcr
elisa
signal
pathway
investiagt
use
western
blot
electromobl
shift
assay
vivo
role
pvl
studi
murin
pneumon
model
lung
tissu
lavag
fluid
assess
cellinflux
cytokinechemokin
releas
result
pvl
rapidli
induc
pore
format
death
neutrophil
contrast
alveolar
macrophag
found
less
sensit
toxic
effect
succumb
prolong
incub
microarray
assay
perform
h
addit
pvl
alveolar
macrophag
reveal
select
induct
gene
upon
stimul
bioinformat
analysi
disclos
upregul
nfkb
target
gene
data
verifi
pcr
protein
level
suggest
pvl
select
induc
nfkb
associ
inflamm
vitro
inhibitor
studi
gene
report
assay
confirm
find
furthermor
pvlinduc
lung
inflamm
mice
confirm
inflammatori
potenti
pvl
illustr
rapid
influx
neutrophil
enhanc
level
proinflammatori
cytokin
chemokin
within
pulmonari
compart
conclus
data
demonstr
pvl
besid
poreform
properti
neutrophil
abl
strongli
induc
inflamm
via
nfkb
activ
alveolar
macrophag
lead
pneumon
vivo
bunk
metzdorf
hartung
knapp
von
aulock
vienna
constanc
de
object
staphylococcu
aureu
aureu
import
human
pathogen
caus
divers
diseas
rang
innocu
skin
infect
often
fatal
form
sepsi
initi
phase
infect
specif
molecular
pattern
aureu
recogn
innat
immun
receptor
host
lead
induct
inflammatori
respons
among
pattern
lipoteicho
acid
lta
compon
gramposit
cell
wall
repres
potent
immunostimulatori
molecul
abl
elicit
cytokin
releas
human
peripher
blood
depend
manner
sinc
contrast
data
lta
mutant
aureu
strain
lack
lipoprotein
delta
lgtlta
describ
investig
immunobiolog
inact
investig
function
requir
delta
lgtlta
mediat
activ
innat
immun
respons
use
ex
vivo
model
base
human
peripher
blood
cell
condit
cofactor
requir
recognit
delta
lgtlta
innat
immun
cell
investig
studi
demonstr
delta
lgtlta
induc
immun
activ
critic
depend
immobil
lta
phagocyt
activ
blood
cell
well
presenc
human
serum
compon
also
observ
lta
respect
wild
type
aureu
wtlta
albeit
lower
degre
signific
experiment
condit
conduc
optim
lta
stimul
found
differ
immunostimulatori
capac
delta
lgt
lta
wtlta
argu
limit
contribut
possibl
lipoprotein
contamin
wtlta
mediat
immun
activ
interestingli
found
lta
specif
igg
antibodi
detect
human
sera
vari
level
bind
immobil
delta
lgtlta
therebi
strongli
augment
delta
lgtlta
mediat
immun
activ
human
peripher
blood
conclus
result
suggest
novel
mechan
delta
lgtlta
mediat
immun
activ
human
blood
cell
involv
opsonizationdepend
uptak
recognit
process
lta
also
provid
conclus
explan
controversi
find
obtain
previou
experi
compar
immunostimulatori
capac
delta
lgtlta
wtlta
pseudomona
aeruginosa
pulmonari
epitheli
cell
object
cystic
fibrosi
cf
autosom
recess
disord
incid
caucasian
pseudomona
aeruginosa
p
aeruginosa
predomin
bacteri
pathogen
cf
grow
within
hypox
biofilm
cf
lung
caus
chronic
infect
associ
inflamm
studi
investig
effect
hypoxia
activ
proinflammatori
transcript
factor
nfkappab
alveolar
epitheli
cell
respons
stimul
p
aeruginosa
method
lung
epitheli
cell
incub
heat
inactiv
p
aeruginosa
specif
tlr
ligand
lp
flagellin
atmospher
oxygen
activ
nfkappab
determin
immunoblot
nuclear
nfkappab
famili
member
cytosol
target
gene
nfkappab
well
luciferas
activ
werebi
cell
transfect
nreluciferas
plasmid
beforehand
result
incub
cell
heat
inactiv
p
aeruginosa
clearli
increas
nuclear
protein
level
luciferas
activ
manner
profoundli
amplifi
either
epitheli
cell
hypoxia
hypox
bacteria
stimul
innat
immun
alveolar
epitheli
cell
larg
mediat
three
tolllik
receptor
incub
cell
tolllik
receptor
specif
agonist
primarili
flagellin
increas
nfkappab
level
manner
also
amplifi
hypoxia
data
indic
microenvironment
hypoxia
major
determin
pulmonari
epitheli
inflammatori
respons
p
aeruginosa
infect
investig
signal
molecul
particip
respons
reveal
new
target
antiinflammatori
therapi
cystic
fibrosi
work
support
grant
ircset
embark
initi
scienc
foundat
ireland
object
contradictori
data
report
regard
role
inflammasom
anticandida
host
defens
order
address
discrep
investig
host
defens
dissemin
candidiasi
knockout
mice
defect
variou
compon
inflammasom
method
mice
defici
asc
infect
intraven
c
albican
surviv
fungal
outgrowth
organ
histolog
modul
cytokin
product
compar
mous
strain
wildtyp
control
mice
pbmc
healthi
volunt
without
reactiv
oxygen
speci
ro
inhibitor
pbmc
patient
chronic
granulomat
diseas
cgd
defici
ro
product
stimul
c
albican
result
mice
mice
decreas
surviv
dissemin
candidiasi
compar
control
mice
mice
increas
fungal
load
kidney
defici
anim
show
preferenti
growth
hypha
pyelum
mice
accompani
remarkbl
littl
inflamm
figur
contrast
mice
higher
fungal
load
show
significantli
stronger
inflammatori
reaction
kidney
show
higher
tnf
product
candida
stimul
display
increas
suscept
dissemin
candidiasi
local
bioactiv
infg
vivo
affect
mice
anim
addit
constitut
activ
ro
defici
monocyt
c
albican
induc
product
reduc
absenc
ro
conclus
process
import
antifung
host
defens
candida
sepsi
contrast
current
think
process
depend
inflammasom
compon
asc
atp
receptor
data
confirm
previou
studi
human
monocyt
show
activ
candida
infect
requir
pathogenmedi
flammasom
activ
asc
play
import
role
dissemin
candidiasi
unexpectedli
seem
differ
function
vivo
specif
regul
tnf
product
local
inflamm
organ
final
ro
play
critic
role
inflammasom
activ
candidainduc
product
object
amphotericin
b
amb
antifung
drug
wide
use
treatment
fungal
infect
cryptococc
mening
caus
encapsul
fungal
pathogen
cryptococcu
neoforman
amb
bind
ergosterol
form
pore
membran
result
cell
death
howev
report
indic
amb
also
act
oxid
work
studi
effect
amb
c
neoforman
method
compar
three
viabil
method
xtt
assay
prodium
iodid
stain
coloni
form
unit
enumer
xtt
reduc
mitochondria
live
cell
produc
compound
quantifi
spetrophotometr
propidium
iodid
dnabind
fluoresc
compound
penetr
cell
lose
membran
integr
final
cfu
enumer
estim
abil
cell
replic
form
viabl
coloni
result
amb
inhibit
format
coloni
concentr
mgl
cell
becom
permeabl
propidium
iodid
condit
suggestin
amb
effect
c
neoforman
differ
pore
format
viabil
measur
use
xtt
assay
correl
cfu
result
observ
confirm
amb
exert
kill
effect
intracellularli
howev
also
observ
paradox
effect
cell
treat
high
amb
concentr
mgl
produc
higher
level
reduc
xtt
cell
treat
intermedi
amb
concentr
mgl
sinc
paradox
effect
correl
cfu
appear
argu
might
reflect
induct
electron
transfer
mitochondria
consequ
increas
oxid
burst
induc
amb
measur
amount
reactiv
oxygen
speci
ro
cell
use
dihydrofluorescein
compound
attack
free
radic
releas
fluoresc
result
demonstr
amb
induc
strong
releas
ro
cell
correl
metabol
inactiv
measur
xtt
assay
conclus
although
amb
bind
ergosterol
produc
pore
membran
result
indic
antifung
drug
induc
kill
c
neoforman
mainli
induct
strong
oxid
burst
find
confirm
b
multipl
effect
cell
suggest
explan
low
antifung
resist
compound
observ
among
clinic
isol
object
protozoan
parasit
trypanosoma
cruzi
aetiolog
agent
chaga
diseas
american
trypanosomiasi
affect
near
million
peopl
sever
consequ
term
morbid
mortal
host
abil
gener
parasitespecif
immun
respons
play
essenti
role
control
evolut
sever
diseas
particular
effici
cell
respons
requir
immun
control
infect
heat
shock
protein
character
immunodomin
antigen
sever
bacteri
infect
tumour
still
parasit
diseas
aim
work
know
whether
cruzi
process
present
lymphocyt
natur
infect
method
peptid
contain
hlaa
motif
select
use
bioinformat
bind
affin
evalu
use
assay
cruzi
infect
transgen
mice
use
predict
immunodomin
epitop
within
protein
cytotox
assay
recognit
candid
peptid
circul
lymphocyt
chagas
patient
assess
ifng
secret
test
result
thirti
peptid
select
put
hlaa
binder
synthes
candid
select
recognit
test
splenocyt
mice
immun
protein
altern
chronic
infect
cruzi
signif
peptid
recognit
observ
noninfect
nonimmun
anim
two
peptid
signif
recogn
immun
infect
mice
recognit
two
peptid
circul
lymphocyt
chagas
patient
test
ifng
secret
assay
peptid
well
recogn
chagas
patient
differ
stage
diseas
data
demonstr
cruzi
immunodomin
epitop
natur
process
present
chaga
diseas
progress
cell
respons
microbi
shown
protect
infect
like
tuberculosi
sinc
current
vaccin
chaga
diseas
avail
character
new
parasit
antigen
provid
protect
respons
great
valu
order
fight
cruzi
infect
object
differ
clinic
trial
kill
leishmania
vaccin
show
limit
efficaci
compar
inocul
live
leishmania
major
leishmanizationlz
cutan
leishmaniasi
cl
reason
discrep
efficaci
live
kill
vaccin
yet
known
vivo
vitro
studi
tcell
function
livekil
stimulatori
effect
might
provid
valuabl
inform
method
nine
leishmanin
skin
test
lst
posit
donor
histori
self
heal
cl
hcl
seven
healthi
lst
neg
donor
includ
studi
cell
isol
peripher
blood
diacet
succinimidyl
ester
cfse
label
lymphocyt
cultur
presenc
mitomycin
treat
autolog
monocyt
micro
gml
kill
leishmania
lysat
kll
ml
live
leishmania
major
llm
cell
harvest
day
incub
analys
prolifer
use
flow
cytometri
cultur
supernat
collect
day
ifng
titrat
use
sandwich
elisa
method
result
hcl
volunt
upon
stimul
kll
number
prolifer
cell
divis
significantli
unstimul
cell
p
llm
stimul
cell
p
cell
control
p
p
cell
cell
hcl
donor
show
significantli
higher
product
llm
stimul
compar
kll
stimul
p
p
cell
compar
control
p
p
cell
stimul
cell
llm
p
kll
p
induc
significantli
higher
ifng
product
compar
cell
control
llm
induc
significantli
ifng
kll
p
compart
significantli
higher
ifng
product
observ
cell
stimul
llm
p
result
snp
strongli
correl
candida
colon
hsct
patient
individu
bear
wildtyp
allel
colon
candida
compar
individu
bear
mutant
allel
p
necessit
frequent
use
fluconazol
treatment
p
function
assay
demonstr
lossoffunct
phenotyp
snp
shown
decreas
cytokin
product
immun
cell
bear
snp
contrast
snp
influenc
suscept
candidaemia
oropharyng
candidiasi
hivinfect
patient
snp
nonredund
recognit
c
albican
influenc
mucos
candida
colon
contrast
lack
function
accompani
increas
suscept
bloodstream
candida
infect
tdt
analysi
show
associ
snp
gene
meningococc
diseas
also
preferenti
transmiss
snp
found
subgroup
patient
mening
shock
shock
mening
bacteraemia
patient
mening
somewhat
higher
preval
allel
c
allel
signific
addit
differ
found
number
day
spent
icu
diseas
sever
activ
meningococc
infect
patient
meningococc
septic
shock
peak
plasma
concentr
pentraxin
appear
depend
genotyp
patient
homozyg
allel
higher
peak
plasma
concentr
individu
p
instead
patient
homozyg
allel
lower
peak
plasma
concentr
ac
cc
individu
approach
signific
p
figur
find
indic
patient
septic
shock
plasmaconcentr
part
depend
genotyp
snp
affect
suscept
meningococc
diseas
object
resist
tuberculosi
propos
mechan
select
high
rate
mannosebind
lectin
mbl
defici
mechanist
low
level
pattern
recognit
receptor
may
lead
rel
lower
degre
phagocytosi
mycobacterium
tuberculosi
protect
tb
howev
evid
date
conflict
aim
systemat
review
publish
literatur
effect
genotyp
andor
mbl
level
tuberculosi
infect
perform
metaanalysi
consid
effect
suscept
infect
seriou
gramposit
infect
becom
increasingli
difficult
treat
escal
incid
multidrugresist
pathogen
methicillinresist
staphylococcu
aureu
mrsa
order
improv
clinic
outcom
select
appropri
therapi
essenti
consid
pharmacokinet
pk
pharmacodynam
pd
paramet
pd
target
relat
dose
use
pk
paramet
measur
exposur
addit
aucmic
ratio
use
predict
clinic
efficaci
relationship
mic
dose
requir
consid
patient
suspect
multidrugresist
infect
prompt
initi
appropri
therapi
import
determin
mortal
european
hospit
mrsa
strain
account
aureu
isol
crucial
chosen
therapi
provid
appropri
coverag
mrsa
current
treatment
guidelin
seriou
gramposit
infect
hospitalacquir
pneumonia
hap
complic
skin
soft
tissu
infect
cssti
recommend
use
vancomycin
linezolid
infect
caus
mrsa
howev
role
agent
treatment
seriou
gramposit
infect
still
uncertain
current
unmet
need
addit
agent
effect
seriou
gramposit
infect
caus
methicillinsuscept
aureu
mssa
mrsa
telavancin
rapidli
bactericid
lipoglycopeptid
novel
dual
mode
action
broad
spectrum
activ
clinic
import
gramposit
pathogen
includ
mrsa
phase
trial
telavancin
demonstr
noninferior
compar
vancomycin
treatment
cssti
hap
includ
ventilatorassoci
pneumonia
caus
gramposit
pathogen
includ
mssa
mrsa
result
suggest
telavancin
would
promis
addit
current
therapeut
option
manag
seriou
gramposit
infect
caus
mssa
mrsa
medic
public
health
impact
rapid
molecular
test
symposium
support
cepheid
despit
notabl
advanc
recent
year
molecular
diagnost
applic
infecti
diseas
detect
yet
reach
full
potenti
often
perform
special
laboratori
far
remov
patient
care
decis
made
specimen
usual
spend
time
transit
actual
analyz
sampl
arriv
lab
delay
incur
obligatori
depend
batch
process
chief
limit
current
molecular
diagnost
approach
due
underli
technolog
rather
technolog
implement
realtim
pcr
perfectli
capabl
gener
result
within
minut
howev
process
lead
analyt
step
often
unwieldi
perform
batch
within
highcomplex
laboratori
environ
moreov
requir
complex
procedur
tie
avail
molecular
diagnost
test
result
limit
avail
highli
train
personnel
mani
case
medic
valu
diagnost
result
tie
directli
quickli
result
link
patient
manag
andor
treatment
decis
fortun
technolog
nucleic
acid
detect
evolv
direct
modern
clinic
chemistri
analyz
success
allow
random
access
high
throughput
stat
test
capabl
addit
virtu
simplic
afford
integr
autom
sampl
process
technolog
fulli
capabl
decentr
order
minim
impact
sampl
transport
turnaround
time
symposium
focu
need
speed
drive
maximum
medic
impact
four
differ
area
relev
molecular
diagnost
respiratori
infect
group
b
strep
prophylaxi
blood
cultur
posit
staphylococci
presurg
prophylaxi
object
despit
increas
understand
treatment
prevent
invas
fungal
infect
ifi
remain
major
challeng
ifi
import
caus
complic
mortal
among
hospitalis
patient
especi
among
immunocompromis
patient
haematolog
set
potenti
voriconazol
vori
primari
secondari
prophylaxi
ifi
recent
evalu
clinic
trial
patient
haematolog
diseas
undergon
allogen
transplant
method
primari
prophylaxi
studi
improvit
patient
year
randomis
receiv
oral
vori
oral
itraconazol
itra
day
transplant
day
primari
composit
endpoint
success
prophylaxi
day
ie
surviv
without
develop
provenprob
ifi
discontinu
prophylaxi
day
first
day
secondari
prophylaxi
studi
vosifi
b
patient
year
provenprob
ifi
previou
month
receiv
vori
hour
iv
hour
po
within
hour
postcondit
chemotherapi
day
primari
endpoint
incid
provenprob
ifi
subsequ
month
result
success
prophylaxi
significantli
higher
vori
group
n
compar
itra
group
n
day
vs
ci
p
vs
ci
p
significantli
patient
treat
vori
itra
vs
p
suffici
day
prophylaxi
median
vs
day
incid
ifi
low
arm
vori
itra
patient
receiv
itra
develop
ifi
compar
none
treatment
vori
b
n
case
ifi
occur
recurr
candida
albican
candidaemia
recurr
scedosporium
prolifican
fungaemia
fatal
new
case
zygomycosi
day
transplant
respect
incid
common
vorirel
advers
event
hepatotox
nausea
headach
hallucinationsvisu
impair
differ
surviv
treatment
group
b
patient
die
median
day
posttranspl
ifi
conclus
base
result
prophylaxi
studi
vori
effect
safe
option
primari
secondari
prevent
ifi
allogen
transplant
current
estim
cancer
case
relat
infecti
event
vari
evid
number
still
grow
besid
helicobact
pylori
parasit
mostli
virus
caus
relat
malign
diseas
demonstr
establish
link
depend
epidemiolog
profil
diseas
put
causal
infecti
agent
well
biolog
properti
experiment
cell
cultur
vivo
model
often
one
classic
koch
postul
isol
put
agent
affect
tissu
fulfil
instanc
even
trace
microb
ie
nucleic
acid
consist
found
tumor
reason
might
cancer
late
rare
consequ
chronic
infect
replic
infecti
agent
longer
take
place
gene
function
requir
mainten
tumor
growth
therefor
combin
observ
experiment
strategi
appli
collect
suffici
evid
initi
attempt
prevent
measur
target
infecti
agent
develop
vaccin
exampl
classic
innov
approach
present
emerg
extendedspectrum
blactamas
esbl
enterobacteriacea
entb
began
alter
laboratori
approach
blactamas
detect
enterobacteriacea
prior
time
result
blactam
report
accord
test
result
specif
detect
acquir
narrow
spectrum
blactamas
sought
arriv
esbl
detect
confirm
consid
import
default
posit
aros
presenc
esbl
test
clinic
strain
whatev
mic
organ
requir
report
organ
resist
cephalosporin
type
mani
suscept
test
method
recommend
use
esbl
screen
confirm
test
routin
basi
howev
number
issu
emerg
routin
use
year
problem
defin
adequ
number
substrat
ensur
suffici
sensit
screen
lack
simpl
reliabl
phenotyp
method
detect
esbl
speci
induc
ampc
blactamas
failur
current
esbl
detect
method
provid
advic
interpret
posit
screen
test
neg
confirm
test
especi
isol
suscept
extendedspectrum
cephalosporin
use
methodrecommend
breakpoint
anim
model
data
show
respons
treatment
entb
measur
vivo
kill
correl
mic
strain
presenc
absenc
esbl
rang
recent
studi
suggest
failur
treatment
extendedspectrum
cephalosporin
like
strain
entb
mic
elev
wildtyp
applic
pharmacokineticpharmacodynam
principl
wide
recommend
dose
schedul
cephalosporin
shown
suscept
breakpoint
recommend
mani
method
high
lower
breakpoint
inject
cephalosporin
publish
clsi
eucast
recommend
option
conduct
specif
esbl
test
instanc
epidemiolog
need
newer
cephalosporin
breakpoint
put
us
posit
almost
esblproduc
plasmidborn
ampcproduc
entb
detect
report
r
new
breakpoint
specif
blactamas
test
requir
appropri
clinic
report
whose
major
purpos
guid
therapi
individu
patient
argu
treatment
outcom
eg
esbl
produc
predict
mic
irrespect
resist
mechan
propon
view
contend
unnecessari
clinic
laboratori
edit
suscept
data
basi
resist
mechan
sought
purpos
epidemiolog
surveil
sever
outcom
studi
support
view
though
other
would
great
merit
perfect
world
routin
mic
rapidli
precis
determin
clinic
isol
realiti
differ
mic
measur
clinic
laboratori
determin
late
geometr
scale
fourfold
runtorun
variat
toler
control
strain
often
zone
diamet
use
proxi
mic
anyon
ever
run
multicentr
discbas
survey
discov
prone
disturbingli
wide
sitetosit
variat
imperfect
realiti
esbl
produc
cefotaxim
mic
mgl
probabl
respons
cefotaxim
vivo
reliabl
distinguish
one
mic
mgl
probabl
respons
simpler
safer
follow
precautionari
approach
seek
esbl
found
report
isol
resist
advantag
seek
mechan
use
select
primari
cultur
media
chromogen
test
found
post
specimen
precis
mic
differenti
like
increas
come
molecular
method
detect
resist
mechan
may
critic
allow
associ
earli
effect
therapi
reduc
mortal
severelyil
patient
object
exist
still
concern
potenti
relationship
abacavir
abc
myocardi
infarct
mi
author
postul
increas
risk
mi
might
caus
proinflammatori
state
increas
decreas
risk
follow
quickli
start
resum
abc
decid
longitudin
evalu
lipoproteinassoci
phospholipas
wide
accept
marker
vascular
inflamm
cardiovascular
diseas
abc
therapi
hiv
patient
due
lack
accuraci
marker
hscrp
tnfalfa
method
eleven
consecut
hivposit
patient
start
abccontain
haart
sampl
month
start
abc
eleven
hivposit
patient
abc
spare
haart
individu
match
potenti
cardiovascular
diseas
marker
hypertens
sex
age
smoke
statu
cholesterol
diabet
sampl
control
result
women
men
case
match
proport
malesfemal
median
age
year
old
men
case
control
respect
women
case
control
respect
result
depict
tabl
valu
express
ngml
mean
valu
everi
patient
given
time
point
higher
clinic
cut
point
establish
low
risk
ngml
interestingli
increas
mean
four
group
month
chang
haart
follow
decreas
month
differ
men
regard
abc
month
increas
men
take
abc
wherea
decreas
men
without
abc
p
women
show
differ
increas
therapi
abc
men
mi
one
year
followup
among
two
group
mean
valu
time
higher
clinic
cut
point
seem
exhibit
risk
threshold
reli
cardiovascular
marker
popul
object
although
increas
avail
antiretrovir
pretreat
patient
high
cost
short
time
sinc
approv
make
nucleosid
revers
transcriptas
inhibitor
nrti
wide
use
backbon
howev
sinc
pre
treat
patient
usual
harbor
mutat
revers
transcriptas
frequent
tenofovir
tdf
abacavir
abc
nrti
avail
sinc
report
combin
abc
tdf
an
concern
drugdrug
interact
made
retrospect
review
establish
effect
abc
plu
tdf
nrti
backbon
haart
pretreat
patient
method
singl
clinic
retrospect
studi
includ
infect
pretreat
patient
year
age
start
abctdf
irrespect
prior
haart
effect
evalu
itt
analysi
result
fortysix
patient
men
mean
age
year
median
cell
count
mean
viral
load
copiesml
among
sampl
patient
undetect
viral
load
start
combin
failur
defin
occur
patient
patient
virolog
failur
patient
resum
therapi
side
effect
drug
patient
lost
follow
patient
among
patient
undetect
viral
load
stop
therapi
median
durat
therapi
nonfailur
patient
month
month
patient
resum
therapi
stratifi
viral
load
start
therapi
found
patient
undetect
viral
load
better
chanc
keep
therapi
patient
start
detect
viral
load
vs
almost
reach
statist
signific
p
conclus
tdfabc
backbon
routin
use
hiv
pretreat
patient
howev
patient
undetect
viral
load
combin
might
use
high
chanc
success
week
followup
itt
analysi
object
despit
success
antiretrovir
therapi
art
major
patient
percentag
patient
receiv
art
sustain
lowlevel
viremia
viral
load
vl
copiesml
object
studi
determin
whether
earli
optim
treatment
base
resist
pattern
determin
patient
vl
copiesml
result
decreas
vl
undetect
level
method
laboratori
develop
method
amplifi
sequenc
proteas
retrotranscriptas
gene
plasma
patient
vl
copiesml
method
hivrna
concentr
use
rna
affin
colum
use
templat
high
fidel
rtpcr
product
sequenc
mutat
determin
analyz
use
method
studi
hiv
patient
sampl
collect
septemb
septemb
genotyp
data
obtain
patient
art
modifi
accord
resist
pattern
previou
clinic
histori
result
genotyp
determin
patient
fullfil
requir
sustain
lowlevel
viremia
resist
mutat
detect
sequenc
common
mutat
proteas
posit
common
mutat
retrotranscriptas
associ
resist
nucleosid
analog
posit
preval
mutat
associ
resist
nonnucleosid
analog
posit
genotyp
patient
receiv
optim
treatment
regimen
patient
vl
becam
undetect
one
patient
thevl
decreas
significantli
undetect
level
one
patient
vl
undetermin
patient
undergo
treatment
chang
patient
vl
decreas
undetect
level
patient
vl
remain
copiesml
patient
vl
increas
copiesml
patient
vl
undetermin
develop
method
allow
genotyp
patient
vl
copiesml
treatment
chang
base
genotyp
data
clinic
signific
sinc
vl
decreas
undetect
level
major
patient
underw
treatment
chang
method
haarttreat
pt
achiev
virolog
suppress
defin
two
consecut
plasma
hivrna
measur
copiesml
least
month
enrol
basi
rv
valu
pt
subdivid
group
pt
undetect
plasma
rna
level
ul
copyml
pt
low
level
copiesml
pt
high
level
hl
copiesml
pt
viral
blip
vb
copiesml
rv
quantifi
ultraultrasensit
method
base
modifi
amplicor
monitor
roch
molecular
system
usa
detect
limit
copyml
quantifi
total
provir
hivdna
copi
number
pbmc
real
time
taqman
protocol
publish
jp
viard
adapt
sensibl
pbmc
object
investig
whether
rapid
diagnosi
tb
mening
children
establish
interferongamma
blood
cerebrospin
fluid
test
routin
clinic
practic
assess
level
agreement
classic
laboratori
method
patient
separ
two
group
first
group
diagnosi
tb
mening
confirm
posit
cultur
csf
efficaci
treatment
second
group
nontb
mening
perform
quantiferontb
gold
tube
qftg
blood
csf
patient
result
total
children
enrol
case
diagnos
tb
mening
patient
control
group
b
f
mean
age
age
rang
month
year
symptom
physic
examin
admiss
may
suggest
tb
mening
fever
headach
vomit
neck
stiff
patient
cranial
nerv
palsi
patient
hemi
paresi
alter
mental
statu
seizur
subject
tst
posit
patient
first
group
second
csf
analys
suggest
tb
patient
pleocytosi
elementsml
high
csf
protein
level
low
csf
glucos
patient
neg
smear
posit
cultur
mean
time
interv
requir
qftg
result
hour
cultur
day
first
group
result
qftg
blood
sampl
subject
qftg
posit
qftg
neg
one
indetermin
csf
patient
posit
result
neg
indetermin
group
non
tb
mening
patient
neg
result
blood
posit
csf
subject
neg
result
indetermin
sensit
qftg
csf
blood
specif
csf
blood
posit
predict
valu
qftg
csf
blood
neg
predict
valu
csf
blood
sensit
tst
specif
sensit
cultur
csf
sensit
specif
qftg
higher
tst
cultur
better
csf
blood
determin
ginterferon
serum
csf
use
diagnost
marker
tuberculosi
could
improv
manag
tb
mening
rapid
diagnosi
earli
treatment
initi
object
treatment
latent
tuberculosi
ltbi
hiv
patient
reduc
incid
tb
interferongamma
releas
assay
igra
may
specif
diagnos
ltbi
tuberculin
skin
test
sensit
lower
count
establish
studi
effect
count
igra
result
method
tspottb
elispot
assay
incorpor
quantiferon
elisa
assay
incorpor
perform
hiv
patient
count
l
n
median
count
l
hiv
control
l
n
median
count
l
activ
tb
exclud
patient
elisa
elispot
respons
relat
patient
characterist
result
elisa
respons
posit
n
patient
l
n
l
differ
ci
p
elispot
respons
posit
among
n
patient
l
n
l
differ
ci
p
howev
multivari
regress
analysi
use
adjust
ltbi
risk
factor
origin
countri
high
tb
preval
elisa
elispot
result
independ
count
migrat
countri
high
preval
tb
cohp
associ
posit
result
multivari
analysi
cohp
posit
elisa
ci
p
posit
elispot
ci
p
inject
drug
use
incarcer
homeless
associ
posit
result
significantli
individu
risk
factor
ltbi
posit
elisa
posit
elispot
patient
one
posit
igra
result
posit
test
agreement
two
igra
moder
cohen
kappa
associ
intertest
agreement
count
origin
cohp
associ
higher
level
agreement
posit
test
conclus
elisa
elispot
respons
independ
count
disagr
test
frequent
relat
count
discord
result
common
patient
lower
pretest
probabl
ltbi
given
high
rate
posit
result
risk
factor
ltbi
may
repres
fals
posit
result
aim
ifng
releas
assay
igra
princip
develop
diagnosi
latent
tuberculosi
infect
ltbi
appear
sensit
specif
tuberculin
skin
test
igra
may
also
offer
attract
option
assist
diagnosi
activ
tb
sever
studi
publish
compar
igra
convent
diagnosi
part
ongo
assess
tb
diagnost
approach
assess
reliabl
igra
within
cohort
region
tropic
infecti
diseas
unit
tidu
object
reactiv
mycobacterium
tuberculosi
infect
major
complic
antitumor
necrosi
factor
tnfa
treatment
thu
screen
latent
tuberculosi
infect
ltbi
mandatori
start
antitnf
therapi
tst
main
disadvantag
low
specif
fals
posit
result
bcg
vaccin
subject
lower
sensit
presenc
immunosuppress
therapi
result
fals
neg
result
diagnosi
ltbi
may
benefit
new
interferongamma
releas
assay
igra
aim
studi
investig
perform
quantiferontb
gold
tube
qftgit
assay
agreement
tst
screen
ltbi
patient
immunemedi
inflammatori
diseas
candid
antitnf
therapi
method
consecut
enrol
patient
affect
rheumatoid
arthriti
n
psoriat
arthriti
n
psoriasi
n
ankylos
spondyl
n
crohn
diseas
n
behcet
diseas
n
enrol
screen
includ
clinic
evalu
chest
xray
tst
qftgit
patient
corticosteroid
andor
immunosuppress
drug
bcgvaccin
result
patient
posit
neg
indetermin
qftgit
result
patient
tst
qftgit
neg
patient
test
posit
discrep
result
tst
qftgit
agreement
two
test
k
diagnosi
ltbi
consid
case
univari
analysi
observ
associ
bcg
vaccin
discord
qftgittst
ci
p
immunosuppress
therapi
indetermin
qftgit
test
ci
p
associ
immunosuppress
therapi
discord
ci
p
found
result
show
qftgit
may
help
screen
ltbi
patient
candid
antitnfa
therapi
confirm
posit
tst
result
also
discrimin
falseneg
tst
result
consequ
previou
longterm
immunosuppress
treatment
perform
qftgit
seem
affect
immunosuppress
patient
igra
appear
offer
better
chanc
tst
monitor
tb
infect
antitnfa
therapi
object
genotyp
detect
herp
simplex
viru
hsv
resist
antivir
base
thymidin
kinas
dna
polymeras
gene
sequenc
interpret
result
requir
distinguish
resist
mutat
natur
interstrain
sequenc
variat
object
work
assess
extens
natur
polymorph
among
hsv
strain
method
three
laboratori
strain
ko
clinic
isol
studi
forti
strain
collect
patient
receiv
previou
antihsv
treatment
strain
exhibit
acyclovir
foscarnet
phenotyp
suscept
use
plaqu
reduct
assay
entir
open
read
frame
gene
sequenc
nucleotid
amino
acid
sequenc
compar
refer
strain
genbank
access
number
strain
strain
result
interstrain
ident
gene
rang
nucleotid
level
hsv
strain
investig
variant
nucleotid
strain
respect
overal
amino
acid
chang
identifi
strain
amino
acid
chang
strain
total
codon
protein
respect
analysi
gene
show
interstrain
ident
among
hsv
strain
surprisingli
strain
variant
nucleotid
evidenc
produc
silent
mutat
wherea
strain
evidenc
produc
silent
mutat
thirti
amino
acid
chang
distribut
across
dna
polymeras
describ
strain
respect
correspond
total
codon
protein
note
one
isol
harbour
delet
codon
ctermin
region
viral
protein
amino
acid
chang
identifi
lie
within
nonconserv
region
result
show
thymidin
kinas
dna
polymeras
highli
conserv
among
hsv
strain
weaker
variabl
strain
besid
previous
describ
mutat
number
previous
undescrib
natur
variat
identifi
work
provid
natur
polymorph
map
among
strain
help
hsv
genotyp
antivir
resist
test
base
phylogenet
analysi
genom
organ
hbov
classifi
parvovirida
famili
hbov
preval
children
worldwid
seem
associ
respiratori
tract
ill
acut
gastroenter
one
three
slightli
differ
genet
lineag
report
among
hbov
isol
worldwid
aim
present
studi
determin
preval
hbov
analysi
hbov
phylogeni
children
suffer
acut
respiratori
tract
ill
acut
gastroenter
nritld
iran
method
clinic
sampl
collect
patient
includ
exacerb
asthma
case
case
respiratori
tract
ill
gastroenter
case
specimen
immedi
transport
cold
box
virolog
laboratori
virolog
research
center
treat
store
use
screen
nest
pcr
perform
use
primer
code
region
posit
sampl
subject
sequenc
gene
junction
phylogenet
molecular
evolutionari
analys
conduct
use
mega
version
hbov
detect
rang
differ
clinic
present
hbov
detect
children
less
year
age
cold
season
statist
differ
observ
age
group
season
distribut
hbov
asthma
exacerb
case
p
gastroenter
p
respect
howev
high
nucleotid
ident
hbov
sequenc
phylogenet
analysi
result
genet
group
figur
nucleotid
posit
variabl
compar
swedish
refer
strain
access
number
transit
transvers
amino
acid
level
sequenc
ident
among
isol
two
chang
found
codon
codon
v
figur
conclus
studi
first
research
phylogenet
analysi
hbov
isol
children
acut
respiratori
tract
ill
gastroenter
iran
phylogenet
analysi
base
gene
junction
show
exist
differ
genet
group
among
hbov
isol
cocircul
iranian
popul
hbov
iran
distribut
among
three
group
show
hbov
highli
conserv
specificgeograph
variat
major
abmu
strain
divers
mssa
contain
strain
spatyp
new
spatyp
sacu
cohort
compris
predomin
clone
n
confirm
pfge
presenc
acm
clone
includ
n
n
n
two
new
spatyp
encount
mrsa
mssa
assign
pend
resist
strain
n
oxacillin
gentamicin
tobramycin
erythromycin
clindamycin
tetracyclin
trimethoprim
tmpsmz
ciprofloxacin
fusid
acid
dtest
reveal
induc
clindamycin
resist
cr
constitut
cr
clindamycin
sensit
strain
erythromycin
resist
strain
signific
differ
seen
sacuabmu
cohort
strain
oxacillin
gentamicin
tetracyclin
p
strike
differ
antibiot
resist
clonal
composit
two
cohort
preval
clone
sacu
cohort
global
distribut
clone
also
repres
none
clone
found
unselect
abmu
cohort
molecular
epidemiolog
analysi
strain
submit
referr
unit
provid
valuabl
inform
need
confirm
investig
unselect
isol
area
ganner
mccormick
smith
c
perri
bd
cookson
mj
ellington
london
uk
object
whilst
role
pvl
staphylococc
diseas
remain
contenti
associ
pvlposit
aureu
pvlsa
recurr
skin
soft
tissu
infect
compel
follow
introduct
initi
enhanc
ascertain
pvlrelat
diseas
england
sought
investig
clinic
epidemiolog
featur
pyogen
skin
infect
caus
pvlposit
versu
pvlneg
aureu
method
isol
aureu
submit
refer
nation
staphylococcu
refer
unit
sru
recov
pyogen
skin
infect
boil
abscess
carbuncl
etc
patient
throughout
england
wale
northern
ireland
includ
studi
isol
characteris
toxin
gene
profil
includ
pvl
meca
test
dna
fingerprint
pulsedfield
gel
electrophoresi
patient
demograph
data
clinic
featur
includ
site
lesion
recurr
infect
analys
result
total
isol
aureu
pyogen
skin
infect
submit
sru
characteris
mssa
mrsa
respect
patient
age
median
male
femal
ratio
total
isol
pvlposit
major
mssa
comparison
case
accord
pvl
statu
show
pvlsa
recov
younger
cohort
median
commonli
associ
buttock
thigh
andor
axilla
lesion
case
contrast
pvlneg
sa
associ
older
individu
median
lesion
wide
rang
bodi
site
commonest
site
breast
back
recurr
infect
appar
among
pvl
group
vs
case
multipl
strainslineag
identifi
differ
clone
pvlmrsa
identifi
lineag
european
south
west
pacif
clone
predomin
conclus
pvlsa
pyogen
skin
infect
predominantli
occur
younger
individu
commonli
affect
buttock
andor
axilla
third
infect
recurr
data
import
implic
recognis
diagnos
manag
infect
commun
concomit
preval
communityand
healthcareassoci
mrsa
among
resid
staff
longterm
care
facil
northern
israel
mj
masarwa
navonvenezia
kandlik
chmelnitski
g
smollan
r
glick
g
neria
carm
tel
aviv
safe
il
background
longterm
care
facil
ltcf
import
reservoir
mrsa
determin
preval
molecular
characterist
mrsa
among
resid
staff
ltcf
northern
israel
method
nasal
swab
obtain
resid
staff
ltcf
februarymay
mrsa
identifi
via
growth
mrsa
plate
coagulas
product
definit
identif
antibiot
suscept
determin
vitek
genet
related
strain
determin
spatyp
multilocu
sequenc
type
mlst
pulsedfield
gel
electrophoresi
pfge
sccmec
type
perform
via
multiplex
pcr
pantonvalentin
leukocidin
pvl
gene
test
pcr
result
total
resid
male
median
age
staff
member
male
median
age
screen
mrsa
isol
resid
staff
member
major
mrsa
strain
carri
among
resid
isol
institut
healthcareassoci
ha
mrsa
strain
sccmec
type
ii
hamrsa
strain
also
carri
among
staff
isol
institut
hamrsa
untyp
sccmec
found
well
among
staff
isol
addit
institut
resid
mrsa
carrier
addit
mrsa
strain
preval
among
staff
institut
isol
communityassoci
ca
mrsa
strain
untyp
sccmec
isol
grown
camrsa
strain
detect
one
resid
isol
institut
strain
found
among
staff
member
tabl
mrsa
isol
lack
pvl
gene
conclus
mrsa
highli
preval
among
resid
staff
ltcf
northern
israel
contrari
priori
assumpt
molecular
analysi
reveal
littl
connect
mrsa
among
staff
among
resid
argu
transmiss
mrsa
strain
camrsa
phenotyp
preval
among
staff
rare
among
patient
two
gram
soilcompost
suspend
ml
tween
ml
plate
sabouraud
agar
ml
glucos
agar
contain
itraconazol
mgl
voriconazol
mgl
posaconazol
mgl
antifung
respect
incub
identif
aspergilli
base
standard
microand
macromorpholog
criteria
aspergillu
isol
grew
azol
contain
agar
underw
suscept
test
use
eucast
edef
microdilut
method
itraconazol
posaconazol
voriconazol
btubulin
sequenc
unless
abl
grow
promot
entir
code
sequenc
gene
sequenc
azol
resist
isol
object
emerg
multidrug
resist
aspergillu
fumigatu
af
caus
invas
aspergillosi
rais
question
whether
evolut
azoleresist
impact
virul
therefor
clinic
outcom
aim
studi
determin
whether
acquir
azol
resist
fungi
mutat
unknown
gene
come
cost
fit
virul
studi
includ
multiazol
resist
af
clinic
isol
differ
mutat
gene
strain
b
wildtyp
azol
suscept
wt
strain
refer
c
isogen
isol
mutat
suscept
resist
strain
serial
recov
singl
patient
preand
postantifung
treatment
microsatellitetyp
method
cspmethod
perform
verifi
genet
relationship
isol
suscept
test
perform
base
method
rtpcr
perform
determin
express
vitro
growth
rate
determin
use
previous
ollivi
aac
analyz
sequenc
hotspot
region
fk
gene
initi
isol
also
analyz
avail
serial
isol
genotyp
use
polymorph
microsatellit
marker
medic
chart
patient
harbour
isol
review
result
episod
involv
isol
reduc
suscept
caspofungin
patient
sex
ratio
f
mean
age
diagnos
candidemia
n
invas
infect
n
oropharyng
candidiasi
n
underli
diseas
hematolog
malign
n
solid
organ
transplant
n
hiv
infect
n
condit
n
candida
speci
c
albican
c
glabrata
c
krusei
isol
recov
patient
treat
caspofungin
durat
rang
day
sever
month
mutat
fk
gene
among
patient
previou
isol
avail
pair
isol
share
ident
genotyp
furthermor
pair
isol
recov
caspofungin
treatment
higher
suscept
mic
mgml
caspofungin
second
one
wildtyp
fk
gene
conclus
caspofungin
resist
candida
spp
alway
associ
prior
exposur
drug
sever
ill
patient
analysi
uncov
factor
treatment
durat
influenc
occurr
invas
infect
due
variou
speci
candida
spp
acquir
reduc
suscept
caspofungin
deserv
attent
innov
multiplex
diagnost
candida
spp
use
mlpa
g
r
boesten
c
klaassen
reijan
j
mei
boekhout
g
simon
maastricht
utrecht
nijmegen
nl
object
candida
yeast
fourth
common
sourc
nosocomi
bloodstream
infect
especi
last
decad
preval
opportunist
candida
infect
increas
becom
seriou
threat
high
risk
patient
date
molecular
diagnost
tool
base
ribosom
region
although
broadli
appli
target
gene
difficulti
discrimin
close
relat
speci
caus
misidentif
underestim
polymicrobi
infect
result
urgent
need
high
discriminatori
accur
detect
method
clinic
purpos
use
novel
probe
aim
project
improv
molecular
diagnost
yeastrel
infect
method
novel
dna
base
diagnost
system
use
multiplex
ligationdepend
probe
amplif
mlpa
technolog
serv
platform
molecular
diagnost
use
newli
develop
diagnost
probe
candidamlpa
assay
contain
probe
c
albican
c
dubliniensi
c
krusei
c
tropicali
c
parapsilosi
c
glabrata
c
guilliermondii
c
lusitania
develop
result
specif
assay
valid
candidanoncandida
spp
cb
fungal
biodivers
centr
addit
clinic
isol
screen
mlpa
assay
result
compar
aflp
profil
case
discord
ident
strain
establish
sequenc
region
furthermor
total
screen
encompass
phylogenet
relat
speci
includ
candida
spp
pichia
spp
cerevisia
candidamlpa
assay
show
concord
sequenc
analyt
sensit
candidamlpa
assay
establish
fg
gdna
repres
less
two
yeast
cell
conclus
demonstr
assay
base
upon
mlpa
technolog
abl
identifi
candida
spp
one
reaction
multipl
infect
speci
one
sampl
could
identifi
due
natur
mlpa
technolog
highli
complex
assay
possibl
provid
room
addit
probe
like
gener
candida
probe
probe
emerg
speci
specif
sensit
multiparamet
assay
show
great
potenti
fast
comprehens
screen
approach
clinic
relev
candida
spp
diagnost
set
object
defin
specif
etiolog
fungal
infect
critic
select
appropri
antifung
therapi
morpholog
identif
fungi
take
day
week
requir
experienc
mycologist
sequenc
base
identif
fungi
could
expedit
identif
estim
fungal
sequenc
deposit
ncbi
incorrect
reliabl
databas
clinic
relev
fungal
sequenc
critic
advanc
molecular
diagnosi
fungal
infect
purpos
studi
compar
morpholog
identif
sequenc
identif
fungi
isol
clinic
sampl
hospit
st
loui
children
hospit
identifi
base
morpholog
andor
biochem
characterist
dna
extract
fungi
use
bd
geneohm
kit
min
lysi
follow
heat
c
min
region
isol
amplifi
pcr
product
bidirect
sequenc
abi
trim
sequenc
align
sequenc
ncbi
nrnt
databas
use
blast
filament
fungi
yeast
genera
speci
includ
studi
result
isol
sequenc
morpholog
identif
match
sequenc
base
identif
morpholog
sequenc
base
identif
dispar
case
isol
sequencebas
identif
equivoc
morpholog
identif
found
top
ten
hit
sequenc
databas
morpholog
identif
first
choic
choic
equal
probabl
match
sequenc
identif
perform
well
yeast
speci
filament
fungi
aspergillu
scedosporium
fusarium
spp
sequenc
identif
accur
identif
dermatophyt
zygomycet
dematiac
mould
conclus
use
ncbi
sequenc
databas
identif
clinic
isol
fungi
may
result
incorrect
identif
administr
appropri
antifung
therapi
data
compil
databas
fungal
sequenc
conduct
challeng
experi
identif
clinic
isol
legionella
pneumophila
human
pathogen
recogn
year
ago
caus
agent
legionnair
diseas
sever
pneumonia
transmit
inhal
aerosol
contamin
water
shortli
discoveri
abil
legionella
multipli
intracellularli
fresh
water
protozoa
discov
long
last
coevolut
eukaryot
host
legionella
led
select
panopli
virul
factor
allow
exploit
import
cellular
process
infect
compel
evid
import
protozoa
evolut
bacterium
come
analysi
complet
genom
sequenc
key
featur
l
pneumophila
genom
presenc
high
number
wide
varieti
eukaryot
like
protein
protein
domain
probabl
acquir
horizont
gene
transfer
andor
converg
evolut
last
year
sever
differ
type
method
aim
investig
molecular
epidemiolog
l
pneumophila
develop
furthermor
access
whole
genom
sequenc
sever
l
pneumophila
strain
allow
appli
larg
scale
compar
genom
studi
use
dna
array
higher
genet
divers
among
environment
isol
respect
clinic
isol
presenc
specif
clone
l
pneumophila
overrepres
human
diseas
caus
legionellosi
world
wide
identifi
recent
appli
new
gener
sequenc
investig
evolutionari
histori
popul
structur
worldwid
distribut
epidem
endem
clone
l
pneumophila
pari
well
newli
emerg
clone
lorrain
interest
dialogu
intracellular
pathogen
eukaryot
host
cell
better
understand
pathogen
commun
host
studi
bacteri
protein
function
manipul
host
cellular
process
lectur
describ
protein
produc
intracellular
pathogen
legionella
pneumophila
deliv
eukaryot
cell
special
type
iv
secret
system
bacteri
protein
function
prevent
fusion
lysosom
vacuol
contain
l
pneumophila
promot
fusion
pathogenoccupi
vacuol
endoplasm
reticulumderiv
vesicl
sever
bacteri
protein
modul
activ
small
gtpbind
protein
belong
arf
rab
famili
biochem
activ
bacteri
effector
protein
specif
host
target
discuss
million
individu
industri
nation
travel
develop
world
year
estim
million
peopl
resid
outsid
countri
birth
recent
year
growth
intern
travel
estim
approxim
per
year
european
travel
repres
vast
major
intern
travel
travel
medicin
focu
protect
health
individu
protect
wider
commun
individu
live
work
travel
initi
deriv
infecti
diseas
tropic
medicin
specialti
encompass
primari
care
migrant
medicin
occup
medicin
wilder
medicin
well
intern
health
travel
spread
new
reemerg
infecti
diseas
initi
appear
develop
countri
act
ideal
sentinel
earli
detect
diseas
past
decad
global
public
health
commun
face
challeng
brought
emerg
rapid
worldwid
spread
novel
influenza
strain
sar
chikungunya
viru
drugresist
tuberculosi
amongst
pathogen
modern
transport
growth
tourism
immigr
busi
travel
factor
contribut
dissemin
high
impact
pathogen
special
traveltrop
medicin
clinic
europ
ideal
situat
effect
detect
emerg
infect
track
ongo
trend
travelrel
ill
emerg
agent
collabor
laboratori
microbiolog
past
decad
global
region
providerbas
surveil
network
emerg
provid
first
time
systemat
robust
data
defin
spectrum
ill
place
exposur
signific
health
risk
face
travel
infect
control
zero
toler
zero
toler
imposs
task
declin
arsen
antibiot
treat
infect
increasingli
clear
tradit
orient
toward
control
hai
hospit
acquir
infect
need
shift
one
prevent
occurr
prioriti
throughout
institut
global
capac
polit
financi
manageri
technic
support
need
worldwid
initi
consider
address
diseas
like
smallpox
polio
measl
dracunculiasi
lymphat
filariasi
onchocerciasi
chaga
diseas
hansen
diseas
target
erad
model
nt
exactli
work
hai
deal
mani
differ
organ
type
infect
human
reservoir
mani
organ
normal
flora
rel
limit
scientif
oper
resourc
actual
dedic
prevent
hai
new
technolog
procedur
virul
pathogen
increas
resist
continu
challeng
healthcar
commun
effort
reduc
hai
one
look
theoret
infect
occur
one
could
divid
two
main
group
prevent
one
prevent
prevent
implement
practic
behavior
procedur
follow
strict
clinic
pathway
other
probabl
prevent
irreduc
amount
get
zero
movement
product
three
forc
expans
extern
pressur
infect
control
program
intrus
suboptim
evid
converg
qualiti
improv
infect
control
zero
obsess
number
worrisom
unintend
consequ
set
unrealist
expect
part
public
healthcar
administr
lead
unreason
demand
infect
control
program
foster
punit
cultur
sinc
someon
must
fault
caus
infect
separ
infect
control
safeti
qualiti
infect
control
concern
trump
import
safeti
issu
shift
develop
intervent
away
approach
base
local
risk
assess
promot
onesizefitsal
approach
healthcar
worker
hospit
epidemiologist
becom
demor
expect
get
zero
persist
elus
zero
attain
concept
target
zero
hai
controversi
mani
peopl
believ
set
unrealist
imposs
expect
hai
prevent
hai
may
occur
due
error
broken
process
target
zero
problemat
address
variat
risk
hai
differ
patient
popul
set
address
denomin
time
frame
necessari
understand
rate
infect
inher
seem
scientif
unrealist
get
zero
sound
bite
mislead
public
help
hospit
epidemiologist
zero
approach
hai
rigid
dishonest
antiintellectu
dive
cultur
blame
emerg
spread
pandem
viru
anim
reservoir
rais
question
futur
approach
influenzaviru
infect
evid
demonstr
influenzaviru
gene
migrat
across
contin
anim
speci
assembl
combin
threat
anim
human
health
result
panzoot
like
pandem
like
latter
contain
uniqu
combin
gene
three
speci
two
hemispher
global
environ
map
gene
movement
across
speci
nation
border
identifi
mutat
gene
constel
pandem
potenti
virul
determin
essenti
enact
prevent
control
strategi
global
level
line
possibl
best
exampl
one
health
vision
multidisciplinari
collabor
approach
improv
health
human
anim
environ
endors
un
food
agricultur
organis
world
organis
anim
health
oie
world
health
organis
vast
improv
capac
build
achiev
result
global
crisi
thousand
viral
isol
zoonot
potenti
obtain
surveil
effort
although
genet
inform
exploit
fulli
addit
circul
influenzavirus
certain
speci
includ
dog
pig
hors
neglect
time
come
invest
novel
approach
influenzaviru
infect
abandon
prefix
compart
link
geograph
origin
speci
isol
analys
influenza
gene
pool
one
entiti
propos
capitalis
exist
achiev
invest
develop
intern
network
perman
observatori
improv
understand
dynam
influenzaviru
gene
pool
anim
human
gener
essenti
inform
support
public
anim
health
one
flu
initi
would
result
intern
synergi
bridg
gap
medic
veterinari
scientist
perman
monitor
viru
evolut
epidemiolog
best
exploit
invest
capac
build
could
challeng
opportun
implement
one
health
vision
possibl
act
model
emerg
zoonot
diseas
p
c
miossec
girard
l
lavallad
black
shlae
j
pace
k
coleman
romainvil
fr
connecticut
philadelphia
us
object
novel
blactamas
inhibitor
shown
vitro
vivo
inhibit
class
class
c
blactamas
current
phase
clinic
develop
combin
ceftazidim
caz
result
macrodilut
mic
valu
mgl
tigecyclin
mgl
colistin
mgl
meropenem
timekil
assay
tigecyclin
meropenem
singl
agent
mostli
bacteriostat
first
hour
incub
bacteri
regrowth
follow
colistin
alon
ineffect
tigecyclin
plu
colistin
combin
case
bactericid
h
incub
case
also
synergist
compar
tigecyclin
alon
although
bacteri
regrowth
observ
h
tigecyclin
plu
meropenem
combin
case
also
bactericid
h
incub
thereaft
regrowth
observ
result
present
studi
indic
tigecyclin
alon
could
therapeut
option
infect
due
multidrug
resist
kpc
produc
bacteriostat
activ
adequ
combin
colistin
meropenem
bactericid
activ
necessari
addit
vivo
test
may
warrant
fulli
assess
kill
kinet
tigecyclin
kpc
produc
immun
system
compet
enterobacteriacea
mushtaq
warner
jc
zhang
maharjan
doumith
n
livermor
london
uk
object
recent
carbapenem
retain
nearunivers
activ
enterobacteriacea
resist
emerg
mediat
either
combin
esbl
ampc
enzym
porin
loss
carbapenemas
preval
emerg
carbapenemas
vari
countri
kpc
enzym
usa
israel
turkey
vim
southern
europ
ndm
itali
uk
see
small
number
isol
type
import
repres
domest
spread
multiresist
examin
suscept
temocillin
deriv
ticarcillin
notabl
stabil
esbl
ampc
method
isol
test
isol
various
kpc
n
imp
vim
ndm
carbapenemas
combin
imperm
ampc
enzym
esbl
includ
klebsiella
spp
enterobact
spp
e
coli
other
transform
transconjug
prepar
e
coli
respect
carbapenemas
gene
identifi
pcr
sequenc
mic
measur
clsi
agar
dilut
result
mic
isol
kpc
carbapenemas
mgl
geom
mean
mgl
introduct
kpc
plasmid
e
coli
rais
mic
mgl
contrast
mic
isol
metalloblactamas
mgl
case
introduct
plasmid
code
ndn
carbapenemas
commonest
mbl
uk
e
coli
rais
temocillin
mic
mgl
temocillin
mic
isol
enzym
mgl
case
mic
shift
transform
e
coli
mgl
temocillin
mic
isol
combin
porin
loss
ampc
esbl
mgl
geom
mean
mgl
conclus
dosag
rais
present
g
bd
temocillin
may
therapeut
option
infect
due
enterobacteriacea
kpc
carbapenemas
combin
ampc
esbl
porin
loss
metallocarbapenemas
p
lassaux
h
gulea
kupper
k
hoffmann
galleni
c
aachen
de
caen
fr
object
metalloblactamas
mbl
repres
emerg
problem
due
capac
hydrolyz
almost
blactam
antibiot
includ
last
gener
cephalosporin
carbapenem
due
presenc
two
chelat
function
sulfanyl
phosphonato
mercaptophosphon
acid
phosphor
analogu
mercaptocarboxyl
acid
potenti
candid
mbl
inhibitor
inhibitori
effect
mercaptophosphon
deriv
repres
three
subclass
mbl
cpha
previous
report
order
determin
interact
mediat
posit
inhibitor
activ
site
enzym
crystallograph
dock
studi
perform
inhibitor
activ
three
subclass
crystallograph
structur
indic
sulphur
atom
phosphonato
group
interact
zinc
ion
respect
molecular
model
enzym
also
brought
light
differ
bind
mode
depend
enzym
inhibitor
consist
crystallograph
structur
investig
mercaptophosphon
deriv
mbl
inhibitor
allow
us
find
potent
inhibitor
activ
repres
member
three
mbl
subclass
moreov
basi
structur
model
data
inhibitori
strength
compound
improv
refer
lassaux
p
hamel
gulea
mercuri
p
horsfal
l
bebron
c
gaumont
ac
j
galleni
mercaptophosphon
compound
broadspectrum
inhibitor
metalloblactamas
abstract
number
ecsmid
weisser
hohler
r
frei
stern
aarau
basel
ch
object
invas
fungal
infect
ifi
major
caus
morbid
mortal
hematolog
patient
emerg
nonaspergillu
mold
observ
recent
year
hormographiella
aspergillata
basidiomycet
previous
implic
human
infect
rare
describ
case
ifi
h
aspergillata
occur
within
one
year
hematolog
ward
univers
hospit
basel
method
patient
hospit
singl
room
special
higheffici
particl
air
filter
surveil
fungal
cultur
air
filter
carri
regularli
primari
mold
prophylaxi
perform
screen
mold
infect
perform
twice
weekli
measur
serum
galactomannan
weekli
pulmonari
ct
scan
sabouraud
agar
inocul
fungal
cultur
identif
h
aspergillata
cultur
molecularli
confirm
suscept
test
perform
etest
improv
microbi
document
febril
neutropenia
impact
implement
automat
ward
addit
dnaemia
detect
c
hicheri
bastujigarin
c
corbel
bretagn
l
gregoir
e
sbidian
mauri
c
cordonni
e
cambau
creteil
pari
fr
object
febril
neutropenia
fn
frequent
complic
highdos
chemotherapyinduc
neutropenia
fn
episod
microbiolog
document
routin
procedur
mainli
blood
cultur
bc
wonder
whether
shorten
time
incub
could
improv
figur
addit
search
microbi
dna
septifast
test
method
adult
patient
elig
fn
episod
neutropen
pmn
l
febril
twice
within
h
central
venou
cathet
cvc
onset
fever
collect
bc
bottl
aerob
anaerob
sampl
cvc
immedi
incub
ward
septifast
perform
ml
blood
sampl
time
parallel
standard
bc
aerob
anaerob
bottl
routin
sampl
cvc
peripher
sent
laboratori
incub
patient
assess
microbi
document
blood
either
bc
posit
dna
detect
time
elaps
blood
sampl
document
latter
posit
pairwis
analys
perform
use
mcnemar
test
document
rate
wilcoxon
signedrank
test
time
posit
result
consecut
fn
episod
includ
feb
mar
acut
leukemiamyelodysplasia
lymphoid
malign
other
episod
allogen
autolog
stem
cell
transplant
rate
bc
posit
episod
studi
process
episod
routin
process
mcnemar
c
p
microbiolog
document
episod
time
elaps
incub
posit
significantli
shorter
bc
bottl
incub
ward
median
rank
min
routin
bc
bottl
median
rank
min
p
septifast
test
posit
episod
posit
also
bc
test
addit
episod
septifast
test
show
low
dna
content
threshold
nevertheless
concord
posit
bc
conclus
immedi
incub
blood
cultur
ward
detect
dnaemia
septifast
test
improv
rate
microbi
document
fn
episod
compar
bc
routin
process
howev
reduc
time
posit
object
ophthalmolog
patient
prone
nosocomi
infect
due
advanc
age
common
underli
medic
condit
eye
infect
caus
multidrug
resist
mdr
pathogen
may
contribut
loss
vision
alreadi
visual
disabl
person
antimicrobi
therapi
often
difficult
due
unsatisfactori
penetr
mani
agent
eye
empir
therapi
base
data
compris
preval
pathogen
includ
mdr
pathogen
method
specimen
bacteriolog
fungal
cultur
obtain
patient
hospit
ophthalmolog
hospit
result
sixti
four
patient
assess
mean
age
year
without
differ
distribut
gender
preval
infect
case
per
inhabit
year
seventi
per
cent
patient
chronic
underli
diseas
cirrhosi
liver
hematolog
neoplasm
chronic
debilit
condit
collagen
vascular
diseas
solid
neoplasm
common
underli
condit
pregnant
woman
seen
primari
bacteremia
meningoenceph
common
present
addit
patient
develop
focal
bacteri
periton
endocard
brain
abscess
although
infect
communityacquir
episod
develop
within
hospit
h
admiss
nosocomi
outbreak
detect
ampicillin
alon
combin
gentamicin
cotrimoxazol
antimicrobi
regimen
frequent
use
find
differ
mortal
rate
among
patient
monotherapi
combin
therapi
cotrimoxazol
success
use
patient
treat
nineteen
patient
die
within
diagnosi
mortal
significantli
higher
patient
hematolog
solid
neoplasm
cirrhosi
underli
debilit
disord
vs
p
patient
without
comorbid
surviv
infect
conclus
human
listeriosi
sever
diseas
still
produc
high
mortal
particularli
immunocompromis
host
hematolog
solid
neoplasm
debilit
condit
despit
synergist
vitro
activ
combin
ampicillin
plu
gentamicin
determin
surviv
benefit
cotrimoxazol
may
use
altern
antimicrobi
therapi
human
listeriosi
taiwan
cellul
mean
pitt
bacterem
score
rang
score
score
patient
systol
blood
pressur
mmhg
conscious
chang
note
patient
leucocytosi
note
patient
mean
valu
white
blood
cell
count
rang
mean
valu
creactiv
protein
mgdl
third
gener
antibiot
commonli
use
empir
treatment
regimen
amoxicillinclavunal
acid
mean
hospit
stay
day
caus
mortal
day
n
n
day
campylobact
coli
lead
speci
caus
invas
campylobacteriosi
immunocompromis
patient
taiwan
antifung
drug
improv
surviv
immunomodul
rather
reduct
fungal
burden
experiment
cerebr
aspergillosi
surviv
time
anim
treat
lamb
alon
differ
untreat
control
fungal
cultur
cerebr
fungal
burden
declin
time
anim
includ
untreat
one
interestingli
signific
differ
control
treat
anim
gm
gm
peak
later
cfu
count
treatment
group
except
lamb
signific
differ
gm
indic
regard
treatment
time
cytokin
infect
ifng
tnfa
fig
b
level
significantli
higher
anim
treat
lamb
alon
compar
ca
p
vcz
p
differ
found
undetect
anim
elev
sever
diseas
conclus
lethal
model
cerebr
aspergillosi
mortal
determin
antifung
drug
effect
cerebr
fungal
burden
modul
host
immun
respons
treatment
group
consist
mice
test
group
treat
clavulan
mgkg
alon
imipenem
mgkg
meropenem
mgkg
alon
combin
clavulan
wherea
posit
control
group
treat
isoniazid
mgkg
neg
control
group
held
without
treatment
end
treatment
surviv
mice
sacrif
lung
harvest
treatment
efficaci
assess
surviv
rate
spleen
weight
lung
cfu
count
result
end
week
mortal
rate
follow
untreat
isoniazid
clavulan
imipenem
meropenem
imipenemclavulan
meropenemclavulan
combin
imipenem
meropenem
plu
clavulan
significantli
improv
surviv
p
vs
untreat
mice
hand
imipenem
meropenem
combin
clavulan
prevent
splenomegali
mg
wherea
isoniazid
mg
p
among
group
mice
surviv
isoniazid
reduc
lung
cfu
count
log
cfu
vs
penemclavulan
combin
prevent
bacteri
growth
log
cfu
vs
conclus
although
less
activ
isoniazid
combin
imipenem
meropenem
clavulan
improv
surviv
mice
infect
tuberculosi
evalu
c
badiou
rousseau
hayez
mahi
g
lina
f
vandenesch
j
etienn
p
bret
p
chavanet
dijon
lyon
pari
fr
object
mani
strain
aureu
harbour
panton
valentin
leukotoxin
pvl
phage
caus
sever
necrotis
pneumonia
young
immunocompet
patient
vitro
studi
show
antistaphylococc
drug
induc
inhibit
pvl
product
anim
model
need
evalu
new
treatment
strategi
infect
compar
efficaci
antibiot
human
therapi
sever
model
pvl
necrot
pneumonia
rabbit
method
isogen
fullysuscept
aureu
strain
use
induc
pneumonia
pvl
anim
random
treatment
control
h
iv
human
equival
dosag
either
vancomycin
va
continu
perfus
mgl
cloxacillin
clox
h
clindamycin
cli
h
linezolid
lzo
h
serum
level
measur
microbiolog
assay
hplc
pharmacokinet
data
obtain
evalu
efficaci
base
bacteri
count
lung
residu
quantiti
pvl
mgresidu
cfu
result
sever
inocula
test
perfect
model
result
inoculum
log
cfuml
tabl
control
mortal
rate
bacteri
content
control
pvl
group
colonis
abil
test
colonis
larg
intestin
streptomycin
treat
mice
differ
colonis
competit
inocul
procedur
test
model
result
ibd
strain
increas
growth
rate
compar
e
coli
healthi
person
e
coli
nissl
strain
likewis
ibd
strain
increas
adhes
capac
cell
adhes
assay
anim
model
strain
abl
colonis
gastrointestin
tract
high
level
inocul
alon
competit
probiot
nissl
strain
ibd
strain
cocolonis
though
log
higher
cfug
faec
nissl
inocul
equal
high
level
e
coli
nissl
inocul
high
level
compar
ibd
strain
low
level
strain
also
cocolonis
end
experi
e
coli
strain
healthi
person
also
cocolonis
e
coli
nissl
intestin
mice
stabilis
log
lower
nissl
strain
inocul
equal
high
level
two
log
lower
inocul
lower
level
e
coli
nissl
conclus
ibd
strain
increas
growth
rate
adhes
abil
compar
e
coli
isol
healthi
person
e
coli
nissl
furthermor
e
coli
ibd
patient
increas
abil
cocolonis
probiot
e
coli
nissl
strain
new
drug
candid
aureu
pk
paramet
safeti
c
soulama
f
moreau
v
gerusz
l
durant
pari
romainvil
fr
background
novel
antistaphylococc
agent
target
essenti
enzym
fabi
present
key
properti
vivo
efficaci
preclin
pharmacokinet
safeti
final
pharmacolog
data
phase
method
standard
procedur
use
evalu
pk
paramet
preclin
safeti
sudi
conduct
mice
rat
dog
glp
condit
vivo
assay
perform
use
mice
model
septicaemia
thigh
infect
use
methicillinsuscept
non
suscept
aureu
mssa
mrsa
linezolid
vancomycin
use
compar
phase
ascend
dose
formul
hpbcd
administr
healthi
volunt
iv
infus
result
pk
studi
speci
indic
given
iv
rapidli
clear
blood
h
molecul
well
distribut
among
tissu
without
accumul
thigh
infect
model
mrsa
strain
singl
sc
administr
mean
static
dose
mgkgd
neutropen
mice
mgkgd
immunocompet
mice
mous
septicaemia
model
use
singl
sc
administr
mean
mssa
atcc
mgkgday
mrsa
strain
mean
mgkgday
mgkgday
gisa
strain
glp
safeti
studi
rat
dog
affect
cv
cn
respiratori
function
phase
administr
singl
intra
venou
dose
mgd
mg
safe
conclus
novel
highli
potent
antistaphylococc
agent
clean
safeti
profil
properti
support
promis
candid
novel
drug
treat
sever
staphylococc
infect
object
novel
siderophor
monocycl
blactam
belong
sulfactam
evalu
vitro
antimicrobi
activ
compound
panel
escherichia
coli
clinic
isol
studi
efficaci
periton
sepsi
mice
caus
esblproduc
strain
e
coli
antimicrobi
activ
test
strain
wild
type
esblproduc
mic
determin
use
agar
dilut
muellerhinton
agar
supplement
bipyridyl
induc
iron
transport
vivo
efficaci
evalu
e
coli
strain
use
lethal
periton
sepsi
model
neutropen
icr
mice
surviv
monitor
seven
day
infect
e
coli
inocula
rang
cfumous
x
administ
intraperiton
time
daili
day
dose
mgkg
mgkg
follow
infect
salin
administ
untreat
control
group
meropenem
administ
treat
control
group
result
wild
type
esblproduc
e
coli
mgl
respect
rang
mgl
respect
mic
esbl
coli
use
mous
model
mgl
vivo
experi
mice
infect
intraperiton
variou
e
coli
inocula
show
dose
mgkg
mgkg
confer
protect
similar
meropenem
surviv
surviv
placebo
group
conclus
effect
antibacteri
agent
clinic
isol
e
coli
includ
esblproduc
strain
highli
effect
treatment
infect
caus
esblproduc
e
coli
demonstr
mice
peritonitissepsi
model
object
novel
sisomicin
deriv
stabl
nearli
aminoglycosidemodifi
enzym
compar
activ
aminoglycosid
vs
clinic
enterobacteriacea
repres
divers
carbapenem
resist
type
emerg
uk
multiresist
method
isol
compris
class
carbapenemas
kpc
n
class
b
enzym
imp
vim
ndm
class
enzym
combin
imperm
plu
ampc
esbl
includ
klebsiella
spp
enterobact
spp
e
coli
other
carbapenemas
gene
identifi
pcr
sequenc
encod
rrna
methylas
arma
rmtac
mic
measur
clsi
agar
dilut
result
activ
nonndm
isol
mgl
mic
mgl
isepamicin
activ
mgl
wherea
resist
gentamicin
mgl
tobramycin
mgl
amikacin
mgl
respect
among
isol
enzym
mani
patient
prior
medic
contact
indian
subcontin
harbour
arma
rmtc
resist
humanus
aminoglycosid
mgl
arma
rmtc
absent
sole
strain
apramycin
veterinari
analogu
activ
mgl
control
strain
ii
isol
arma
rmtc
iii
strain
except
serratia
enzym
mic
mgl
conclus
potent
activ
vs
carbapenemresist
isol
screen
except
combin
enzym
arma
rmtc
rrna
methylas
intern
preval
enzym
need
urgent
surveil
evas
arma
rmtc
apramycin
strike
may
facilit
futur
human
drug
develop
object
ever
increas
resist
pathogen
bacteria
toward
current
arsen
antimicrobi
therapeut
emphas
urgent
requir
develop
novel
agent
current
estim
clinic
infect
also
biofilm
associ
therefor
agent
effect
multipli
resist
biofilm
form
would
extrem
advantag
aim
current
studi
assess
effect
novel
antimicrobi
agent
rang
pathogen
bacteria
clinic
isol
staphylococcu
epidermidi
display
methicillin
resist
biofilm
phenotyp
method
defer
antagon
method
use
assess
rang
activ
select
pathogen
gramposit
gramneg
bacteria
tradit
biofilm
form
assay
also
employ
use
prepar
inhibitori
activ
auml
coat
microtitr
well
also
treat
matur
hour
biofilm
defer
antagon
assay
show
good
activ
rang
gramposit
pathogen
includ
vancomycin
resist
enterococci
methicillin
resist
staphylococcu
aureu
streptococcu
pneumonia
streptococcu
pyogen
listeria
sp
bacillu
subtilli
bacillu
cereu
gramneg
isol
moraxella
catarrhali
also
show
good
activ
staphylococcu
epidermidi
biofilm
coat
microtitr
plate
well
result
complet
inhibit
biofilm
develop
treatment
matur
biofilm
result
signific
reduct
biofilm
densiti
p
result
obtain
current
studi
demonstr
broadspectrum
activ
antimicrobi
agent
rang
pathogen
bacteria
abil
inhibitor
prevent
disrupt
biofilm
gramneg
bacteria
produc
acquir
metalloblactamas
mbl
repres
one
greatest
challeng
modern
antimicrobi
therapi
mbl
produc
commonli
exhibit
resist
broadspectrum
blactam
also
varieti
nonblactam
agent
owe
associ
mbl
gene
affect
differ
group
antibiot
imp
vim
enzym
common
acquir
mbl
enzym
first
report
japan
europ
broadli
dissemin
mani
countri
popul
contin
product
acquir
mbl
often
observ
p
aeruginosa
ubiquit
enzym
less
frequent
acinetobact
spp
enterobacteriacea
mainli
klebsiella
pneumonia
enterobact
cloaca
typic
variant
latter
speci
mbl
genet
group
either
identifi
isol
caus
sporad
infect
local
outbreak
eg
endem
type
geograph
area
eg
latin
america
howev
recent
report
intern
import
brazil
switzerland
india
uk
provid
continu
evid
increas
complex
mbl
epidemiolog
preval
mblproduc
vari
significantli
among
differ
countri
epidemiolog
rang
sporad
monoclon
outbreak
polyclon
endem
furthermor
mblproduc
strain
longer
confin
nosocomi
environ
identifi
also
resid
longtermcar
facil
even
patient
communityacquir
infect
associ
mbl
gene
mobil
genet
platform
eg
transposon
case
blavim
gene
broad
host
rang
plasmid
highli
epidem
clone
eg
p
aeruginosa
clonal
complex
appar
implic
rapid
spread
import
resist
determin
class
blactamasemedi
resist
blactam
increasingli
report
last
decad
enzym
also
known
oxacillinas
oxa
wide
distribut
among
gram
neg
usual
possess
narrow
spectrum
blactam
hydrolysi
profil
possess
abil
hydrolys
carbapenem
even
low
level
name
carbapenemhydrolys
class
blactamas
chdl
chdl
known
intrins
gram
neg
rod
includ
acinetobact
baumannii
enzym
pseudomona
aeruginosa
enzym
usual
play
minor
role
natur
resist
phenotyp
besid
naturallyoccur
chdl
other
identifi
acquir
mostli
identifi
acinetobact
spp
mostli
baumannii
belong
four
distinct
group
accord
amino
acid
sequenc
name
group
gene
encod
chdl
baumannii
either
plasmidor
chromosomeencod
interestingli
progenitor
shown
acinetobact
radioresisten
nonpathogen
environment
speci
despit
weak
abil
hydrolys
carbapenem
chdl
respons
high
level
resist
compound
express
associ
mechan
efflux
overepress
penicillinbind
protein
modif
porin
loss
anoth
chdl
distantli
relat
chdl
identifi
baumannii
identifi
sever
enterobacteri
speci
mostli
klebsiella
pneumonia
gene
found
origin
shewanella
spp
plasmidmedi
increasingli
report
differ
countri
respons
resist
carbapenem
associ
permeabl
deffect
acquir
chdl
encod
gene
mostli
identifi
associ
insert
sequenc
either
respons
express
acquisit
particular
gene
identifi
insid
composit
integron
structur
respect
carbapenem
exclud
ertapenem
treatment
choic
infect
caus
multiresist
baumannii
emerg
carbapenem
resist
seriou
problem
gramneg
speci
carbapenem
resist
attribut
multipl
mechan
includ
reduc
permeabl
loss
outer
membran
protein
alter
penicillinbind
protein
overexpress
weakli
carbapenemhydrolyz
blactamas
major
mechan
carbapenemas
product
divers
carbapenemas
report
baumannii
differ
region
preval
isol
imp
vim
metalloenzym
global
scatter
associ
particularli
far
east
observ
rare
oxa
class
enzym
domin
carbapenemas
baumannii
phylogenet
distinct
group
identifi
enzym
intrins
speci
associ
carbapenem
resist
upregul
adjac
insert
sequenc
usual
contrast
carbapenemas
acquir
via
horizont
gene
spread
enzym
usual
confer
clinic
signific
carbapenem
resist
although
mic
individu
isol
influenc
particular
gene
present
copi
number
presenc
accessori
mechan
eg
loss
caro
porin
blaoxa
gene
may
locat
chromosom
part
larg
resist
island
plasmid
local
outbreak
carbapenemresist
baumannii
typic
includ
predomin
strain
strain
epidemiolog
unlink
site
may
show
suffici
similar
regard
clone
two
domin
carbapenemresist
clone
uk
clone
enzym
southeast
clone
enzym
affect
hospit
belong
sequenc
group
base
ompa
csue
allel
european
clone
ii
countri
may
greater
evid
horizont
gene
spread
addit
strain
spread
observ
enzym
taiwanes
hospit
therapeut
option
infect
caus
carbapenemresist
strain
polymyxin
glycylcyclin
effect
infect
control
remain
essenti
control
spread
impact
hostpathogen
interact
determin
outcom
tuberculosi
infect
influenc
key
control
point
natur
histori
infect
includ
progress
latent
infect
activ
diseas
clinic
spectrum
activ
diseas
understand
natur
histori
epidemiolog
tuberculosi
infect
base
two
key
centuryold
tool
tuberculin
skin
test
chest
radiographi
advent
new
accur
marker
infect
present
opportun
reevalu
convent
understand
hostpathogen
relationship
tuberculosi
includ
natur
histori
epidemiolog
tuberculosi
infect
applic
interferongamma
releas
assay
epidemiolog
welldefin
tuberculosi
outbreak
longitudin
cohort
point
toward
new
class
hostpathogen
interact
subset
tuberculosi
contact
like
involv
transient
selfresolv
infect
entiti
previous
appreci
signific
implic
understand
hostpathogen
interact
tuberculosi
infect
discuss
cellbas
test
tuberculosi
infect
also
uncov
role
bcg
vaccin
prevent
infect
despit
tuberculosi
exposur
implic
phenomenon
design
evalu
new
tuberculosi
vaccin
well
tuberculosi
control
discuss
newer
biomark
measur
multipl
facet
host
respons
tuberculosi
infect
diseas
recent
develop
may
enabl
discrimin
sever
stage
natur
histori
tuberculosi
infect
eg
differenti
activ
latent
tuberculosi
infect
new
type
biomark
review
well
new
insight
could
provid
understand
hostpathogen
equilibrium
tuberculosi
infect
new
medicin
tuberculosi
tuberculosi
tb
one
oldest
infecti
diseas
known
man
infect
one
third
world
popul
result
someon
die
diseas
everi
second
million
peopl
lose
live
tb
next
decad
although
directli
observ
short
cours
chemotherapi
dot
avail
treat
diseas
treatment
old
slow
ineffici
current
standard
pharmaceut
industri
furthermor
efficaci
dot
programm
sever
compromis
certain
region
emerg
multidrugand
extens
drugresist
strain
mycobacterium
tuberculosi
new
menac
particular
concern
europ
countri
former
soviet
union
integr
approach
discov
new
tb
drug
pursu
new
class
antimycobacteri
compound
known
benzothiazinon
btz
btz
kill
tuberculosi
vitro
ex
vivo
mous
model
tb
except
potent
use
genet
biochemistri
identifi
enzym
decaprenylphosphorylbdribos
major
btz
target
inhibit
critic
enzym
activ
abolish
format
decaprenylphosphoryl
arabinos
key
precursor
requir
synthesi
cellwal
arabinan
therebi
provok
cell
lysi
bacteri
death
advanc
compound
current
late
preclin
stage
candid
inclus
combin
therapi
drugsensit
extens
drugresist
tb
case
report
causal
quantifi
rare
advers
event
consid
treatment
decis
rare
advers
event
drug
vaccin
therapeut
agent
usual
identifi
product
licens
widespread
use
histor
surveil
reli
case
report
case
report
identifi
mani
import
problem
drawback
includ
unknown
sensit
detect
event
interest
inabl
provid
quantit
estim
risk
need
make
inform
decis
balanc
benefit
risk
quantit
inform
risk
also
benefit
becom
increasingli
avail
secondari
use
electron
health
data
electron
medic
record
administr
data
collect
routin
deliveri
health
care
among
earliest
exampl
us
center
diseas
control
vaccin
safeti
datalink
perform
activ
near
realtim
surveil
vaccineassoci
advers
event
retrospect
epidemiolog
studi
method
modifi
work
group
health
plan
ten
million
member
address
sequela
exposur
drug
well
vaccin
import
featur
method
requir
minim
share
confidenti
person
inform
need
creat
larg
pool
dataset
order
identifi
signal
advers
event
present
illustr
issu
use
current
experi
evalu
safeti
influenza
vaccin
other
also
address
us
food
drug
administr
plan
creat
sentinel
network
use
inform
electron
medic
record
cover
million
peopl
perform
routin
safeti
evalu
market
medic
product
addit
consider
regard
assess
benefit
address
mrsa
bacteremia
endocard
repres
challeng
difficult
infect
overcom
antibiot
understand
relationship
antibiot
pharmacokinet
pharmacodynam
target
organ
site
infect
potenti
resist
develop
key
success
patient
outcom
optim
therapi
exploit
specif
antibiot
pharmacodynam
paramet
best
predict
vivo
efficaci
exampl
case
blactam
improv
time
mic
target
pathogen
may
accomplish
prolong
infus
time
util
continu
infus
administr
aminoglycosid
use
highdos
oncedaili
therapi
increas
cmaxmic
recent
base
need
improv
perform
vancomycin
higher
trough
recommend
higher
trough
need
order
achiev
higher
aucmic
ratio
thought
import
seriou
infect
like
complic
bacteremia
infect
endocard
pneumonia
addit
factor
affect
antibiot
perform
includ
abil
reach
site
infect
barrier
penetr
condit
site
infect
ph
protein
bind
inoculum
lectur
discuss
specif
antibiot
pkpd
characterist
condit
site
infect
diminish
antibiot
activ
opportun
improv
perform
f
agyekum
b
nkrumah
ekuban
n
sarpong
ng
schwarz
h
j
may
adusarkodi
dortmund
de
kumasi
gh
hamburg
cologn
de
object
evalu
preval
antimicrobi
resist
enterobacteriacea
isol
blood
cultur
children
rural
ghana
method
octob
june
blood
cultur
collect
children
admit
agogo
presbytarian
hospit
locat
rural
area
ashanti
akim
north
district
popul
ped
bottl
system
use
detect
strain
identifi
gram
stain
select
subcultur
biochem
test
specif
agglutin
test
minimum
inhibitori
concentr
mic
isol
enterobacteriacea
product
extendedspectrumblactamas
esbl
determin
method
result
studi
isol
enterobacteriacea
n
nontyphoid
salmonella
enterica
nt
salmonella
typhi
escherichia
coli
klebsiella
sp
shigella
boydii
enterobact
sp
nt
highli
resist
ampicillin
cotrimoxazol
chloramphenicol
tetracyclin
strain
resist
ciprofloxacin
one
strain
reduc
suscept
ceftriaxon
major
typhi
strain
also
resist
ampicillin
cotrimoxazol
chloramphenicol
tetracyclin
complet
suscept
ciprofloxacin
ceftriaxon
e
coli
isol
resist
ampicillin
produc
esbl
resist
cotrimoxacol
tetracyclin
chloramphenicol
ciprofloxacin
frequent
detect
klebsiella
strain
resist
ampicillin
tetracyclin
produc
esbl
one
strain
suscept
cotrimoxazol
resist
chloramphenicol
one
third
ciprofloxacin
enterobact
strain
procuc
esbl
suscept
ciprofloxacin
shigella
boydii
isol
suscept
ceftriaxon
ciprofloxacin
conclus
studi
indic
major
enterobacteriacea
caus
bacteraemia
children
studi
area
resist
major
local
avail
antibiot
moreov
massiv
emerg
multidrugresist
enterobacteriacea
esbl
produc
e
coli
klebsiella
strain
clinic
isol
indic
seriou
medic
econom
burden
african
healthcar
system
surveil
program
prevent
strategi
establish
face
challeng
dissemin
escherichia
coli
within
famili
l
p
egea
navarro
l
serrano
j
pascual
sevil
es
object
mean
transmiss
esblproduc
e
coli
esblec
isol
commun
poorli
understood
previous
report
preval
faecal
carriag
esblec
higher
rel
patient
urinari
tract
infect
uti
caus
organismsin
household
aim
studi
analys
molecular
relationship
esblec
within
famili
set
plasmid
identifi
method
studi
esblproduc
e
coli
isol
famili
patient
uti
caus
esblec
least
faecal
carrier
within
famili
identifi
patient
uti
rel
isol
evalu
xbai
pfge
molecular
related
determin
upg
method
use
dice
similar
index
fingerprint
phylogenet
group
assign
multiplex
pcr
transfer
bla
gene
carri
conjug
experi
transform
electropor
e
coli
respect
plasmid
compar
size
use
nucleas
digest
pattern
result
southern
hybrid
hindiiidigest
plasmid
dna
transform
transconjug
result
total
differ
pfge
pattern
identifi
distribut
among
phylogenet
group
nine
rel
famili
carri
pulsotyp
esbl
patient
uti
famili
famili
isol
differ
member
yield
differ
pulsotyp
harbour
enzym
among
esbl
locat
similar
rflp
plasmid
pattern
famili
bla
gene
hybridaz
singl
kb
hybrid
band
plasmid
wherea
bla
gene
locat
fragment
differ
size
plasmid
conclus
common
sourc
horizont
transmiss
esblproduc
strain
plasmid
found
famili
esblproduc
carrier
acquisit
differ
clone
produc
differ
esbl
enzym
member
household
less
frequent
studi
denot
rout
spread
commun
result
enrol
person
submit
faecal
sampl
questionnair
travel
includ
analysi
travel
person
colonis
esblp
respect
kpc
found
e
coli
commonli
found
speci
gender
age
use
oral
cholera
vaccin
antibiot
durat
travel
similar
among
person
acquir
esblp
travel
travel
associ
ta
carrier
n
person
never
colonis
esblp
noncarri
n
tacarri
often
report
diahorrea
abdomin
symptom
travel
compar
noncarri
busi
common
caus
travel
among
tacarri
noncarri
wherea
tacarri
often
report
travel
backpack
vs
frequenc
tacarri
travel
visit
countri
travellerscountri
india
egypt
peru
thailand
south
africa
tanzania
respect
conclus
travel
increas
risk
faecal
colonis
esblp
acquisit
esblp
travel
associ
abdomin
symptom
diahorrea
object
extendedspectrum
blactamas
esbl
worldwid
public
health
problem
data
avail
esbl
egypt
aim
studi
compar
fecal
carriag
esblproduc
enterobacteria
esbl
patient
admit
hepatolog
depart
hospit
special
liver
diseas
theodor
bilharz
research
institut
tbri
cairo
egypt
beaujon
hospit
bj
clichi
franc
method
patient
admit
mayjun
h
hepatolog
depart
tbri
bj
screen
admiss
rectal
swab
detect
esbl
digest
carriag
ctxm
group
identifi
pcr
tem
shv
deriv
check
point
system
phylogenet
group
e
coli
determin
multiplex
pcr
clone
pcr
gene
pabbth
follow
demograph
clinic
data
collect
gender
age
previou
hospit
underli
diseas
ascit
result
studi
period
preval
patient
esbl
tbri
bj
previou
hospit
common
p
bj
patient
tbri
patient
popul
also
differ
regard
underli
diseas
p
studi
esbl
tbri
bj
patient
respect
esbl
esbl
tbri
e
coli
k
pneumonia
e
cloaca
respect
esbl
bj
e
coli
e
cloaca
k
pneumonia
k
oxytoca
respect
speci
distribut
differ
countri
tbri
esbl
enzym
group
shv
respect
wherea
bj
group
tem
shv
respect
signific
differ
observ
enzym
group
shv
tbri
e
coli
belong
phylogenet
group
wherea
bj
e
coli
belong
esbl
group
significantli
higher
bj
tbri
p
tbri
isol
belong
clone
preval
patient
esbl
fecal
carriag
high
tbri
patient
previou
hospitalis
suggest
high
preval
esbl
commun
egypt
object
two
recent
studi
identifi
admiss
room
previous
occupi
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
patient
independ
risk
factor
acquisit
bacteria
aim
studi
determin
whether
admiss
icu
room
previous
occupi
multidrugresist
gram
neg
bacilli
mdrgnb
carrier
increas
risk
acquir
bacteria
subsequ
patient
method
prospect
observ
cohort
studi
perform
icu
period
patient
hospit
h
elig
patient
mdrgnb
icu
admiss
exclud
mdrgnb
defin
mdr
pseudomona
aeruginosa
resist
imipenem
ceftazidim
acinetobact
baumannii
extend
spectrum
blactamas
esbl
produc
gnb
patient
hospit
singl
room
infect
control
polici
includ
isol
techniqu
routin
screen
mdr
bacteria
mdrgnb
mrsa
written
antibiot
treatment
protocol
continu
surveil
nosocomi
infect
isol
techniqu
use
patient
icu
admiss
receipt
screen
result
addit
techniqu
use
patient
mdr
bacteria
immunosuppress
patient
routin
screen
mdr
bacteria
nasal
anal
swab
tracheal
aspir
intub
patient
perform
patient
icu
admiss
weekli
thereaft
conclus
admiss
icu
room
previous
occupi
mdr
p
aeruginosa
baumannii
carrier
independ
risk
factor
acquisit
microorgan
subsequ
room
occup
object
recent
studi
nejm
select
digest
decontamin
sdd
compar
select
oropharyng
decontamin
sod
associ
signific
reduct
icuacquir
bacteremia
caus
gramneg
bacteria
gnb
differ
sdd
sod
intestin
tract
decontamin
standard
day
cefotaxim
sdd
sod
hypothes
intestin
colon
gnb
associ
subsequ
icuacquir
gnb
bacteremia
patient
receiv
sdd
method
retrospect
cohort
studi
tertiari
care
icu
netherland
includ
patient
receiv
sdd
sept
sept
rectal
carriag
gnb
determin
twice
weekli
icustay
patientday
statu
intestin
gnb
colon
determin
creat
patientday
without
intestin
gnb
colon
incid
densiti
icuacquir
gnb
bacteremia
calcul
patientday
without
intestin
gnb
colon
result
patient
patientsday
risk
includ
episod
rectal
gnb
colon
icustay
patient
episod
icuacquir
gnb
bacteremia
incid
icuacquir
gnb
bacteremia
per
patient
day
period
without
intestin
gnb
colon
rel
risk
ci
median
onset
icuacquir
bacteremia
without
intestin
gnb
iqr
iqr
respect
p
icuacquir
bacteremia
occur
within
first
day
icuadmiss
episod
bacteremia
preced
rectal
colon
speci
frequent
serratia
spp
n
pseudomona
aeruginosa
n
patient
alreadi
lost
rectal
carriag
time
bacteremia
speci
conclus
intestin
colon
gnb
sdd
associ
almost
risk
develop
gnb
bacteremia
icuacquir
bacteremia
occur
day
indic
associ
seem
influenc
cefotaxim
use
ih
retted
k
sundsfjord
stavang
object
molecular
character
multiresist
extendedspectrum
blactamas
esbl
produc
klebsiella
pneumoniaestrain
associ
outbreak
neonat
intens
care
unit
nicu
stavang
univers
hospit
norway
evalu
long
term
colon
affect
newborn
transmiss
famili
member
method
rectalfec
sampl
cultur
modifi
macconkey
agar
chrom
id
esblplat
suscept
test
perform
disk
diffus
etest
esblproduct
confirm
doubl
disk
approxim
test
blactamasegen
detect
pcr
type
dna
sequenc
clonal
related
examin
pfge
followup
studi
initi
monthli
rectalfec
sampl
collect
newborn
famili
outbreak
disclos
jan
identif
multiresist
k
pneumonia
clinic
sampl
three
patient
subseq
children
found
colon
esblproduc
k
pneumonia
screen
patient
nicu
colon
children
discharg
nicu
matern
ward
nov
jan
colon
cohort
strengthen
infect
control
measur
anoth
four
children
nicu
colon
feb
april
one
patient
sever
clinic
infect
septicaemia
recov
success
treatment
meropenem
isol
n
express
resist
aztreonam
gener
cephalosporin
clavulan
acid
synergi
well
coresist
aminoglycocid
trimethoprimsulfamethoxazol
nitrofurantoin
ctxmtype
confirm
pcr
dna
sequenc
isol
examin
n
display
indistinguish
colon
children
famili
member
includ
followup
studi
nine
month
followup
children
still
colon
transmiss
famili
member
detect
conclus
first
major
hospit
outbreak
caus
esblproduc
enterobacteriacea
norway
outbreak
onset
two
month
esblproduc
k
pneumoniaestrain
identifi
subclin
outbreak
like
difficult
detect
unless
patient
regularli
screen
long
time
carriag
newborn
possibl
reservoar
spread
esblproduc
bacteria
hospit
commun
object
infect
control
practic
extend
spectrum
blactamas
esbl
includ
barrier
precaut
flag
carrier
dutch
guidelin
infect
control
esbl
recommend
perform
twiceweekli
surveil
cultur
end
precaut
consecut
cultur
neg
costeffect
cultur
depend
proport
pt
remain
posit
data
howev
avail
addit
carrier
flag
howev
littl
data
durat
esbl
colon
therefor
recommend
durat
flag
lack
aim
studi
determin
durat
esbl
colon
hospit
commun
acquir
determin
proport
pt
remain
posit
hospitalis
databas
nation
antimicrobi
resist
surveil
system
isisar
pt
posit
cultur
either
escherichia
coli
ec
klebsiella
pneumonia
kp
intermedi
resist
ir
third
gener
cephalosporin
ceph
least
one
follow
cultur
ec
kp
identifi
pt
time
period
determin
first
esbl
posit
first
neg
cultur
primari
end
point
juli
durat
colonis
estim
kaplanmei
surviv
analysi
pt
without
last
neg
cultur
censor
figur
day
gen
cephalosporin
suscept
isol
pt
posit
cultur
isol
ir
ceph
esbl
confirm
test
posit
pt
pt
esbl
posit
followup
cultur
median
colonis
time
day
ci
first
quartil
day
ci
third
quartil
day
ci
figur
pt
first
posit
isol
cultur
admiss
follow
cultur
proport
pt
posit
isol
week
week
conclus
least
pt
remain
esbl
posit
least
month
pt
still
carrier
one
year
implic
flag
continu
screen
cultur
admiss
shown
neg
least
patient
remain
esbl
posit
hospitalis
sinc
real
percentag
like
higher
due
interfer
antimicrobi
therapi
cultur
result
advic
perform
surveil
cultur
reconsid
pointpreval
studi
postacutecar
facil
pacf
previous
identifi
type
ward
prolong
length
stay
lo
infect
control
polici
ecolog
factor
associ
crkp
colon
import
distinguish
ecolog
individuallevel
risk
factor
order
direct
intervent
appropri
extend
analysi
assess
individu
risk
factor
colon
among
resid
without
histori
crkp
carriag
method
pointpreval
studi
conduct
pacf
rectal
swab
obtain
resid
without
histori
crkp
carriag
ward
suspici
coloni
grow
kpc
plate
speciat
test
carbapenem
suscept
vitek
supplement
etest
use
nest
match
casecontrol
studi
design
assess
individu
risk
factor
colon
case
defin
patient
posit
rectal
screen
control
select
patient
neg
rectal
screen
match
case
ward
patient
data
collect
medic
record
includ
demograph
characterist
comorbid
condit
presenc
skin
lesion
presenc
invas
devic
antibiot
exposur
number
colon
roommat
pacf
lo
result
resid
without
histori
crkp
colon
detect
covari
enter
match
multivari
model
includ
norton
score
antibiot
exposur
past
month
skin
lesion
receipt
amoxicillinclavulan
past
month
colon
resist
pathogen
independ
risk
factor
crkp
colon
antibiot
exposur
past
month
ci
p
colon
resist
pathogen
ci
p
conclus
nest
match
casecontrol
studi
identifi
import
modifi
risk
factor
crkp
colon
identifi
ecolog
analysi
antibiot
exposur
antibiot
control
program
may
import
role
decreas
burden
crkp
pacf
season
ascend
trend
incid
extendedspectrum
blactamaseproduc
e
coli
klebsiella
sp
two
german
univers
hospit
k
u
frank
conrad
e
meyer
freiburg
berlin
de
object
present
studi
incid
extend
spectrum
b
lactamas
esbl
produc
strain
analys
gener
trend
season
method
monthli
data
esbl
produc
strain
collect
retrospect
two
larg
univers
hospit
southwest
northeast
germani
analysi
focuss
e
coli
klebsiella
pneumonia
klebsiella
oxytoca
consist
two
set
studi
period
multivari
timeseri
analys
carri
explain
variat
monthli
incid
densiti
esbl
case
e
coliandor
klebsiellarel
esbl
case
per
patient
day
two
set
berlin
freiburg
final
model
abl
incorpor
variabl
ascend
linear
trend
variabl
repres
averag
monthli
temperatur
result
model
show
gener
incid
esbl
case
show
increas
trend
addit
incid
esbl
case
respond
posit
averag
temperatur
mean
summer
temperatur
high
esbl
case
detect
winter
month
see
figur
detail
studi
methodolog
also
appli
incid
mrsa
two
set
associ
averag
temperatur
could
detect
present
studi
affirm
esblproduc
e
coli
k
pneumonia
emerg
problem
german
hospit
furthermor
demonstr
monthli
incid
esbl
strain
highli
correl
mean
monthli
temperatur
fact
consid
experiment
studi
addit
paramet
influenc
incid
esbl
introduct
incid
invas
candidaemia
increas
world
mainli
critic
ill
immunocompromis
patient
shift
nonalbican
speci
grow
resist
common
antifung
notic
last
year
object
aim
studi
analyz
differ
candida
speci
isol
bloodstream
infect
relat
antifung
suscept
pattern
three
year
period
policlinico
umberto
rome
method
blood
cultur
analyz
autom
manual
method
candida
speci
isol
identifi
use
chromogen
cultur
media
api
system
biomerieux
card
use
perform
antifung
agent
sensit
follow
drug
flucytosin
amphotericin
b
fluconazol
itraconazol
voriconazol
determin
suscept
resist
pattern
clsi
breakpoint
use
overal
incid
invas
candidaemia
three
year
studi
mark
increas
speci
isol
follow
c
albican
nonalbican
speci
c
krusei
c
glabrata
c
parapsilosi
c
tropicali
c
lusitania
observ
detect
c
albican
rais
wherea
c
krusei
c
parapsilosi
c
tropicali
incid
decreas
three
year
period
c
glabrata
isol
almost
whole
period
far
c
albican
concern
notic
increas
resist
amphotericin
b
voriconazol
c
krusei
show
rais
resist
amphotericin
b
fluconazol
itraconazol
voriconazol
respect
c
glabrata
mark
increas
resist
antifung
agent
observ
isol
c
parapsilosi
resist
voriconazol
contrast
c
tropicali
suscept
antimycot
agent
conclus
studi
confirm
high
incid
candidaemia
set
critic
ill
patient
c
albican
result
preval
speci
overal
rate
resist
increas
studi
period
candida
strain
consider
neonatolog
major
heart
surgeri
paediatr
select
isol
per
episod
isol
patient
coinfect
differ
speci
antifung
suscept
fluconazol
voriconazol
determin
use
clsi
microdilut
procedur
fungemia
episod
caus
c
albican
n
c
parapsilosi
n
c
glabrata
n
c
tropicali
n
c
albican
c
parapsilosi
n
arxula
adeninivoran
n
rhodotorula
mucilaginosa
n
trichosporon
inkin
n
result
total
patient
includ
studi
icu
patient
develop
invas
candida
infect
age
gender
sap
ii
euroscor
patient
type
durat
cardiothorac
procedur
parenter
nutrit
signific
risk
factor
studi
popul
invas
candida
infect
patient
sever
candida
colon
p
leukocytosi
gl
leukopenia
gl
p
sofa
score
p
found
risk
invas
candida
infect
cardiothorac
icu
patient
calcul
use
follow
determin
sever
candida
colon
leukocytosi
leucopenia
highest
sofa
score
redo
surgic
procedur
addit
git
surgeri
conclus
cardiothorac
icu
patient
risk
invas
candida
infect
presenc
sever
candida
colon
leukocytosi
leucopenia
sofa
score
addit
git
surgeri
undergo
multipl
cardiothorac
intervent
object
candida
bloodstream
infect
caus
signific
morbid
mortal
hospit
patient
clinic
microbiolog
factor
affect
prognosi
identifi
impact
immun
respons
mediat
cytokin
outcom
infect
remain
studi
present
studi
assess
role
genet
variat
cytokin
gene
suscept
andor
clinic
outcom
candidaemia
method
singl
nucleotid
polymorph
snp
six
cytokin
gene
ifng
one
cytokin
receptor
gene
genotyp
analyz
logist
regress
patient
candidaemia
noninfect
control
addit
presenc
snp
measur
concentr
proinflammatori
cytokin
analyz
associ
persist
fungemia
day
posit
blood
cultur
american
candidaemia
variabl
assess
includ
type
candida
spp
identifi
total
parenter
nutrit
tpn
dialysi
depend
malign
immunocompromis
state
renalliv
failur
variabl
p
univari
analysi
analyz
use
multivari
logist
regress
result
none
snp
examin
associ
suscept
candidaemia
mean
age
candidaemia
patient
year
femal
african
american
immunocompromis
activ
malign
neutropen
recent
surgeri
receiv
total
parenter
nutrit
tpn
dialysi
liver
diseas
icu
resid
follow
speci
identifi
c
albican
c
glabrata
c
parapsilosi
c
tropicali
c
krusei
candida
speci
addit
significantli
lower
proinflammatori
cytokin
concentr
measur
serum
patient
persist
fungemia
conclus
snp
associ
persist
fungemia
candidaemia
patient
also
associ
low
serum
concentr
proinflammatori
cytokin
may
provid
insight
futur
target
manag
strategi
patient
high
mortal
condit
object
mortal
candida
bloodstream
infect
cbsi
high
treat
adequ
recent
clinic
trial
cbsi
treatment
echinocandin
result
higher
success
rate
howev
superior
demonstr
given
similar
trial
design
definit
data
trial
combin
metaanalysi
compar
efficaci
measur
global
clinic
success
end
intraven
therapi
echinocandin
vs
compar
af
agent
treatment
cbsi
method
use
standard
metaanalysi
methodolog
random
effect
model
conduct
literatur
search
identifi
random
control
trial
rct
assess
efficaci
echinocandin
caspofungin
micafungin
anidulafungin
csbi
evalu
whether
compar
fluconazol
amphotericin
prepar
success
rate
consist
previous
publish
data
conduct
addit
literatur
search
rct
agent
evalu
articl
review
independ
review
correspond
author
sponsor
approach
addit
data
result
rct
includ
compar
echinocandin
compar
antifung
caf
compar
two
echinocandin
compar
amphotericin
prepar
fluconazol
summari
odd
ratio
global
success
ci
favor
echinocandin
therapi
remov
highrecruit
center
high
anidulafungin
responser
insignific
impact
result
ci
global
success
rate
observ
includ
rct
fluconazol
treatment
arm
amphotericin
arm
echinocandin
arm
respect
echinocandin
trial
success
rate
observ
caf
arm
consist
prior
publish
trial
addit
analysi
includ
cbsi
caus
c
albican
echinocandin
therapi
result
higher
success
rate
vs
caf
ci
vs
ci
patient
cbsi
compar
amphotericin
prepar
fluconazol
echinocandin
therapi
associ
higher
global
success
rate
better
effect
maintain
restrict
analysi
c
albican
suggest
effect
differ
may
unrel
level
fluconazol
suscept
object
neonat
intens
care
unit
suscept
blood
stream
infect
invas
procedur
underdevelop
immun
system
prolong
hospit
broad
spectrum
antibiot
risk
develop
candidemia
report
written
share
success
stori
control
candidemia
major
outbreak
adopt
strict
infect
control
practic
indirectli
result
reduct
candidemia
neonat
intens
care
unit
nicu
method
retrospect
laboratori
base
analysi
studi
januari
august
spectrum
distribut
candida
isol
blood
cultur
taken
nicu
hospit
univers
sain
malaysia
major
outbreak
analyz
preval
candidemia
outbreak
compar
trend
candida
spp
determin
candida
spp
identifi
use
standard
microbiolog
test
commerci
identif
system
system
result
altogeth
candida
isol
studi
period
gener
signific
reduct
preval
candidemia
candida
albican
nonalbican
reduct
sustain
past
five
year
candida
parapsilosi
predomin
speci
isol
follow
candida
albican
candida
glabrata
candida
tropicali
conclus
adher
strict
infect
control
practic
import
control
candidemia
candida
parapsilosi
major
speci
implic
candidemia
among
neonat
factor
prompt
earli
central
venou
cathet
remov
cancer
patient
candidaemia
background
studi
address
time
cvc
remov
prognost
factor
mortal
cancer
patient
candidemia
object
evalu
clinic
factor
associ
earli
central
venou
cathet
remov
cancer
patient
candidemia
surviv
day
index
blood
cultur
method
retrospect
analysi
candidemia
studi
conduct
januari
june
oncolog
cancer
center
brazil
elig
patient
whose
cathet
eventu
remov
exclud
patient
die
within
h
candidemia
onset
cathet
place
h
earli
cathet
remov
defin
cathet
withdrawn
h
onset
candidemia
result
enrol
patient
overal
mortal
rate
multivari
analysi
reveal
temporari
nontunnel
central
venou
cathet
type
ci
variabl
independ
associ
earli
remov
among
episod
cathet
relat
cathet
remov
doctor
discret
due
urgenc
cancer
treatment
continu
remov
n
occur
within
day
index
blood
cultur
differ
overal
mortal
rate
seen
among
patient
earli
delay
cathet
remov
p
nevertheless
stratifi
analysi
show
surviv
benefit
p
earli
remov
subgroup
patient
perform
karnofski
score
studi
show
shortterm
nontunnel
central
venou
cathet
type
factor
associ
earli
cathet
remov
high
proport
remov
cathet
purpos
interrupt
underli
cancer
treatment
overal
earli
cathet
remov
benefici
impact
mortal
nevertheless
observ
favor
surviv
benefit
earli
late
cathet
remov
subgroup
patient
without
signific
medic
ill
merit
investig
clinic
trial
enrol
suffici
number
homogen
patient
necessari
analyz
impact
central
venou
cathet
manag
outcom
cancer
patient
candidemia
strategi
stay
one
step
ahead
bacteria
symposium
support
janssencilag
bacteri
challeng
time
react
chang
pattern
antimicrobi
resist
present
challeng
need
met
mani
front
combin
lack
develop
new
antimicrobi
necessit
review
current
treatment
strategi
strategi
discuss
symposium
includ
benefit
appropri
empir
antimicrobi
treatment
seriou
infect
ration
way
administr
higher
dose
vari
infus
time
antimicrobi
resist
develop
well
monitor
europ
resourc
european
antimicrobi
resist
surveil
system
earss
addit
countri
local
surveil
eg
pegsurveil
germani
austria
switzerland
data
present
resist
profil
evolut
rate
within
intens
care
unit
challeng
contain
prevent
spread
resist
data
critic
ration
choic
adequ
empir
antibiot
treatment
lead
failur
achiev
use
broadspectrum
potent
agent
least
like
select
resist
chang
target
therapi
deescal
suscept
determin
method
allow
us
use
limit
armamentarium
effect
approach
follow
risk
failur
increas
mortal
associ
initi
inadequ
antibiot
treatment
emerg
resist
strain
therapi
subsequ
spread
other
main
consequ
number
new
antibiot
treat
multidrugresist
pathogen
pipelin
particularli
gramneg
bacteria
new
mechan
action
new
strategi
need
close
gap
burden
infect
due
multidrugresist
bacteria
develop
new
antibiot
develop
resist
antibiot
long
thorn
side
infecti
diseas
physician
dr
livermor
discuss
current
resist
issu
microbiolog
perspect
concept
potenc
relat
minim
inhibitori
concentr
mic
breakpoint
cover
particular
refer
carbapenem
pseudomona
aeruginosa
simpl
mutat
lead
loss
carbapenemspecif
porin
oprd
confer
frank
resist
imipenem
wherea
resist
meropenem
doripenem
addit
requir
upregul
efflux
reason
remain
obscur
latter
combin
mechan
usual
lesser
effect
doripenem
mic
meropenem
circumst
potenti
dose
carbapenem
affect
likelihood
resist
develop
though
practic
signific
remain
confirm
clinic
studi
particularli
meropenem
doripenem
comparison
contrast
p
aeruginosa
carbapenemresist
acinetobact
spp
due
oxacarbapenemas
lowlevel
produc
may
remain
margin
suscept
imipenem
meropenem
doripenem
seem
littl
gener
scope
overcom
resist
dosag
adjust
compound
among
enterobacteriacea
carbapenem
resist
aris
either
via
combin
porin
loss
togeth
product
extendedspectrum
ampclactamas
via
product
true
carbapenemas
former
mechan
mostli
seen
klebsiella
enterobact
spp
affect
ertapenem
analogu
compound
therefor
seem
like
act
selector
true
carbapenemas
includ
imp
vim
ndm
new
delhi
metallo
zincenzym
well
kpc
serin
type
affect
carbapenem
seem
unlik
could
overcom
dosag
adjust
though
might
futur
overcom
carbapeneminhibitor
combin
consider
pharmacokinet
pk
pharmacodynam
pd
principl
use
optimis
dose
blactam
antibiot
blactam
timedepend
action
time
minim
inhibitori
concentr
mic
critic
maximum
efficaci
pkpd
data
use
mont
carlo
simul
predict
probabl
obtain
exposur
target
given
dose
evid
mont
carlo
simul
anim
model
clinic
studi
led
realworld
recommend
use
extend
infus
strategi
maximis
effici
blactam
prolong
continu
infus
give
better
efficaci
lower
likelihood
resist
develop
higher
trough
level
elimin
least
reduc
need
increas
dose
blactam
antibiot
dose
via
continuousprolong
infus
includ
penicillin
cephalosporin
carbapenem
howev
data
assess
antimicrobi
exampl
doripenem
exhibit
linear
pharmacokinet
accumul
repeat
dose
day
support
use
prolong
infus
dr
pea
compar
differ
carbapenem
classic
blactam
dose
strategi
differ
carbapenem
discuss
includ
stabil
safeti
profil
practic
consider
prolong
infus
includ
knowledg
relationship
serum
level
target
organ
level
differ
antimicrobi
awar
differ
pk
pd
paramet
among
divers
patient
group
dr
pea
conclud
discuss
particular
patient
popul
pseudomona
infect
may
benefit
continu
infus
also
discuss
effect
differ
comorbid
use
patient
sever
sepsi
septic
shock
renal
failur
glomerular
hyperfiltr
pathophysiolog
affect
drug
level
dr
welt
discuss
blactam
newli
approv
latestag
develop
clinic
perspect
discuss
includ
summari
vivo
data
includ
pivot
clinic
studi
recent
metaanalysi
activ
studi
pseudomona
acinetobact
new
clinic
data
carbapenem
doripenem
data
dose
g
use
intraven
antibiot
patient
renal
failur
discuss
includ
consider
use
hemofiltr
continu
renal
replac
therapi
crrt
compar
safeti
data
present
carbapenem
recent
health
econom
hospit
util
dataset
also
discuss
dr
welt
illustr
talk
exampl
particularli
patient
fail
therapi
reason
failur
complex
techniqu
approach
minimis
possibl
treatment
failur
discuss
appropri
initi
empir
treatment
prolong
infus
present
conclud
brief
review
blactam
current
pipelin
includ
ceftobiprol
ceftarolin
faropenem
epidemiolog
human
cytomegaloviru
focu
motherchild
transmiss
g
tubingen
de
human
cytomegaloviru
hcmv
affect
adult
worldwid
depend
geographi
lifestyl
age
year
two
possibl
sourc
sexual
transmiss
hcmv
viru
femal
cervix
semen
men
frequenc
hcmv
infect
adult
correl
number
sexual
partner
sexual
experi
bherpesviru
viru
commonli
transmit
fetu
birth
occur
live
birth
anoth
even
much
frequent
transmiss
rout
motherchild
breastfeed
local
viral
reactiv
hcmv
antibodi
posit
mother
lactat
highli
frequent
self
limit
follow
unimod
kinet
vertic
transmiss
rate
mother
child
also
horizont
hcmv
transmiss
newborn
young
children
mother
individu
taken
care
infant
happen
children
may
shed
viru
saliva
urin
month
year
rel
portion
kind
horizont
transmiss
children
children
children
adult
unknown
also
horizont
transmiss
among
adult
besid
sexual
intercours
well
descript
unlik
medic
care
hcmv
transmit
blood
product
organ
transplant
herpesvirus
hcmv
abil
establish
latentsil
infect
host
primari
infect
activ
silent
infect
occur
immunosuppress
pregnanc
lactat
individu
infect
multipl
strain
mean
secondari
infect
exogen
reinfect
endogen
reactiv
may
occur
hcmv
diseas
variou
symptom
result
either
primari
secondari
infect
also
primari
infect
diseas
sever
frequent
outcom
congenit
hcmv
infect
variabl
infect
newborn
exhibit
clinic
symptom
birth
cn
sequela
hear
loss
cognit
impair
cerebr
palsi
remark
hcmv
infect
newborn
asymptomat
birth
later
develop
hear
loss
symptomat
clinic
asymptomat
newborn
sequela
often
appar
first
month
year
life
urgent
need
specif
hcmv
diagnost
procedur
interpret
pregnant
women
newborn
guid
solid
manag
fetalinf
infect
growth
antimicrobi
resist
particular
prolifer
esblproduc
enterobacteriacea
mean
carbapenem
increasingli
front
line
therapi
nosocomi
infect
consequ
numer
carbapenemhydrolys
blactamas
emerg
begun
dissemin
across
geograph
speci
boundari
sever
class
carbapenemas
describ
kpc
enzym
immedi
clinic
relev
grow
number
report
indic
presenc
kpc
variant
enterobacteriacea
notabl
eastern
unit
state
israel
also
china
number
south
american
european
countri
kpcexpress
isol
frequent
contain
addit
blactamas
well
resist
determin
sever
limit
treatment
option
affect
patient
outcom
although
class
carbapenemas
extens
studi
molecular
basi
activ
remain
obscur
light
close
structur
resembl
class
enzym
establish
acylenzym
form
carbapenem
react
class
blactamas
tem
shv
adopt
two
conform
associ
tautomeris
ultim
result
inhibit
howev
equival
studi
yet
report
speci
form
carbapenem
associ
class
carbapenemas
use
xray
crystallographi
studi
interact
carbapenem
meropenem
model
class
carbapenemas
serratia
fonticola
use
direct
mutagenesi
trap
substrat
acylenzym
complex
structur
show
bind
carbapenem
singl
well
defin
orient
contrast
carbapeneminhibit
enzym
like
shv
blactam
amid
nitrogen
remain
close
activ
site
propos
model
repres
product
bind
substrat
like
appli
class
carbapenemas
includ
kpc
enzym
one
approach
combat
carbapenemaseproduc
organ
combin
blactam
appropri
blactamas
inhibitor
howev
avail
blactamaseinhibitor
combin
variabl
effect
carbapenemas
produc
accordingli
number
blactamas
inhibitor
develop
test
kpc
class
carbapenemas
recent
result
area
review
mani
gramneg
bacteria
especi
pseudomona
aeruginosa
acinetobact
baumannii
enterobacteriacea
includ
enterobact
citrobact
serratia
speci
possess
chromosom
encod
class
c
blactamas
ampc
import
determin
resist
toward
broad
rang
blactam
antibiot
even
carbapenem
lose
activ
confront
class
c
lactamas
organ
also
restrict
outer
membran
permeabl
exampl
loss
oprd
outer
membran
porin
p
aeruginosa
essenti
rapid
entri
imipenem
periplasm
lead
highlevel
resist
class
c
blactamas
express
last
decad
number
ampc
enzym
mobil
plasmid
genet
element
spread
organ
escherichia
coli
klebsiella
pneumonia
usual
express
ampc
carbapenemresist
strain
k
pneumonia
alter
porin
express
plasmidencod
ampc
blactamas
report
sever
countri
gener
class
c
lactamas
well
inhibit
clinic
avail
blactamas
inhibitor
clavulan
acid
sulbactam
tazobactam
insight
mechan
class
c
blactamas
aid
ration
design
specif
inhibitor
group
enzym
also
potenti
optim
penetr
outer
membran
p
aeruginosa
present
review
fundament
step
mechan
class
c
blactamas
knowledg
appli
design
novel
inhibitor
catalyt
effici
class
blactamas
depend
critic
unusu
carboxyl
lysin
gener
base
residu
enzym
acyl
deacyl
step
catalysi
differ
class
blactamas
xray
structur
indic
activ
site
surround
hydrophob
core
compris
residu
evid
present
interact
indol
group
carboxyl
lysin
essenti
stabil
posttransl
modifi
substitut
gli
ala
phe
yield
non
carboxyl
enzym
display
poor
catalyt
effici
reduc
stabil
compar
wild
type
comparison
three
dimension
structur
differ
protein
also
indic
mutat
modifi
overal
structur
induc
increas
flexibl
omegaloop
activ
site
final
deacyl
impair
mutant
use
determin
structur
acylenzym
complex
benzylpenicillin
stoppedflow
quenchedflow
experi
indic
deacyl
step
clearli
rate
limit
blactamas
observ
acylenzym
complex
mutant
xray
crystallographi
also
suggest
deacyl
step
rate
limit
acyl
step
also
affect
lysin
mutant
inde
valu
acyl
constant
clearli
lower
wildtyp
enzym
catalyt
effic
mutant
decreas
substrat
test
structur
mutant
indic
partial
carboxyl
ph
monom
wherea
monom
b
contain
noncarboxyl
confirm
valin
residu
hydrophob
core
import
promot
carboxyl
report
class
blactamas
inhibit
chlorid
ion
interestingli
could
show
inhibiton
due
replac
side
chain
carboxyl
group
modifi
lysin
chlorid
ion
final
structur
modif
induc
also
apparit
detect
carbapenemas
activ
oxa
variant
final
deep
analysi
structurefunct
relationship
class
blactamas
yield
new
approach
select
synthesi
new
inhibitor
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
emerg
major
health
problem
worldwid
camrsa
frequent
caus
skin
softtissu
infect
also
report
caus
rapidli
progress
lifethreaten
infect
unusu
sever
patholog
includ
necrot
pneumonia
sever
sepsi
necrot
fasciiti
larg
number
epidemiolog
clinic
studi
establish
strong
associ
sever
camrsa
infect
strain
harbour
poreform
toxin
pantonvalentin
leukocidin
pvl
although
compel
epidemiolog
data
alon
insuffici
establish
role
pvl
diseas
pathogenesi
howev
issu
address
larg
number
studi
util
differ
experiment
system
includ
pvldefici
mutant
variou
vivo
model
result
studi
highli
conflict
consequ
topic
matter
great
debat
staphylococc
field
current
progress
toward
understand
enhanc
virul
potenti
camrsa
special
emphasi
pvl
also
includ
relev
staphylococc
virul
factor
summar
discuss
talk
healthcareassoci
mrsa
hamrsa
infect
widespread
throughout
world
recent
new
strain
communityassoci
mrsa
camrsa
emerg
affect
peopl
histori
healthcar
contact
commun
strain
mssa
acquir
meca
gener
virul
hamrsa
caus
primari
infect
healthi
peopl
includ
children
camrsa
often
possess
gene
encod
put
virul
factor
pantonvalentin
leukocidin
pvl
camrsa
clone
defin
multilocu
sequenc
st
sccmec
type
camrsa
appear
countri
world
common
usa
much
less
common
increas
elsewher
mani
differ
clone
whose
distribut
differ
geograph
particularli
success
pvl
replac
pvl
commonest
type
usa
european
clone
pvl
common
europ
south
west
pacif
clone
pvl
far
east
south
america
europ
great
clonal
divers
new
type
continu
report
includ
pigassoci
strain
usual
common
denmark
netherland
spread
elsewher
although
new
camrsa
clone
continu
appear
success
older
one
introduc
new
geograph
area
travel
immigr
camrsa
pneumonia
uncommon
worldwid
increas
may
follow
influenza
previous
healthi
peopl
may
caus
fatal
necrot
diseas
usual
associ
pvlproduc
camrsa
pvlposit
staphylococci
produc
necrot
pneumonia
anim
experi
role
pvl
human
diseas
still
debat
although
pvl
frequent
strain
caus
pneumonia
may
common
remain
seen
whether
type
camrsa
includ
strain
also
abil
continu
spread
camrsa
ongo
influenza
pandem
expect
incid
sever
camrsa
pneumonia
increas
hamrsa
pneumonia
ventil
patient
well
recognis
poor
prognosi
camrsa
spread
hospit
becom
increasingli
multidrug
resist
mdr
physician
awar
threat
hospitalacquir
pneumonia
virul
pvlproduc
mdr
camrsa
nation
intern
organis
provid
appropri
surveil
system
camrsa
mani
patient
requir
central
venou
cathet
arteri
line
although
indispens
benefit
vascular
access
devic
pose
potenti
risk
complic
due
central
lineassoci
bloodstream
infect
clabsi
risk
clabsi
vari
episod
per
catheterday
depend
wardtyp
institut
socioeconom
statu
countri
success
clabsi
prevent
strategi
multimod
includ
combin
effect
singl
intervent
measur
measur
procedur
use
maxim
steril
barrier
precaut
cathet
insert
avoid
femor
site
strict
hand
hygien
appli
nontouch
techniqu
cathet
handl
open
hub
antisepticimpregn
pad
chang
tube
indic
avoid
unnecessari
access
system
furthermor
indic
central
line
insert
must
justifi
cathet
remov
soon
possibl
intervent
measur
technic
chlorhexidinecontain
product
skin
antisepsi
chlorhexidin
dress
cathet
insert
site
impregn
cathet
antibiot
chlorhexidin
silversulfadiazin
access
devic
coat
silver
particl
close
infus
system
promis
approach
clabsi
prevent
use
locksolut
consist
taurolidinecitr
ethanol
edta
citratemethyleneblueparaben
although
evid
intervent
combin
bundl
effect
specif
combin
consid
superior
anoth
howev
effort
complex
cost
may
limit
possibl
appli
measur
togeth
even
import
infect
prevent
measur
especi
procedur
use
respect
daili
practic
episod
clabsi
identifi
intens
care
unit
care
complex
environ
attent
may
drawn
away
infect
control
measur
thu
infect
control
measur
must
simpl
easi
integr
daili
practic
furthermor
indispens
promot
infect
control
cultur
among
nurs
physician
ensur
prevent
measur
observ
stress
condit
although
technic
devic
may
help
stress
situat
failur
adopt
safeti
cultur
replac
use
impregn
cathet
chlorhexidin
dress
lock
solut
antimicrobi
biofilmbas
catheterrel
infect
new
perspect
last
decad
differ
strategi
develop
prevent
microbi
colon
intravascular
cathet
surfac
adsorpt
incorpor
devic
polym
matrix
antibioticantifung
agent
howev
current
avail
medic
cathet
shown
inhibit
microbi
biofilm
format
rel
short
period
mainli
due
massiv
releas
load
antimicrobi
agent
first
h
follow
slow
releas
subinhibitori
concentr
drug
exhaust
phenomenon
involv
risk
emerg
antibioticresist
strain
overcom
limit
focus
research
effort
develop
differ
experiment
approach
prevent
microbi
colon
central
venou
cathet
base
adsorpt
antimicrobi
agent
synthes
properli
function
polyurethan
aim
control
drug
adsorpt
releas
firstli
impregn
appropri
function
polyurethan
two
antibiot
differ
mechan
action
rifampicin
cefamandol
nafat
along
pore
form
agent
albumin
polyethylen
glycol
vitro
model
exhibit
good
polymerantibiot
affin
abil
obtain
control
releas
larg
amount
antimicrobi
day
result
suggest
entrap
antibiot
molecul
poreform
properli
function
polyurethan
may
repres
promis
approach
prevent
cathet
colon
onset
bacteri
resist
antibiofilm
strategi
deal
concern
develop
antimicrobi
polym
use
polyurethan
abl
coordin
metal
ion
ag
etc
ii
exploit
biofilm
matrixdegrad
enzym
dispersin
b
allow
better
penetr
antibiot
microbi
biofilm
thu
improv
activ
iii
develop
magnet
nanoparticlesbas
target
system
fight
catheterrel
infect
situ
demand
antimicrobi
treatment
present
focu
chang
epidemiolog
fever
import
region
reflect
travel
infect
databas
use
brief
vignett
highlight
import
clinic
diagnost
manag
issu
travel
detail
travel
exposur
immunis
histori
essenti
combin
knowledg
patient
comorbid
may
predispos
acquir
certain
infect
gener
malaria
less
like
caus
fever
infect
contrast
strongli
differenti
diagnosi
travel
arriv
africa
howev
recent
increas
malaria
transmiss
tourist
area
goa
remind
us
need
maintain
high
index
suspicion
continu
review
pretravel
advic
prevent
emerg
artemesinin
resist
thaimyanmar
border
area
concern
futur
recent
return
travel
arboviru
infect
dengu
chikungunya
common
caus
fever
confirm
use
molecular
techniqu
first
week
ill
serolog
test
thereaft
import
scrub
typhu
less
common
tick
typhu
travel
africa
leptopirosi
associ
fresh
water
activ
popular
tourist
south
east
asia
white
water
raft
tube
import
schistosomiasi
area
rare
eosinophilia
like
due
enter
system
helminth
fluke
infect
enter
fever
common
travel
indian
subcontin
recent
predomin
paratyphoid
often
resist
fluoroquinolon
multidrug
resist
first
line
agent
empir
treatment
await
cultur
result
resist
data
avoid
agent
includ
third
gener
cefalosporin
andor
azithromycin
antimicrobi
resist
common
infect
import
area
includ
extend
spectrum
blactamas
produc
gram
neg
bacteria
multidrug
resist
tuberculosi
respiratori
infect
common
travel
influenza
demonstr
frequent
vaccin
prevent
infect
acquir
tourist
south
east
asia
recent
experi
sar
ongo
concern
region
avian
influenza
remind
us
continu
risk
region
emerg
novel
viru
infect
spread
respiratori
rout
studi
perform
geo
sentinel
publish
recent
found
among
north
american
fever
travel
south
america
common
includ
malaria
salmonellosi
dengu
etc
import
make
geograph
distinct
mexico
amebiasi
hepat
abscess
typhoid
fever
alway
includ
central
america
typhoid
fever
dengu
main
caus
fever
histoplasmosi
toxoplasmosi
detect
immunosuppress
patient
south
america
malaria
p
falciparum
p
vivax
frequent
caus
fever
sinc
frequenc
typhoid
decreas
strain
typhi
continu
sensit
chloramphenicol
ampicillin
fluoroquinolon
contrast
asia
multidrug
resist
strain
detect
dengu
enter
hepat
frequent
caus
fever
peru
brucellosi
well
mexico
venezuela
bartonellosi
consid
import
diseas
occasion
region
mycos
histoplasmosi
exposur
cave
paracoccidioidomycosi
seen
j
van
den
antwerp
kabisa
comput
base
tutori
tropic
medicin
develop
sinc
first
version
foxpro
second
c
third
ms
access
xp
last
delphi
van
den
end
et
al
develop
countri
didact
tool
challeng
student
case
electron
assembl
randomli
gener
diseas
randomli
chosen
relat
present
symptom
student
find
diagnosi
set
diseas
characterist
avail
context
hospit
develop
countri
logic
engin
base
upon
pattern
recognit
bayesian
logic
western
context
programm
offer
also
expert
system
import
fever
base
prospect
gener
databas
patient
expert
modul
innov
suggest
new
test
base
data
alreadi
provid
user
suggest
threshold
driven
logic
follow
pauker
kassir
highest
rank
diagnosi
strong
exclud
ask
diagnosi
work
less
probabl
hypothes
examin
also
rank
suggest
test
take
account
power
feasibl
risk
cost
session
real
exampl
play
applic
logic
shown
want
detail
explan
program
given
particip
invit
bring
laptop
program
instal
distribut
free
refer
pauker
g
kassir
j
p
threshold
approach
clinic
decis
make
new
england
journal
medicin
vol
pp
medicin
vol
pp
van
den
end
j
blot
k
kesten
l
vangompel
vandenenden
e
kabisa
interact
computerassist
train
program
tropic
diseas
med
educ
vol
hospit
resourc
capabl
deal
highli
infecti
diseas
euronhid
data
survey
isol
facil
european
countri
schill
h
brodt
r
gottschalk
b
bannist
p
brouqui
fm
hc
maltez
g
thomson
v
puro
g
conclus
accord
preliminari
data
analysi
gener
hospit
resourc
isol
adequ
despit
fact
differ
level
prepared
among
differ
countri
still
present
particular
field
intens
care
capabl
avail
train
staff
data
repres
valuabl
tool
survey
facil
order
identifi
strength
weak
european
author
provid
onthefield
evalu
european
hospit
capabl
deal
hid
greec
n
itali
n
latvia
n
luxemburg
n
portug
n
slovenia
n
spain
n
observ
perform
train
research
nurs
random
date
time
bed
space
month
use
standard
protocol
deriv
moment
method
feedback
result
train
staff
allow
standard
test
use
assess
interobserv
variat
result
mean
bed
occup
rate
icu
averag
bed
patient
ventil
averag
nursetopati
ratio
per
occupi
bed
hhc
rate
vari
mean
nurs
hhc
higher
physician
hhc
mean
vs
two
center
auxiliari
nurs
healthcar
worker
intermedi
hhc
respect
separ
per
indic
categori
ie
hand
hygien
action
requir
hand
hygien
hhc
higher
latter
group
vs
p
miss
hand
hygien
opportun
involv
use
glove
mainli
perform
asept
task
possibl
bodi
fluid
contact
glove
use
opportun
miss
nurs
compar
physician
p
achiev
sustain
improv
hospit
hygien
clean
use
peergroup
benchmark
p
b
dick
e
eck
boston
toledo
passadena
us
object
ongo
contamin
surfac
patient
zone
pittet
becom
increasingli
recogn
play
role
transmiss
major
healthcareassoci
pathogen
past
five
year
indirect
monitor
system
use
improv
environment
hygien
relat
discharg
clean
almost
hospit
view
result
undertook
prospect
evalu
multihospit
benchmark
program
analyz
approach
improv
thorough
disinfect
clean
tdc
discharg
tdc
fourteen
high
touch
object
evalu
use
fluoresc
dye
base
target
method
two
hospit
system
consist
hospit
group
hospit
group
b
administr
relat
within
group
geograph
function
independ
institut
three
phase
intervent
util
previous
describ
ich
tdc
score
provid
environment
servic
administr
hospit
regular
basi
part
systemwid
qualiti
assur
review
system
meet
tdc
score
review
effect
programmat
educ
intervent
share
result
note
figur
patient
among
treat
patient
receiv
less
combin
parenter
top
three
class
prescrib
similar
group
correspond
combin
penicillin
blactamas
inhibitor
fluoroquinolon
thirdgener
cephalosporin
group
infect
repres
indic
respect
respiratori
tract
infect
commonest
infect
group
follow
skinsofttissuesandbonejoint
infect
urinari
tract
infect
proport
surgic
prophylaxi
lower
oldest
patient
day
durat
surgic
prophylaxi
group
prescrib
dose
parenter
ie
benzylpenicillin
gentamicin
cefuroxim
piperacillintazobactam
vancomycin
higher
whilst
amoxycillin
cefazolin
higher
result
studi
show
differ
elderli
age
group
particularli
proport
combin
parenter
use
infect
site
becam
clear
line
improv
qualiti
life
elderli
popul
industri
countri
treatment
compar
younger
adult
importantli
futur
analys
use
take
sever
age
group
elderli
popul
consider
nh
resid
receiv
ab
total
nhpopul
urinari
cathet
receiv
ab
wound
present
popul
ab
prescrib
vascular
cathet
uncommon
subpopul
use
ab
among
resid
ab
recent
hospit
stay
total
ab
molecul
use
ab
administ
oral
parenter
nasal
decolonis
mrsa
treatment
concern
urinari
tract
prophylact
respiratori
tract
empir
prescrib
regimen
empir
treatment
rti
uti
prophylact
uti
rti
document
infect
uti
preval
ab
use
significantli
lower
nh
regular
train
prescrib
p
written
guidelin
appropri
abus
p
nh
therapeut
formulari
p
compar
nh
without
tool
conclus
strong
differ
abpreval
deviceus
observ
eu
nh
micro
casemix
macro
determin
cultur
differ
partial
contribut
differ
high
proport
abus
urinari
tract
especi
import
part
uroprophylaxi
surpris
need
explor
median
mean
nh
resid
n
diagnos
undefin
wound
among
resid
treat
ab
n
wound
howev
consid
woundand
ab
preval
dichotom
median
institut
level
signific
relat
p
ab
use
resid
treat
ie
prophylact
empir
document
wound
infect
wi
among
ab
use
resid
wound
treat
wi
remark
resid
report
wound
treat
wi
ab
treat
nh
resid
admit
hospit
within
last
three
month
wound
without
hospit
admiss
wound
p
escherichia
coli
account
microorgan
mo
detect
among
resid
without
wound
contrast
p
resid
wound
methicillinresist
staphylococcu
aureu
found
among
resid
wound
without
p
resid
wound
receiv
often
empir
document
ab
treatment
resid
without
wound
p
p
respect
prophylact
ab
use
less
patient
without
wound
p
resid
contrast
without
wound
receiv
often
combin
penicillin
blactamas
inhibitor
vs
respect
p
cephalosporin
vs
p
contrari
resid
wound
receiv
antimicrobi
significantli
less
p
final
resid
compar
without
wound
receiv
less
often
oral
ab
vs
respect
p
significantli
often
parenter
ab
vs
p
presenc
wound
seem
significantli
influenc
ab
preval
howev
relat
presenc
wound
recent
hospit
admiss
regist
mo
ab
indic
type
ab
rout
administr
object
aim
present
studi
explor
differ
antimicrobi
consumpt
belgian
hospit
includ
differ
ward
type
report
restrict
antibacteri
system
use
whoatc
classif
method
belgian
hospit
invit
report
antimicrobi
use
feder
scientif
institut
public
health
iph
respons
data
collect
convers
defin
daili
dose
ddd
analysi
feed
back
data
collect
split
nonpediatr
pediatr
ward
also
option
report
intens
care
ward
hematologyoncolog
ward
overal
result
shown
icustrama
programm
develop
ten
year
ago
use
regular
audit
antibiot
use
antibiot
resist
infect
control
procedur
swedish
icu
joint
project
icustrama
swedish
intens
care
registri
central
compon
webbas
applic
includ
system
automat
feedback
purpos
report
increas
awar
use
programm
provid
ten
year
trend
analysi
antibiot
consumpt
materi
method
data
antibiot
consumpt
base
anatom
therapeut
chemic
atc
classif
system
collect
swedish
icu
enter
databas
use
web
applic
antibiot
consumpt
express
defin
daili
dose
ddd
per
occupi
bed
day
use
annual
updat
ddd
calcul
collabor
centr
drug
statist
methodolog
averag
mainten
dose
per
day
adult
main
indic
drug
http
wwwwhoccnoatcddd
data
analys
use
nonparametr
test
trend
across
order
group
spearman
rank
correl
use
statas
statacorp
lp
colleg
station
tx
usa
spss
version
spss
inc
chicago
il
usa
statist
signific
assum
p
median
antibiot
consumpt
increas
antibiot
consumpt
vari
wide
differ
unit
rang
median
trend
analys
usag
differ
class
antibiot
perform
show
increas
carbapenem
triazol
piperacillintazobactam
consumpt
p
signific
chang
consumpt
cephalosporin
ten
year
period
trend
toward
decreas
consumpt
last
two
year
signific
correl
antibiot
consumpt
standardis
mortal
rate
shown
conclus
high
antibiot
consumpt
concur
figur
european
us
icu
gener
like
icu
programm
rel
low
antibiot
consumpt
report
switzerland
lower
antibiot
consumpt
suggest
possibl
reduc
antibiot
consumpt
critic
ill
accompani
qualiti
control
system
make
sure
compromis
patient
outcom
develop
databas
facilit
assess
antimicrobi
consumpt
acut
tertiari
hospit
lw
kyaw
tun
solanki
foley
dublin
ie
background
monitor
antimicrobi
consumpt
trend
part
effect
systemat
surveil
programm
prevent
control
healthcareassoci
infect
antimicrobi
resist
express
antimicrobi
consumpt
data
world
health
organizationrecommend
measur
unit
defin
daili
dose
ddd
per
bedday
import
benchmark
purpos
also
partfulfil
nation
guidelin
antimicrobi
stewardship
hospit
ireland
object
achiev
aim
follow
carri
nation
survey
opinion
pharmacist
data
collect
antimicrobi
consumpt
hospit
develop
antimicrobi
consumpt
databas
express
bedday
hospitalwid
individu
group
special
wardsunit
evalu
antimicrobi
consumpt
trend
obtain
databas
origin
data
present
unit
dose
obtain
hospit
inform
databas
call
diver
solut
tm
interfac
microsoft
excel
aggreg
inhospit
consumpt
data
includ
issu
return
pharmaci
collect
abc
calc
version
adapt
excel
worksheet
creat
antimicrobi
consumpt
databas
convert
consumpt
data
unitdos
bedday
survey
found
variat
method
data
collect
antimicrobi
consumpt
among
hospit
lack
appropri
pharmaci
inform
technolog
inadequ
educ
train
antimicrobi
consumpt
data
collect
report
main
issu
concern
result
evalu
consumpt
trend
demonstr
need
monitor
hospitalwid
individu
special
wardsunit
separ
limit
atcddd
system
identifi
taken
consider
interpret
result
conclus
variat
exist
method
collect
report
antimicrobi
consumpt
studi
shown
set
antimicrobi
consumpt
databas
express
bedday
done
local
level
antimicrobi
consumpt
databas
avail
hospit
facilit
close
monitor
antimicrobi
consumpt
frequent
feedback
report
prescrib
also
supplement
surveil
microbi
resist
result
total
patient
antibiot
prescrib
prescript
contain
antibiot
mean
antibiot
per
prescript
indic
respiratori
tract
infect
vagin
discharg
urinari
tract
infect
skin
soft
tissu
infect
diarrhoea
prophylaxi
quinolon
commonest
group
prescrib
antibiot
prescrib
less
academ
hospit
p
prescrib
peak
raini
season
patient
prescrib
antibiot
independ
predictor
antibiot
prescrib
season
winter
winter
facil
profit
academ
age
group
adult
children
educ
level
illiter
educ
product
cough
present
ear
discharg
pneumonia
dysenteri
number
patient
per
diagnosi
prescript
rate
commonest
prescrib
antibiot
group
ddd
tpd
per
group
shown
tabl
conclus
statist
signific
associ
antibiot
prescrib
season
profit
hospit
age
group
educ
level
symptom
product
cough
present
ear
discharg
pneumonia
dysenteri
found
high
use
quinolon
caus
concern
system
antifung
therapi
european
hospit
dual
therapi
use
patient
tripl
therapi
patient
commonli
prescrib
antifung
fluconazol
account
antifung
therapi
follow
caspofungin
frequent
use
antifungalantibacteri
combin
includ
fluconazol
plu
either
quinolon
blactam
mainli
medic
prophylaxi
proport
parenter
use
within
total
antimycot
prescript
oral
rout
account
fluconazol
prescript
case
site
infect
undefin
whilst
common
site
respiratori
gastrointestin
ent
medic
specialti
account
major
antifung
use
hospit
acquir
infect
repres
indic
follow
medic
prophylaxi
conclus
esacpp
result
show
minim
variat
treatment
fungal
infect
mainli
observ
predomin
fluconazol
howev
high
use
fluconazol
increas
preval
fungi
eg
candida
glabrata
therefor
increas
need
newer
antifung
activ
inher
resist
pathogen
ongo
surveil
enhanc
effort
limit
extent
antifung
use
resist
antifung
prophylaxi
immunocompromis
host
need
explor
esacpp
methodolog
right
tool
analysi
piperacillintazobactam
vs
clearli
higher
imipenem
vs
perhap
also
ciprofloxacin
vs
mani
mic
close
breakpoint
conclus
resist
rate
hospitalacquir
lower
respiratori
isol
broadli
similar
bacteraemia
may
differ
substanti
case
data
analysi
need
clarifi
influenc
factor
patient
age
treat
special
appar
differ
resist
respiratori
blood
isol
direct
surveil
resist
specif
infect
prefer
extrapol
data
obtain
bacteraemia
possibl
ramirez
j
melocristino
lisbon
pt
object
although
pyogen
univers
suscept
penicillin
treatment
complic
group
streptococci
ga
infect
necrot
fasciiti
stss
associ
penicillin
clindamycin
advoc
resist
latter
describ
ga
associ
resist
macrolid
aim
work
evalu
resist
ga
invas
isol
sever
antimicrobi
agent
character
macrolid
resist
isol
method
total
invas
ga
isol
recov
portug
test
suscept
penicillin
vancomycin
erythromycin
tetracyclin
levofloxacin
chloramphenicol
clindamycin
quinupristindalfopristin
linezolid
disk
diffus
intermedi
suscept
confirm
mic
determin
use
etest
strip
resist
genotyp
determin
pcr
result
ga
isol
suscept
penicillin
vancomycin
chloramphenicol
quinupristindalfopristin
linezolid
two
present
reduc
suscept
levofloxacin
mic
ugml
total
isol
resist
erythromycin
also
constitut
resist
clindamycin
cmlsb
phenotyp
wherea
present
phenotyp
cmlsb
phenotyp
associ
presenc
erm
b
gene
wherea
phenotyp
associ
mef
nonsuscept
tetracyclin
found
isol
also
express
cmlsb
phenotyp
phenotyp
conclus
erythromycin
resist
among
invas
ga
isol
portug
vari
significantli
contrarili
report
isol
caus
pharyng
whose
macrolid
resist
decreas
macrolid
resist
observ
studi
invas
ga
isol
line
report
countri
well
overal
rate
report
pharyng
isol
portug
object
continu
concern
ertapenem
e
neg
effect
imipenem
suscept
pseudomona
aeruginosa
pa
purpos
monitor
e
effect
suscept
pa
antipseudomon
formulari
piperacillin
tazobactam
pt
cefepim
c
tobramycin
also
examin
proport
expand
also
replac
hamrsa
chang
occur
princip
among
abscess
wound
isol
children
young
adult
lesser
degre
also
among
isol
sourc
age
group
four
five
isol
outpati
set
possess
camrsa
phenotyp
find
may
prevent
therapeut
implic
manag
aureu
infect
h
langvatn
j
schrama
g
hallan
h
dale
b
espehaug
h
sjursen
l
engesaet
bergen
object
antibiot
prophylaxi
commonli
use
prosthesi
surgeri
system
local
cement
examin
bacteri
find
specimen
taken
revis
due
deep
infect
report
norwegian
arthroplasti
regist
nar
suscept
aminoglycosid
gentamicin
tobramycin
netilmicin
blactamasest
penicillin
meticillin
oxacillin
cloxacillin
methicillingroup
present
antibiot
commonli
use
prophylaxi
treatment
prosthet
joint
infect
pji
method
collect
bacteri
find
oper
report
revis
infect
nar
inform
collect
note
ten
hospit
norway
report
revis
infect
period
revis
report
nar
ten
hospit
total
number
report
revis
norwegian
hospit
studi
includ
oper
one
posit
sampl
bacteria
test
differ
antibiot
differ
hospit
differ
time
period
use
c
test
linear
trend
evalu
chang
distribut
sensit
intermedi
resist
r
bacteria
time
exclud
first
fiveyear
period
due
low
number
case
compar
latter
three
fiveyear
period
vs
respect
frequent
bacteria
isol
coagulaseneg
staphylococci
con
aureu
sa
overal
oper
con
sa
found
among
con
bacteria
resist
aminoglycosid
proport
resist
increas
p
overal
resist
con
meticillingroup
mrse
found
mrse
proport
increas
object
clostridium
difficil
infect
lead
caus
nosocomi
diarrhea
emerg
spread
resist
c
difficil
complic
treatment
prevent
purpos
present
studi
investig
antimicrobi
suscept
pattern
resist
mechan
chines
c
difficil
strain
method
toxigen
c
difficil
isol
collect
decemb
may
fudan
univers
hospit
huashan
analyz
antibiot
suscept
pattern
use
agar
dilut
method
heteroresist
metronidazol
fresh
isol
detect
disc
diffus
etest
method
resist
molecular
basi
investig
use
polymeras
chain
reaction
pcr
dna
sequenc
result
differ
pcr
ribotyp
identifi
domin
clone
account
isol
follow
h
ribotyp
found
one
isol
belong
ribotyp
isol
suscept
vancomycin
piperacillintazobactam
howev
isol
found
transient
heteroresist
metronidazol
resist
moxifloxacin
ciprofloxacin
levofloxacin
erythromycin
clindamycin
tetracyclin
rifampin
rifaximin
fusid
acid
found
isol
respect
isol
common
pcr
ribotyp
resist
uncommon
ribotyp
preval
resist
gene
mutat
among
resist
isol
follow
ermb
tetm
gyra
mutat
gyrb
mutat
gyra
gyrb
mutat
rpob
mutat
respect
fusa
mutat
found
one
isol
minimum
inhibitori
concentr
mic
mgl
genu
flaviviru
famili
flavivirida
compris
differ
viru
speci
mani
arthropodborn
transmit
vertebr
host
mosquito
tick
among
import
human
pathogen
yellow
fever
viru
dengu
virus
type
japanes
enceph
viru
west
nile
viru
tickborn
enceph
viru
depend
specif
differ
natur
host
system
virus
differ
respect
area
geograph
distribut
least
instanc
potenti
emerg
new
pathogen
previous
nonendem
region
flavivirus
positivestrand
rna
virus
lipid
envelop
three
structur
protein
design
c
capsid
membran
e
envelop
noninfecti
immatur
particl
contain
precursor
protein
prm
form
intracellularli
proteolyt
cleavag
prm
cellular
proteas
furin
gener
matur
infecti
virion
shortli
releas
infect
cell
respect
structur
flavivirus
among
beststudi
envelop
virus
atom
structur
e
protein
sever
flavivirus
determin
use
xray
crystallographi
architectur
immatur
matur
virion
known
cryoelectron
microscop
studi
combin
structur
immunolog
investig
gain
detail
understand
effect
antibodybind
viru
differ
antigen
includ
definit
viru
neutral
antibodymedi
enhanc
ade
infect
molecular
level
latter
phenomenon
propos
play
import
role
immunopatholog
sever
form
dengu
viru
infect
hemorrhag
dengu
fever
dengu
shock
syndrom
cours
sequenti
infect
differ
dengu
serotyp
structur
insight
also
shed
new
light
differ
degre
crossreact
flavivirus
includ
exist
cryptic
epitop
recogn
broadli
flaviviru
crossreact
nocardia
infect
antibodi
without
lead
neutral
current
pictur
antibodi
interact
flavivirus
present
context
biolog
signific
treatment
invas
aspergillosi
pharmacokinet
vs
resist
clinic
impact
azol
resist
p
nijmegen
nl
class
azol
becom
promin
class
compound
manag
invas
aspergillosi
clinic
licens
triazol
activ
aspergillu
includ
itraconazol
voriconazol
posaconazol
azol
also
drug
administ
oral
azol
interact
biosynthesi
ergosterol
import
compon
fungal
cell
membran
intrins
resist
azol
document
calidoustu
vast
major
speci
suscept
vitro
recent
aspergillu
speci
acquir
resist
azol
report
especi
fumigatu
appear
resist
may
develop
azol
therapi
especi
patient
chronic
therapi
includ
patient
chronic
infect
aspergilloma
anoth
rout
resist
develop
may
exposur
aspergillu
azol
fungicid
use
environ
patient
would
inhal
azoleresist
conidia
develop
azoleresist
aspergillosi
consequ
rout
transmiss
azoleresist
diseas
may
occur
patient
without
previou
exposur
azol
compound
azol
resist
commonli
due
mutat
associ
differ
phenotyp
isol
may
resist
singl
azol
compound
commonli
crossresist
phenotyp
observ
sever
case
azoleresist
aspergillosi
report
commonli
patient
fail
respond
azol
therapi
azoleresist
fumigatu
isol
remain
virul
capabl
caus
invas
diseas
patient
risk
efficaci
azol
compound
azoleresist
isol
differ
resist
mechan
investig
experiment
model
invas
aspergillosi
indic
minim
inhibitori
concentr
major
impact
efficaci
azol
elev
mic
associ
loss
efficaci
azol
compound
vivo
use
azol
avoid
patient
azoleresist
aspergillosi
possibl
altern
agent
lipidformul
amphotericin
b
caspofungin
appear
retain
efficaci
azoleresist
isol
signific
problem
earli
diagnosi
azoleresist
major
case
isol
obtain
isol
cultur
vitro
suscept
test
caus
delay
treatment
effect
agent
infecti
diseas
time
pose
tremend
challeng
medic
commun
confront
emerg
infecti
diseas
increas
antimicrobi
resist
stagnant
develop
new
antibiot
poor
qualiti
antimicrobi
prescrib
poor
complianc
hospit
hygien
revolut
microbiolog
increas
number
immunocompromis
frail
patient
upcom
immunotherapeut
possibl
cope
problem
success
way
synergi
clinic
microbiologist
clinician
infecti
diseas
expertis
need
ever
view
profil
ideal
microbiologist
welltrain
physician
receiv
specialti
train
encompass
laboratori
skill
microbiolog
molecular
biolog
practic
train
clinic
infecti
diseas
epidemiolog
public
health
hygien
research
commun
ideal
set
close
partnership
id
physician
complementar
optim
collabor
mutual
recognit
trust
daili
practic
howev
obstacl
may
encount
compet
mistrust
ego
psycholog
factor
financ
time
organiz
constraint
hurdl
recogn
dealt
natur
infecti
diseas
id
chang
significantli
past
decad
mani
id
success
erad
vaccin
cours
infect
chang
due
improv
standard
life
hand
chang
life
style
longer
life
expect
promot
emerg
spread
new
id
spite
rigor
attempt
control
hospit
care
associ
infect
infect
becom
grow
problem
modern
medicin
appear
multipli
resist
organ
shortag
new
antibiot
pipelin
place
demand
develop
expertis
difficult
field
antibiot
stewardship
therefor
profess
id
doctor
centuri
complex
one
good
skill
knowledg
recogn
tradit
infecti
diseas
even
believ
erad
frequent
area
practic
howev
past
decad
infecti
diseas
typic
clinic
present
well
defin
pathogen
signific
extent
replac
infect
whose
symptom
overlap
symptom
underli
diseas
patient
easili
differenti
caus
system
inflammatori
respons
syndrom
therefor
id
doctor
good
commun
skill
deal
colleagu
differ
specialti
use
work
team
appreci
differ
skill
brought
differ
disciplin
clinic
microbiologist
point
view
ideal
infecti
diseas
specialist
recogn
field
clinic
microbiolog
cm
undergon
transform
mostli
research
public
health
orient
microbiolog
toward
microbiolog
patient
bedsid
mani
patient
individu
approach
team
work
produc
satisfactori
diagnosi
treatment
infect
fact
skill
compet
modern
id
cm
doctor
overlap
greater
extent
specialti
make
solid
ground
close
collabor
partnership
two
profess
import
field
clinic
practic
well
field
research
grow
number
literatur
relat
infecti
diseas
anyon
involv
manag
patient
basic
knowledg
research
methodolog
compet
practic
evid
base
medicin
nocardiosi
uncommon
bacteri
infect
wide
varieti
clinic
manifest
immunocompet
immunocompromis
patient
number
case
report
literatur
increas
might
due
absolut
increas
number
immunocompromis
patient
also
improv
laboratori
techniqu
detect
nocardiosi
host
resist
nocardi
infect
depend
neutrophil
earli
lesion
cellmedi
immun
respons
common
predispos
factor
opportunist
nocardia
infect
longterm
steroid
usag
chronic
obstruct
pulmonari
diseas
neoplast
diseas
human
immunodefici
viru
infect
clinic
manifest
nocardiosi
rang
cutan
infect
caus
traumat
inocul
normal
host
sever
pulmonari
central
nervou
system
diseas
immunocompromis
host
genu
nocardia
rapidli
expand
speci
distribut
vari
differ
geograph
locat
previou
studi
also
emphas
import
determin
speci
nocardia
differ
speci
isol
vari
antimicrobi
suscept
pattern
sulphonamid
use
treatment
nocardiosi
sinc
still
drug
choic
common
antimicrobi
use
treat
infect
sulphonamid
monotherapi
howev
associ
mortal
rate
almost
patient
central
venou
system
cn
nocardi
infect
addit
patient
noncn
infect
overwhelm
dissemin
diseas
high
mortal
rate
treat
sulphonamid
alon
howev
current
avail
therapeut
altern
scarc
compris
amoxicillinclavulan
carbapenem
imipenem
meropenem
doripenem
ertapenem
amikacin
resist
previous
administ
drug
toxic
intoler
antimicrobi
even
therapeut
failur
necessit
search
altern
agent
result
vitro
studi
suggest
nemonoxacin
nonfluorin
quinolon
linezolid
tigecyclin
show
promis
altern
treatment
nocardiosi
clinic
trial
need
clarifi
role
treatment
infect
efficaci
safeti
oseltamivirzanamivir
combin
compar
monotherapi
season
influenza
random
doubleblind
placebocontrol
trial
object
sever
studi
provid
evid
neuraminidas
inhibitor
reduc
durat
influenza
symptom
yet
data
regard
effect
reduc
influenza
complic
scarc
method
evalu
effect
neuraminidas
inhibitor
reduc
influenza
complic
mortal
patient
season
influenza
perform
metaanalysi
random
control
trial
rct
retriev
pubm
cochran
scopu
databas
compar
neuraminidas
inhibitor
placebo
result
eleven
rct
doubleblind
openlabel
design
includ
involv
adult
adolesc
total
patient
includ
confirm
infect
total
influenzarel
complic
occur
significantli
less
like
otherwis
healthi
patient
confirm
infect
treat
antivir
versu
placebo
rct
patient
odd
ratio
confid
interv
ci
find
pronounc
highrisk
patient
rct
patient
compar
otherwis
healthi
patient
p
comparison
regard
respiratori
complic
trend
favour
antivir
observ
regard
acut
otiti
media
specif
signific
differ
observ
significantli
fewer
antibiot
also
administ
patient
confirm
infect
treat
antivir
versu
placebo
rct
patient
differ
found
comparison
regard
safeti
outcom
metaanalysi
mortal
data
scarc
report
death
report
respect
trial
conclus
neuraminidas
inhibitor
appear
effect
reduc
total
influenzarel
complic
otherwis
healthi
confirm
infect
highrisk
patient
also
reduc
addit
antibiot
consumpt
solid
tumor
lymphoma
multipl
myeloma
chronic
leukemia
patient
fever
acut
respiratori
symptom
previou
chemotherapi
neutropenia
histori
steroid
therapi
commonli
present
patient
laboratorydocu
bacteri
infect
ill
onset
howev
receiv
antibacteri
agent
present
seventeen
patient
develop
bilater
pulmonari
infiltr
sever
hypoxemia
present
case
underw
mechan
ventil
twentytwo
patient
treat
oseltamivir
doubl
dose
prescrib
median
time
admiss
antivir
therapi
start
day
rang
day
antivir
therapi
start
within
h
symptom
patient
main
reason
therapi
delay
lack
specif
symptom
neutropen
patient
initi
difficulti
obtain
antivir
drug
five
patient
die
two
never
receiv
oseltamivir
case
therapi
start
day
hospit
admiss
studi
present
seri
cancer
patient
viru
infect
elev
mortal
observ
high
number
case
young
patient
consid
clinic
data
nosocomi
transmiss
ruledout
data
show
possibl
associ
mortal
lack
delay
antivir
therapi
initi
faster
avail
antivir
medic
therapi
prophylaxi
vaccin
program
reinforc
among
cancer
patient
close
contact
healthcar
worker
impact
antisept
base
oral
care
rate
ventilatorassoci
pneumonia
intens
care
unit
patient
metaanalysi
k
van
de
vyver
labeau
n
brussela
vogela
ghent
object
ventilatorassoci
pneumonia
vap
frequent
nosocomi
infect
intens
care
unit
reduc
inoculum
oral
pathogen
microorgan
adequ
oral
care
could
prevent
vap
method
systemat
review
literatur
concern
oral
decontamin
chlorhexidin
povidoneiodin
intub
patient
subsequ
metaanalysi
evalu
effect
oral
decontamin
incid
vap
perform
relev
articl
search
electron
databas
pubm
cinahl
web
scienc
central
supplement
manual
search
refer
list
random
control
trial
evalu
effect
oral
care
use
chlorhexidin
povidoneiodin
vs
oral
care
without
use
antisept
incid
vap
adult
intub
patient
includ
data
extract
dichotom
variabl
data
analysi
perform
use
revman
statist
analysi
conduct
accord
mantelhaenszel
model
obtain
rel
risk
rr
confid
interv
ci
heterogen
assess
use
test
result
eleven
studi
includ
analysi
n
patient
investig
effect
oral
care
use
chlorhexidin
n
patient
assess
effect
oral
care
use
povidoneiodin
n
patient
use
antisepticum
result
signific
reduct
incid
vap
rr
ci
p
result
valid
chlorhexidin
rr
ci
p
povidoneiodin
rr
ci
p
among
studi
import
differ
exist
concern
concentr
antisept
use
frequenc
oral
care
studi
methodolog
diagnost
criteria
vap
clinic
heterogen
confirm
statist
moder
c
p
trial
use
chlorhexidin
high
c
p
assess
povidoneiodin
subgroup
analys
reveal
benefici
effect
concentr
chlorhexidin
povidoneiodin
popul
cardiac
surgeri
patient
conclus
analysi
show
oral
decontamin
antisept
reduc
incid
vap
significantli
chlorhexidin
povidoneiodin
show
effect
howev
research
need
make
recommend
concentr
frequenc
applic
treat
panobacumab
thirteen
patient
complet
receiv
infus
patient
noncomplet
receiv
infus
studi
drug
safe
well
toler
panobacumab
reveal
pharmacokinet
profil
similar
nativ
igm
panobacumab
could
detect
bal
sampl
collect
treatment
indic
antibodi
reach
inflam
lung
tissu
clinic
initi
mean
cpi
apacheii
score
expect
mortal
overal
observ
mortal
within
day
start
treatment
despit
apacheii
score
expect
mortal
complet
surviv
within
first
day
noncomplet
show
surviv
rate
resolut
pneumonia
achiev
complet
day
includ
two
patient
initi
inadequ
treat
earli
administr
antibodi
seem
correl
posit
resolut
pneumonia
mean
cmax
third
dose
panobacumab
higher
patient
resolut
continu
pneumonia
day
respect
overal
clinic
cure
microbiolog
erad
respect
median
dose
hd
dap
rie
vs
lie
mgkgday
vs
mgkgday
respect
safeti
patient
object
osteomyel
om
complic
divers
diseas
long
term
efficaci
safeti
antibiot
import
determin
select
optim
therapi
first
report
larg
seri
om
case
treat
daptomycin
dap
across
mani
countri
europ
method
data
collect
part
european
cubicin
outcom
registri
experi
eucor
program
retrospect
nonintervent
observ
multicent
studi
design
describ
clinic
use
dap
patient
pt
diagnosi
om
select
databas
pt
treat
least
one
dose
dap
safeti
paramet
assess
includ
safeti
popul
efficaci
popul
subset
safeti
popul
clinic
outcom
cure
improv
failur
nonevalu
assess
investig
pt
enrol
jan
aug
includ
result
pt
enrol
male
year
diagnos
om
case
om
nonprosthet
devic
relat
perman
prosthet
devic
relat
temporari
prosthet
devic
relat
pt
primari
pathogen
report
aureu
frequent
speci
mrsa
n
signific
subset
coagulaseneg
staphylococci
rank
second
pt
receiv
dap
dose
mgkg
median
durat
dap
outpt
therapi
day
rang
inpt
therapi
rang
overal
clinic
success
cure
improv
seen
pt
failur
pt
nonevalu
subgroup
analys
clinic
success
observ
pt
without
devic
pt
perman
devic
pt
temporari
prosthet
devic
serum
creatin
phosphokinas
cpk
valu
report
pt
dap
therapi
pt
cpk
level
remain
within
normal
rang
discontinu
dap
due
treatment
failur
report
pt
seriou
ae
report
pt
ae
lead
studi
drug
discontinu
report
conclus
dap
dose
mgkg
daili
frequent
dose
regimen
use
osteomyel
europ
dap
welltoler
also
longer
treatment
durat
promis
result
warrant
confirm
addit
studi
object
treatment
recommend
invas
enterococc
infect
advoc
synergist
combin
ampicillin
plu
gentamicin
case
resist
one
even
drug
vancomycin
therapi
propos
albeit
poorli
bactericid
swiss
surveil
program
report
resist
enterococcu
faecium
aminopenicillin
highlevel
gentamicin
high
respect
wwwanresisch
leav
clinician
therapeut
conundrum
sinc
establish
therapeut
regimen
exist
daptomycin
approv
complic
skin
soft
tissu
infect
gramposit
bacteria
show
efficaci
e
faecium
experiment
endocard
model
method
report
case
seri
patient
sever
e
faecium
infect
treat
daptomycin
univers
hospit
basel
strain
resist
ampicillin
mic
mgl
suscept
vancomycin
strain
also
highli
resist
gentamicin
mic
mgl
result
patient
treat
multipl
broadspectrum
antibiot
prior
isol
e
faecium
sever
underli
diseas
five
haematolog
malign
two
repeat
episod
cholangiosepsi
two
suffer
sever
atherosclerosi
multipl
vascular
surgic
procedur
one
undergon
liver
transplant
one
colon
cancer
foci
mainli
blood
stream
infect
cholang
reason
daptomycin
treatment
renal
failur
n
vancomycin
failur
n
despit
vancomycin
suscept
mic
mgl
outpati
parenter
therapi
n
uncontrol
infect
n
one
isol
patient
persist
bacteremia
vitro
killcurv
perform
show
bactericid
effect
daptomycin
loss
h
mgl
mgl
drug
contrast
mgl
vancomycin
bacteriostat
daptomycin
use
dose
mgkgd
patient
recov
patient
die
death
relat
uncontrol
infect
one
case
death
attribut
underli
diseas
conclus
case
seri
suggest
salvag
therapi
daptomycin
like
effici
patient
refractori
invas
infect
due
multiresist
e
faecium
thu
daptomycin
might
safe
option
case
object
outbreak
pandrugresist
pdr
acinetobact
baumannii
ab
emerg
singapor
combin
therapi
often
remain
viabl
option
new
antibiot
avail
polymyxin
b
p
may
remain
viabl
treatment
option
heteroresist
becom
major
problem
evalu
efficaci
p
rifampicin
r
tigecyclin
combin
pdr
ab
isol
local
hospit
method
pdr
ab
isol
public
hospit
singapor
collect
mic
determin
accord
modifi
clsi
brothdilut
method
timekil
studi
tk
perform
maximum
clinic
achiev
unbound
concentr
mgl
p
r
alon
combin
pdr
ab
isol
hollowfib
infect
model
hfim
use
valid
quantit
assess
combin
kill
isol
select
base
uniqu
genotyp
repres
pdr
ab
popul
resist
select
isol
p
alon
hfim
quantifi
use
drugfre
select
p
mic
media
result
among
nonrepeat
ab
isol
screen
pdr
ab
isol
found
suscept
p
mic
mgl
resist
antibiot
class
wherea
r
mic
rang
mgl
tk
p
r
alon
bacteriostat
regrowth
h
isol
pr
pt
rt
achiev
kill
baselin
isol
regrowth
h
assess
consist
observ
hfim
studi
observ
bacteri
kill
h
pr
pharmacokinet
valid
hfim
studi
satisfactori
minim
kill
isol
seen
expos
p
alon
regrowth
seen
h
due
select
amplic
resist
subpopul
p
supplement
plate
repeat
mic
test
resist
isol
confirm
p
resist
mic
mgl
conclus
shown
pdr
ab
propens
exhibit
heteroresist
combin
therapi
p
need
pr
may
potenti
antibiot
combin
therapi
pdr
ab
infect
vivo
relev
result
warrant
investig
data
avail
antibiot
activ
intracellular
pa
develop
infect
model
use
cell
human
cell
line
known
permiss
infect
sever
import
human
pathogen
model
use
test
activ
antibiot
repres
class
drug
use
clinic
treat
pseudomon
infect
method
phagocytosi
bacteria
opson
human
serum
allow
h
bacteriamacrophag
ratio
extracellular
bacteria
elimin
wash
incub
min
gentamicin
x
mic
infect
cell
cfumg
cell
prot
incub
antibiot
mic
activ
bacteria
broth
cfuml
determin
parallel
conc
span
activ
express
chang
initi
inoculum
h
data
use
fit
concentrationrespons
curv
hill
equat
calcul
emax
cstatic
pharmacodynam
paramet
aac
tabl
show
tob
dor
cidal
broth
emax
log
cfu
intracellular
maxim
efficaci
markedli
reduc
less
neg
emax
toward
intracel
pa
lvx
also
affect
lesser
extent
cst
bacteriostat
extracel
bacteria
also
show
decreas
intracellular
efficaci
addit
cst
tob
show
fold
decreas
rel
potenc
higher
cstatic
compar
intracel
extracel
bacteria
conclus
model
show
intracel
bacteria
antibiot
consider
less
activ
class
less
potent
intracellular
form
compar
bacteria
broth
irrespect
mode
action
may
contribut
difficulti
erad
p
aeruginosa
vivo
object
develop
popul
pharmacokinet
pk
model
delafloxacin
dfx
use
model
estim
pharmacokineticpharmacodynam
pkpd
indic
phase
patient
treat
complic
skin
skin
structur
infect
csssi
method
data
phase
studi
singl
dose
two
multipl
dose
phase
csssi
studi
pool
develop
popul
pharmacokinet
model
dose
administ
iv
infus
dose
rang
mg
phase
studi
employ
dose
mg
bid
intens
pk
sampl
employ
phase
studi
phase
patient
contribut
sampl
steadyst
one
dose
interv
popul
pk
model
perform
use
mont
carlo
parametr
expect
maxim
implement
sadapt
two
compart
model
explor
use
linear
andor
nonlinear
elimin
steadyst
auc
cmax
estim
calcul
use
individu
pk
paramet
estim
phase
patient
index
observ
pathogen
mic
calcul
pkpd
indic
previou
anim
studi
indic
freedrug
auc
mic
ratio
fauc
mic
associ
net
bacteri
stasi
cfu
reduct
respect
staphylococcu
aureu
result
final
analysi
dataset
includ
subject
phase
phase
plasma
concentr
compart
model
mix
linear
nonlinear
elimin
provid
robust
fit
data
r
fit
paramet
estim
excel
precis
interindividu
variabl
paramet
defin
clearanc
linear
clearanc
intrins
clearanc
michaelismenten
constant
rang
twelv
patient
requisit
mic
data
calcul
pkpd
index
faucss
mic
estim
rang
patient
classifi
clinic
microbiolog
cure
median
min
max
fcmax
mic
ratio
seven
patient
mrsa
primari
pathogen
mic
valu
univers
low
conclus
develop
popul
pk
model
allow
estim
drug
exposur
phase
csssi
studi
use
rel
spars
pk
sampl
base
pkpd
indic
phase
studi
mg
bid
clinic
dose
appropri
treatment
csssi
result
also
support
coverag
mic
valu
mcgml
pharmacokinet
penetr
ciprofloxacin
bronchial
secret
critic
ill
patient
chronic
obstruct
pulmonari
diseas
p
k
chatzika
g
pitsiou
boutou
p
argyropoul
kioumi
thessaloniki
gr
object
ciprofloxacin
cip
one
antibiot
choic
treatment
sever
exacerb
chronic
obstruct
pulmonari
diseas
copd
antibiot
penetr
site
infect
critic
obtain
optim
clinic
outcom
sinc
copd
patient
infect
develop
within
airway
lumen
import
know
drug
concentr
achiev
bronchial
secret
bs
purpos
studi
evalu
cip
pharmacokinet
pk
profil
plasma
penetr
bs
mechan
ventil
copd
patient
administ
current
recommend
dose
mg
per
day
method
ninenteen
critic
ill
copd
patient
receiv
infus
mg
cip
h
respiratori
infect
well
risk
factor
ps
aeruginosa
intub
serial
blood
bs
sampl
obtain
steadi
state
concentr
determin
valid
hplc
assay
penetr
ratio
calcul
divid
h
area
curv
auc
bs
auc
plasma
pharmacodynam
pd
paramet
cip
also
calcul
result
valu
volum
distribut
clearanc
halflif
auc
l
lh
h
respect
mean
peak
c
max
trough
level
plasma
mgl
respect
bs
mean
c
max
mgl
achiev
hour
penetr
ratio
thirteen
patient
demonstr
penetr
equal
even
pd
target
auc
mic
plasma
shown
predict
efficaci
gramneg
infect
attain
patient
major
mic
mgml
respect
patient
none
higher
mic
mgml
slightli
better
result
obtain
pd
threshold
c
max
mic
conclus
cip
exhibit
excel
penetr
bs
wide
interindividu
variabl
pk
paramet
critic
ill
copd
patient
inadequ
pd
exposur
bacteria
mic
mgml
data
confirm
need
combin
therapi
pathogen
high
mic
ps
aeruginosa
well
institut
therapeut
drug
monitor
individu
antimicrobi
dose
order
optim
efficaci
antibiot
therapi
icu
initi
problem
challeng
infect
identifi
infect
organ
focu
infect
usual
problem
acut
infect
sinc
bacteria
readili
obtain
swap
sampl
infect
area
chronic
infect
usual
problemat
except
cystic
fibrosi
cf
easi
access
purul
sputum
cough
patient
regular
basi
harbor
bacteria
chronic
infect
routin
sampl
either
use
swab
scrape
biopsi
howev
might
fail
sampl
bacteria
chronic
wound
swab
collect
bacteria
surfac
bacteria
embed
wound
bed
hand
sinc
bacteria
heterogen
distribut
chanc
biopsi
fail
contain
bacteria
also
implant
cathet
relat
infect
diagnos
bacteria
prove
difficult
five
year
ago
bacteria
surfac
biofilm
gener
consid
uncultur
problem
surfac
adher
bacteria
simpli
attach
extrem
well
surfac
foreign
bodi
uncultur
releas
surfac
vigor
vortex
even
mechan
scrape
enough
implant
cathet
treat
ultra
sound
sonic
releas
bacteria
problem
diagnos
bacteria
chronic
infect
far
solv
today
bacteria
detect
cultur
pcr
microscopi
diagnost
imag
method
advantag
limit
cultur
problem
collect
bacteria
either
next
surfac
sampl
cathet
implant
pcr
detect
even
tini
amount
avail
dna
rna
avail
sampl
addit
bacterium
present
necessarili
indic
contribut
pathogenesi
infect
microscopi
gramstain
fluoresc
situ
hybrid
fish
enabl
direct
visual
infect
bacteria
surround
tissu
inflammatori
cell
bacteria
need
present
collect
sampl
mean
mani
biopsi
need
analyz
correct
diagnost
eg
wound
hand
bacteria
present
might
hard
statist
imposs
observ
use
tradit
stain
gram
streptococcu
pyogen
group
streptococcu
ga
respons
divers
rang
clinic
manifest
mild
skinsoft
tissu
infect
pharyng
seriou
manifest
bacteremia
cellul
puerper
sepsi
mening
pneumonia
necrot
fasciiti
drug
choic
streptococc
infect
treatment
still
remain
penicillin
fact
abil
penicillin
relat
antibiot
eg
amoxicillin
kill
group
streptococci
chang
year
date
never
report
group
streptococcu
resist
class
antibiot
hand
macrolid
resist
show
increas
trend
resist
rate
vari
consider
differ
countri
reach
almost
part
europ
effect
treatment
utmost
import
even
streptococc
pharyng
primarili
aim
prevent
nonsuppur
suppur
complic
decreas
infect
even
frequent
pyogen
infect
may
fail
respond
antibiot
therapi
lead
persist
throat
carriag
recurr
infect
failur
alway
explain
occurr
antibiot
resist
determin
first
suggest
erythromycinresist
pyogen
may
escap
antimicrobi
treatment
host
immun
respons
invas
epitheli
cell
later
ga
recent
shown
abl
form
biofilm
charact
known
provid
organ
improv
antibiot
resist
besid
support
colon
persist
biofilm
suggest
possibl
respons
unexplain
treatment
failur
recurr
due
suscept
microorgan
preliminari
data
shown
biofilm
may
produc
andor
upregul
pyogen
respons
either
antibiot
treatment
therapeut
molecul
environment
stimuli
particular
submic
antibiot
concentr
appear
stimul
biofilm
format
phenomenon
observ
increas
frequenc
number
microorgan
biofilm
virul
factor
latest
find
known
biofilm
produc
pyogen
possibl
role
pathogenesi
streptococc
infect
interact
antibiot
therapeut
molecul
streptococc
biofilm
examin
aspergillu
fumigatu
caus
infect
immunocompromis
host
patient
chronic
lung
infect
initi
establish
fumigatu
infect
involv
germin
conidia
subsequ
hyphal
invas
lung
tissu
histolog
microscop
examin
bronchopulmonari
lavag
sampl
reveal
presenc
numer
fumigatu
hypha
form
complex
mesh
like
structur
similar
fungal
biofilm
develop
vitro
model
aspergilu
fumigatu
biofilm
model
possess
classic
element
biofilm
growth
name
multicellular
matrix
product
sessil
resist
show
distinct
development
phase
genotyp
phenotyp
discuss
vitro
antifung
activ
voriconazol
amphotericin
b
caspofungin
model
may
relat
use
antifung
clinic
also
better
understand
biolog
aspergillu
fumigatu
vitro
may
lead
differ
approach
diagnosi
invas
fungal
infect
imag
microdos
fit
antimicrobi
agent
drug
exert
effect
within
plasma
compart
defin
target
tissu
drug
distribut
central
compart
unfortun
complet
last
equilibr
blood
tissu
alway
taken
grant
drug
distribut
process
may
character
high
intertissueand
intersubject
variabl
target
site
drug
level
may
substanti
differ
correspond
plasma
level
suboptim
target
site
concentr
may
import
clinic
implic
potenti
explan
therapeut
failur
particular
antimicrobi
agent
knowledg
drug
tissu
distribut
primal
import
tissu
drug
exposur
shown
directli
relat
outcom
therapi
therefor
determin
drug
tissu
penetr
play
import
role
antimicrobi
drug
develop
positron
emiss
tomographi
pet
nuclear
imag
method
use
studi
tissu
distribut
drug
label
positronemit
radionuclid
noninvas
type
studi
term
petmicrodos
studi
amount
drug
administ
pet
studi
usual
less
microgram
due
low
administ
drug
dose
potenti
toxicolog
risk
human
subject
limit
consequ
regulatori
author
requir
reduc
preclin
safeti
test
compar
convent
phase
studi
present
talk
recent
applic
petmicrodos
antimicrobi
drug
develop
review
pk
model
obtain
pk
profil
despit
spars
sampl
object
tissu
penetr
studi
pose
signific
challeng
pharmacokineticpharmacodynam
pkpd
model
especi
one
tissu
sampl
obtain
per
patient
sought
systemat
evalu
abil
variou
optim
nonoptim
clinic
trial
design
determin
rate
extent
tissu
penetr
subject
variabl
bsv
mont
carlo
simul
model
perform
berkeley
madonna
simul
plasma
tissu
concentr
patient
intraven
moxifloxacin
exampl
drug
simul
scenario
assum
tissu
concentr
proport
concentr
peripher
compart
scenario
b
rate
extent
tissu
penetr
estim
tissu
volum
fix
small
valu
popul
optim
sampl
time
determin
winpopt
sampl
schedul
dataset
patient
drawn
randomli
analyz
mcpem
algorithm
sadapt
use
true
model
popul
pk
analys
total
bia
precis
mean
popul
pk
paramet
varianc
repres
bsv
calcul
result
except
design
sampl
plasma
tissu
time
patient
scenario
bia
precis
popul
mean
bia
gener
precis
bsv
pk
paramet
scenario
b
design
optim
plasma
sampl
time
one
tissu
sampl
per
patient
design
tissu
sampl
time
show
bia
extent
tissu
penetr
rate
tissu
penetr
design
random
tissu
sampl
time
bia
precis
popul
mean
design
four
group
n
patient
sampl
one
optim
tissu
sampl
time
achiev
bia
precis
popul
mean
bia
precis
bsv
estim
conclus
tissu
sampl
obtain
multipl
optim
time
point
determin
rate
extent
penetr
even
one
tissu
sampl
per
patient
obtain
design
serial
plasma
sampl
popul
optim
time
benefici
design
one
plasma
one
tissu
sampl
per
patient
time
perform
poorli
benefit
full
bayesian
approach
pk
analysi
import
dilig
pharmacokinet
pk
profil
earli
drug
research
develop
stage
reduc
late
attrit
rate
increasingli
recogn
last
decad
major
advanc
made
base
result
adm
screen
absorpt
distribut
metabol
excret
lead
optim
phase
relev
predict
inform
pharmacokinet
behavior
preclin
candid
typic
obtain
two
three
anim
speci
administr
human
preclin
pk
assess
provid
input
vitro
vivo
pkpd
pharmacodynam
model
evalu
exposureeffect
relationship
pkpd
model
power
tool
dose
select
clinic
phase
drug
develop
phase
pk
data
avail
popul
base
pkpd
model
support
effect
dose
select
late
stage
clinic
trial
moreov
pkpd
guid
approach
provid
decis
support
suscept
breakpoint
well
strategi
mitig
resist
develop
recent
late
stage
clinic
failur
illustr
import
understand
impact
pk
protein
bind
concentr
infect
site
incorpor
earli
adequ
pkpd
evalu
epsteinbarr
viru
ebv
infect
immun
suppress
transplant
recipi
frequent
potenti
lifethreaten
complic
ebv
caus
bcell
lymphoprolif
disord
collect
name
ptld
may
lead
malign
lymphoma
left
untreat
incid
clinic
appear
sever
ptld
may
quit
variabl
requir
appropri
riskstratif
onset
accur
standard
diagnost
monitor
approach
posttranspl
period
aim
earli
identif
ebv
involv
distinct
reject
infecti
complic
biolog
pathogenesi
underli
ptld
solid
organ
sot
stem
cell
transplant
sct
recipi
differ
featur
implic
diagnosi
treatment
primari
infect
sot
nearli
activ
ebv
infect
sct
pose
highest
risk
fatal
complic
distinct
made
earli
lateonset
ptld
former
directli
ebv
driven
frequent
revers
simpl
therapeut
intervent
latter
seen
consequ
misdiagnos
earli
ebvdriven
bcell
amplif
allow
addit
genet
defect
accumul
therebi
increas
malign
phenotyp
frequent
requir
sever
intervent
strategi
includ
chemotherapi
earli
ptld
recogn
dynam
increas
ebvdna
load
blood
rel
short
time
interv
sot
ebv
load
usual
cell
associ
wherea
sct
cell
plasma
dna
load
observ
whole
blood
may
prefer
well
standard
sampl
diagnost
monitor
depend
type
transplant
therapeut
intervent
may
vari
mildmoder
reduct
immunosuppress
treatment
ist
via
use
rituximab
rtx
infus
ex
vivo
activ
ebvreact
tcell
persist
decreas
ebvdna
load
may
taken
sign
therapeut
efficaci
monitor
ebvreact
tcell
tetram
fac
elispot
test
may
provid
inform
patient
immun
capac
conquer
ebvdriven
bcell
prolifer
restor
ebv
latenc
long
term
treatment
failur
indic
persist
increas
ebvdna
time
taken
sign
drastic
intervent
earli
ptld
ebvinfect
cell
frequent
dissemin
via
circul
thu
becom
easili
detect
wherea
late
ptld
may
confin
tissu
littl
circul
cell
ebv
transcript
profil
reveal
differ
ebv
gene
express
biopsi
materi
circul
ebvcarri
cell
patient
earli
ptld
suggest
transcript
regul
affect
lymphoid
tissu
furthermor
analysi
ebv
gene
express
ptld
lesion
singl
cell
level
reveal
heterogen
ebv
gene
express
reflect
complex
underli
pathogen
event
rather
simpl
prolifer
latencyiii
growth
program
express
bcell
infrequ
measur
ebv
dna
load
consid
proper
diagnost
approach
mere
ebv
dna
level
may
vari
patient
gener
clinic
implic
stabl
time
suggest
frequent
weekli
measur
chang
ebvdna
load
earli
time
posttranspl
use
sensit
standard
techniqu
coupl
appropri
time
ebv
loadguid
therapeut
intervent
may
reduc
even
prevent
ptld
transplant
set
human
adenovirus
hadv
highli
genet
diverg
group
dna
virus
consist
seven
speci
type
hadv
type
clearli
associ
infect
immunosuppress
patient
exampl
haematopoiet
stem
cell
recipi
hadv
type
typic
opportunist
agent
also
caus
less
sever
diseas
immunocompet
patient
hadv
persist
sever
month
year
acut
infect
even
immunocompet
host
preval
children
adult
complic
due
hadv
haematopoet
stem
cell
recipi
may
origin
hadv
persist
de
novo
infect
due
hadv
persist
diagnosi
hadv
diseas
made
mere
detect
hadv
dna
case
organ
relat
hadv
diseas
diagnosi
feasibl
hadv
detect
put
infect
site
eg
case
cystiti
hadv
detect
urin
hadv
infect
also
lead
potenti
fatal
dissemin
hadv
diseas
main
risk
factor
young
age
lymphopenia
cell
deplet
high
dosag
immunosuppress
drug
diagnosi
dissemin
hadv
diseas
simplifi
hadv
load
test
peripher
blood
sampl
use
quantit
hadv
pcr
high
viru
load
genom
equivalentsml
clearli
associ
dissemin
diseas
wherea
low
viru
load
genom
equivalentsml
observ
case
hadv
latenc
howev
precis
threshold
hadv
load
valu
yet
determin
dissemin
diseas
may
predict
case
rapidli
rise
hadv
load
blood
pathophysiolog
hadv
dissemin
diseas
includ
massiv
viru
replic
affect
organ
exampl
liver
may
infect
interact
hadv
capsid
clot
factor
x
furthermor
bind
hadv
capsid
platelet
format
immun
complex
preform
hadv
specif
antibodi
well
induct
cytokin
may
contribut
pathophysiolog
dissemin
hadv
diseas
antivir
treatment
hadv
diseas
yet
establish
cidofovir
may
benefici
effect
applic
earli
may
fail
applic
case
high
viru
load
hadv
specif
tlymphocyt
seem
promis
therapeut
approach
risk
dissemin
hadv
diseas
clearli
associ
lymphopenia
howev
hadv
specif
lymphocyt
must
prepar
onset
diseas
order
avail
time
identif
microbi
isol
malditof
ms
whole
cell
gain
accept
clinic
microbiolog
reliabl
technolog
depend
larg
refer
databas
algorithm
spectral
comparison
simpli
sampl
spectrum
directli
compar
spectra
refer
strain
result
rate
list
match
provid
elabor
approach
realiz
spectral
archiv
microbi
identif
system
sarami
sarami
use
comprehens
databas
mass
spectral
data
refer
strain
autom
identif
two
type
spectral
data
contain
databas
call
superspectra
fulli
autom
firstlin
identif
includ
result
transmiss
refer
spectra
semiautom
secondlin
identif
concept
superspectra
develop
consider
natur
intraspecif
divers
encount
microbi
speci
divers
also
reflect
mass
spectral
fingerprint
individu
isol
variat
peak
pattern
complic
select
appropri
refer
data
comput
superspectra
spectral
fingerprint
number
isol
speci
search
conserv
mass
signal
summar
consensu
spectrum
second
step
mass
consensu
spectrum
compar
entir
refer
databas
establish
specif
differ
taxonom
level
mass
signal
select
specif
desir
taxonom
level
eg
speciesspecif
exclud
mass
consensu
spectra
specif
higher
taxonom
level
pattern
remain
mass
highli
specif
make
random
match
highli
improb
practic
exclud
fals
identif
sarami
databas
contain
present
superspectra
repres
microbi
speci
sinc
superspectra
definit
repres
typic
isol
speci
confus
type
strain
certain
percentag
isol
given
speci
captur
autom
routin
analysi
case
secondlin
identif
start
appli
direct
comparison
refer
spectra
databas
repres
speci
twostep
approach
basic
clinic
veterinari
increasingli
environment
isol
reliabl
identifi
larg
autom
procedur
object
compar
identif
routin
bacteri
isol
use
sarami
identif
system
convent
method
method
consecut
bacteri
isol
urineand
bloodcultur
identifi
use
convent
biochem
method
vitek
ii
isol
subsequ
identifi
use
malditof
axima
sarami
discrep
isol
identifi
mean
rna
sequenc
result
total
isol
blood
urin
includ
isol
show
fulli
agreement
specieslevel
anoth
fulli
agreement
genuslevel
achiev
isol
could
identifi
malditof
use
identificationscor
isol
two
method
gave
differ
identif
isol
current
subject
character
rna
sequenc
conclus
malditof
axima
sarami
give
fast
reliabl
identif
commonli
encount
bacteri
isol
clinic
microbiolog
laboratori
certain
limit
enterobacteriacea
apart
shigella
pseudomona
aeruginosa
stenotrophomona
maltophilia
haemophilu
influenza
staphylococcu
enterococcu
faecali
e
faecium
could
usual
identfi
speci
level
anaerob
streptococci
often
unidentifi
maier
b
wegemann
kostrzewa
bremen
munich
de
object
autom
blood
cultiv
patient
suspicion
sepsi
routin
clinic
approach
fast
accur
speci
identif
microorgan
signal
growth
fundament
interest
current
identif
take
two
day
necess
subcultiv
biochem
identif
present
simpl
protocol
potenti
shorten
identif
time
minut
method
blood
cultur
spike
bacteria
yeast
use
method
establish
inocul
blood
cultur
routin
sampl
optim
valid
protocol
blood
cultur
mix
lysi
solut
follow
vortex
centrifug
therebi
blood
cell
disrupt
bacteria
yeast
surviv
supernat
remov
pellet
care
suspend
wash
solut
centrifug
supernat
remov
bacteria
pellet
transfer
maldi
target
directli
short
extract
procedur
speci
id
achiev
measur
malditof
ms
mass
spectromet
follow
analysi
maldi
biotyp
softwar
method
optim
vari
volum
ratio
blood
cultur
liquid
lysi
solut
result
posit
blood
cultur
show
averag
cell
densiti
cfuml
high
number
blood
cell
present
protocol
abl
remov
blood
cell
extens
without
signific
loss
microorgan
therefor
result
malditof
spectra
high
qualiti
differ
bacteri
speci
enterobacteria
gram
neg
nonfer
bacteria
staphylococci
enterococci
streptococci
haemophilu
sp
could
identifi
procedur
reliabl
also
yeast
could
detect
previous
publish
protocol
identifi
case
identif
possibl
even
h
blood
cultur
flag
posit
autom
show
high
sensit
method
mix
cultur
case
lead
nonidentif
observ
one
speci
work
bioinformat
algorithm
improv
new
protocol
speci
identif
posit
blood
cultur
could
demonstr
fast
accur
altern
classic
method
identif
time
shorten
day
minut
major
sampl
therebi
enabl
quicker
adopt
antibiot
therapi
g
bizzini
c
durussel
j
bill
g
greub
lausann
ch
object
blood
cultur
best
approach
establish
etiolog
bloodstream
infect
rapid
identif
etiolog
agent
sever
infect
pivot
guid
antimicrobi
therapi
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
allow
identif
speci
level
minut
bacteria
measur
molecular
mass
protein
whole
bacteri
extract
appli
simpl
procedur
lyse
erythrocyt
posit
blood
cultur
prepar
bacteri
pellet
malditof
ms
analysi
method
pellet
posit
blood
cultur
vial
detect
bactec
becton
dickinson
prepar
use
ammonium
chlorid
lyse
solut
centrifug
step
pellet
analyz
malditof
either
direct
deposit
target
plate
formic
acid
acetonitril
extract
step
mass
spectra
acquir
use
microflex
malditof
ms
bruker
dalton
identif
consid
valid
speci
level
score
valu
valid
genu
level
score
valu
valid
score
identif
obtain
malditof
ms
analysi
compar
biochem
identif
result
monobacteri
posit
blood
vial
patient
analyz
bacteri
identif
obtain
malditof
ms
analysi
exhibit
score
valu
score
valu
regardless
score
valu
bacteri
identif
obtain
malditof
ms
correct
speci
level
correct
genu
level
case
reliabl
identif
obtain
score
valu
bacteria
gram
posit
mainli
streptococci
n
coagulaseneg
staphylococci
n
unidentifi
streptococci
streptococcu
pneumonia
among
gram
neg
bacteria
score
encapsul
speci
klebsiella
pneumonia
haemophilu
influenza
conclus
use
ammonium
chloridedriven
hemolysi
analyz
directli
posit
blood
cultur
malditof
ms
promis
new
method
allow
fast
accur
inexpens
identif
etiolog
agent
lifethreaten
bloodstream
infect
c
u
berlin
de
object
earli
appropri
antimicrobi
therapi
critic
determin
outcom
bloodstream
infect
rapid
identif
id
antimicrobi
suscept
test
ast
henc
mandatori
adjust
empir
antimicrobi
therapi
institut
first
two
hour
onset
symptom
reduc
turnaround
time
tat
aliquot
posit
blood
cultur
bottl
bc
subject
differenti
centrifug
gel
separ
use
bd
vacutain
sst
ii
tube
prepar
use
direct
identif
malditof
mass
spectrometri
ms
addit
optim
protocol
rapid
ast
use
phoenix
bd
system
method
blood
cultur
drawn
septic
patient
incub
use
bactec
bd
blood
cultur
devic
rapid
arm
aliquot
consecut
posit
bc
bottl
process
direct
identif
mass
spectrometri
use
maldi
biotyp
bruker
system
control
process
accord
standard
procedur
inocul
solid
media
subsequ
id
ast
use
maldi
biotyp
vitek
system
respect
case
discrep
id
result
isol
subject
rrna
gene
sequenc
far
test
posit
bc
direct
maldi
tof
analysi
result
speci
identif
show
discrep
result
compar
identif
coloni
grown
bc
bc
isol
could
grown
plate
thu
monoinfecti
bc
maldi
tof
reveal
etiolog
agent
less
h
conclus
compar
convent
procedur
combin
use
malditof
ms
rapid
ast
may
significantli
reduc
tat
diagnosi
blood
stream
infect
kostrzewa
c
boogen
j
maier
u
bremen
cologn
de
object
direct
identif
bacteria
infect
urin
maldibiotyp
mbt
shown
previous
enabl
quantif
well
identif
necessari
routin
diagnost
test
combin
autom
quantif
system
uroquattro
alifax
hb
l
malditof
workflow
method
proof
concept
studi
urin
sampl
routin
analys
parallel
novel
combin
workflow
ml
aliquot
transfer
hb
l
tube
nutrient
broth
stirrer
place
uroquattro
instrument
h
cfu
valu
read
turbid
vial
monitor
bacteri
count
calcul
incub
ml
aliquot
posit
vial
pipet
onto
ml
ficollpaqu
plu
cushion
centrifug
min
g
ml
eppendorf
cup
supernat
discard
part
pellet
transfer
onto
maldi
target
air
dri
overlay
matrix
solut
hcca
air
dri
subject
identif
mass
spectrometri
use
mbt
system
approach
compar
standard
workflow
plate
urin
petri
dish
quantit
way
mbt
identif
coloni
night
incub
result
bacteri
count
cfu
obtain
sampl
patient
consid
bacteri
infect
bacteri
count
ident
larg
extend
method
howev
mbt
identif
possibl
sampl
incub
hb
l
result
match
standard
protocol
due
presenc
one
pathogen
shown
standard
workup
current
identif
softwar
mbt
resolv
conclus
protocol
enabl
reliabl
bacteri
identif
togeth
bacteri
count
hour
case
monobacteri
infect
use
standard
protocol
hb
l
ongo
improv
mbt
identif
algorithm
resolv
problem
polybacteri
infect
extens
approach
usual
steril
bodi
fluid
tracheal
secret
pleural
aspir
also
may
lead
dramat
reduct
turnaround
time
microbiolog
lab
identif
subsequ
asttest
maier
v
bremen
de
object
malditof
fingerprint
analysi
becam
valuabl
tool
microorgan
identif
classif
recent
bacteria
yeast
simpl
robust
approach
sampl
prepar
report
lead
reproduc
result
low
impact
cultiv
condit
growth
state
situat
filament
fungi
keep
complic
particular
sampl
prepar
mold
rigid
cell
wall
challeng
fingerprint
spectra
deriv
spore
mycel
show
signific
differ
also
fingerprint
spectra
seem
depend
cultiv
media
present
novel
approach
sampl
prepar
fungi
prior
malditof
ms
improv
reproduc
qualiti
spectra
significantli
method
fungal
speci
eg
aspergillu
spp
fusarium
spp
harvest
solid
media
grown
night
liquid
medium
subsequ
cell
materi
harvest
centrifug
wash
water
pellet
dri
well
extract
use
formic
acetonitril
extract
spot
onto
maldi
target
dri
air
overlaid
hcca
matrix
mass
spectra
acquir
linear
mode
mass
rang
da
use
microflex
malditof
mass
spectromet
bruker
daltonik
gmbh
bremen
spectra
analys
use
flexanalysi
softwar
refer
librari
creat
bioinformat
analys
perform
maldi
biotyp
softwar
bruker
daltonik
result
cultur
liquid
medium
lead
mycelia
without
spore
therebi
larg
homogen
cell
materi
sampl
facilit
success
protein
extract
simpl
short
standardis
method
mass
spectra
gener
base
novel
sampl
prepar
method
reproduc
contain
mani
characterist
peak
therebi
lead
significantli
improv
identif
secur
higher
qualiti
spectra
increas
differenti
power
method
could
highlight
subspeci
differ
core
databas
filament
speci
establish
use
first
compar
studi
technic
biolog
replic
could
identifi
success
well
isol
includ
databas
reproduc
result
obtain
differ
mass
spectromet
could
demonstr
present
approach
may
lead
signific
improv
fungal
identif
clinic
routin
applic
object
method
mass
spectrometri
present
modern
analyt
tool
fungal
strain
type
diagnos
fungal
infect
result
qualit
quantit
proteom
approach
document
variou
aspergillu
strain
virul
protein
factor
present
fungal
spore
identifi
peptid
map
peptideand
de
novosequenc
quantit
proteom
address
novaq
housedevelop
softwar
improv
precis
result
sampl
label
silac
metabonom
approach
illustr
detect
minor
macrolid
antibiot
produc
streptomyc
strain
peptidom
repres
track
nonribosom
cyclic
peptid
depsipeptid
produc
beauveria
paecilomyc
pseudallescheria
genera
peptid
profil
use
chemotaxonom
tool
patent
uniqu
nonribosom
lassopeptid
structur
report
extrem
specif
fungal
marker
glycom
lipidom
armori
illustr
hexosylceramid
analysi
scedosporium
fouriertransform
ion
cyclotron
reson
mass
spectrometri
clinic
sampl
tissu
whole
blood
handl
advanc
ambient
ioniz
techniqu
report
special
focu
lipid
brain
eye
bulb
lung
murin
porcin
fungal
infect
plant
address
dappi
mass
imag
current
advanc
mass
spectrometri
lay
experiment
foundat
modern
sensit
diagnost
tool
predict
particularli
mass
imag
tissu
infect
mold
lead
discoveri
specif
fungal
biomark
sukhorukova
nikulin
e
ilina
zhukova
edelstein
maier
kostrzewa
v
govorun
moscow
smolensk
ru
bremen
de
object
aureu
sever
speci
coagulaseneg
staphylococci
common
human
pathogen
therefor
comprehens
accur
identif
staphylococcu
speci
great
import
sever
id
method
base
convent
physiolog
biochem
character
commerci
avail
manual
autom
format
present
studi
aim
examin
accuraci
manual
identif
test
bd
phoenix
tm
system
maldi
biotyp
system
discrimin
staphylococcu
speci
method
total
clinic
isol
staphylococci
studi
convent
speci
identif
manual
semi
autom
biochem
identif
system
franc
use
isol
also
identifi
phoenix
tm
autom
microbiolog
system
bd
diagnost
system
usa
well
maldi
biotyp
techniqu
bruker
daltonik
gmbh
germani
base
fingerprint
mass
spectra
acquir
fresh
bacteri
cultur
rrna
gene
sequenc
perform
confirmatori
approach
discord
case
result
clinic
isol
region
russian
feder
investig
includ
isol
presum
identifi
convent
microbiolog
method
coagulaseneg
staphylococci
isol
report
aureu
discord
convent
method
identif
test
technolog
found
case
maldi
biotyp
techniqu
one
bd
phoenix
tm
autom
system
discord
result
id
use
biotyp
phoenix
obtain
isol
unambigu
speci
id
achiev
maldi
biotyp
techniqu
phoenix
tm
autom
system
case
respect
likewis
isol
respect
identifi
genu
level
two
isol
belong
staphylococcu
genu
accord
approach
discrep
case
analyz
rrna
gene
sequenc
confirm
benefit
maldi
biotyp
id
result
case
maldi
biotyp
techniqu
superior
manual
autom
bd
phoenix
biochem
test
speci
identif
staphylococci
mz
pino
jv
oslo
object
compar
malditof
mass
spectrometri
ms
establish
autom
identif
system
anaerob
bacteria
method
compar
rdna
sequenc
method
isol
routin
diagnost
laboratori
cultur
nonselect
media
secur
pure
cultur
age
hour
underw
gram
stain
catalas
test
spot
indol
request
identif
method
otherwis
standard
procedur
specifi
manufactur
follow
vitek
anaerob
corynebacteria
identif
vitek
bd
bbl
crystal
anaerob
id
kit
bbl
autoread
sequenc
rrna
gene
dna
extract
use
prepman
ultra
protocol
appli
bioscienc
thereaft
perform
accord
standard
procedur
use
abi
sequenc
blastn
search
tool
identif
microorgan
ms
perform
use
microflex
malditof
mass
spectromet
bruker
daltonik
gmbh
biotyp
softwar
prepar
bacteria
perform
use
ethanolform
acid
extract
procedur
accord
manufactur
bruker
daltonik
gmbh
bacteria
analyz
duplic
biotyp
softwar
gener
list
speci
match
rank
log
score
valu
studi
accept
score
valu
higher
duplic
match
differ
anaerob
speci
identifi
proport
isol
identifi
correctli
accord
speci
group
compar
rdna
sequenc
present
tabl
gener
malditof
ms
perform
better
autom
system
although
short
come
present
speci
two
autom
system
anaerob
corynebacteria
identif
card
perform
margin
better
bd
bbl
crystal
tm
anaerob
id
kit
conclus
autom
system
anaerob
identif
show
limit
perform
although
malditof
ms
perform
better
signific
shortcom
also
present
latter
could
explain
databas
limit
maldi
biotyp
softwar
ie
sever
subspeci
fusobacterium
nucleatum
describ
includ
present
time
rdna
sequenc
remain
gold
standard
may
somewhat
replac
maldi
tof
ms
near
futur
depend
develop
databas
autom
identif
system
use
adjunct
convent
identif
object
despit
identif
sarscovlik
virus
horsesho
bat
china
evolutionari
possibl
recombin
origin
sarscov
remain
undetermin
better
defin
epidemiolog
evolut
batsarscov
china
role
recombin
origin
sarscov
civet
fouryear
studi
coronavirus
chines
horsesho
bat
hong
kong
guangdong
provinc
southern
china
conduct
method
respiratori
alimentari
sampl
collect
chines
horsesho
bat
captur
hong
kong
guangdong
provinc
southern
china
fouryear
period
detect
coronavirus
reversetranscriptas
polymeras
chain
reaction
five
hundr
eleven
bat
hong
kong
also
tag
studi
migrat
pattern
bat
viral
persist
complet
genom
strain
batsarscov
obtain
differ
time
sequenc
compar
previous
character
genom
result
batsarscov
detect
alimentari
specimen
bat
peak
activ
spring
bat
carri
virus
appear
healthi
viral
clearanc
occur
two
week
four
month
tag
exercis
show
migrat
distanc
chines
horsesho
bat
hong
kong
rang
km
complet
genom
sequenc
strain
batsarscov
reveal
frequent
recombin
differ
strain
especi
among
bat
virus
china
recombin
detect
batsarscov
guangxi
hubei
possibl
gener
civet
sarscov
breakpoint
region
conclus
batsarscov
caus
acut
selflimit
infect
horsesho
bat
serv
reservoir
recombin
viru
strain
differ
geograph
locat
within
reachabl
forag
rang
civet
sarscov
like
recombin
viru
aris
batsarscov
strain
close
relat
frequent
recombin
anim
may
account
crossspeci
transmiss
emerg
sar
epidemiolog
control
q
fever
netherland
object
q
fever
caus
coxiella
burnetii
sheep
goat
frequent
describ
sourc
human
usual
infect
inhal
half
infect
show
symptom
q
fever
rare
diseas
netherland
sinc
q
fever
emerg
small
rumin
subsequ
human
popul
lead
largest
q
fever
outbreak
record
date
method
analysi
data
public
health
facil
region
laboratori
anim
health
servic
nation
institut
public
health
environ
describ
q
fever
outbreak
occur
netherland
result
spring
q
fever
occur
villag
provinc
noord
brabant
case
increasingli
larger
outbreak
occur
increasingli
wider
area
novemb
case
notifi
six
patient
die
number
chronic
case
known
far
contact
haymanur
hous
locat
close
infect
dairi
goat
farm
identifi
import
risk
factor
human
q
fever
affect
area
dairi
goat
farm
common
goat
densiti
per
squar
kilometr
highest
netherland
sinc
preced
human
outbreak
abort
wave
caus
c
burnetii
notic
dairi
goat
farm
dairi
sheep
farm
region
human
case
occur
sampl
incrimin
farm
anim
surround
result
detect
c
burnetii
preliminari
mlva
analysi
point
spread
singl
clone
goat
howev
presenc
clone
yet
wide
confirm
human
control
measur
includ
mandatori
veterinari
notif
well
hygien
measur
spread
manur
lamb
season
mass
vaccin
goat
sheep
implement
preliminari
result
monitor
vaccin
indic
decreas
abort
rate
vaccin
group
zero
drop
bulkmilk
level
c
burnetii
dna
conclus
q
fever
outbreak
start
netherland
still
go
mainli
restrict
south
countri
area
intens
dairi
goat
farm
howev
epidem
expand
area
effect
control
measur
still
await
epidemiolog
data
point
toward
intens
dairi
goat
farm
main
sourc
outbreak
object
outbreak
qfever
notifi
case
ongo
netherland
sinc
immunofluoresc
assay
ifa
cornerston
qfever
serolog
hospit
ifa
howev
timeconsum
subject
interobserv
variabl
furthermor
lag
phase
antibodi
respons
coxiella
burnetii
administr
within
hour
later
administr
time
associ
lot
tc
shortand
longterm
mortal
ci
ci
lot
day
ci
ci
tc
day
ci
ci
mortal
focu
random
doubleblind
multicentr
phase
studi
efficaci
safeti
ceftarolin
vs
ceftriaxon
communityacquir
bacteri
pneumonia
p
hd
friedland
j
lee
l
lloren
critchley
thye
oakland
us
object
communityacquir
bacteri
pneumonia
cabp
major
caus
morbid
mortal
streptococcu
pneumonia
remain
common
pathogen
grow
concern
rise
incid
resist
highli
virul
pathogen
multidrugresist
pneumonia
mdrsp
communityacquir
methicillinresist
staphylococcu
aureu
mrsa
ceftarolin
cpt
novel
parenter
broadspectrum
cephalosporin
bactericid
activ
common
gramposit
organ
includ
mdrsp
mrsa
well
common
gramneg
pathogen
evalu
treatment
cabp
clinic
trial
id
method
hospit
adult
patient
centr
countri
moder
sever
cabp
port
risk
class
iii
iv
requir
intraven
therapi
receiv
cpt
mg
h
ceftriaxon
cro
g
h
day
random
clinic
microbiolog
respons
advers
event
ae
assess
primari
object
determin
noninferior
prespecifi
ci
margin
clinic
cure
rate
cpt
compar
cro
testofcur
visit
day
posttherapi
clinic
evalu
ce
modifi
intenttotreat
efficaci
mitt
popul
secondari
object
includ
evalu
clinic
cure
microbiolog
evalu
microbiolog
modifi
intenttotreat
efficaci
mmitt
popul
tabl
cpt
cro
well
toler
common
ae
cpt
diarrhoea
vs
cro
headach
vs
insomnia
vs
ae
led
studi
drug
discontinu
patient
treat
cpt
cro
respect
conclus
cpt
demonstr
noninferior
ceftriaxon
treat
patient
hospit
moder
sever
cabp
ce
mitt
studi
popul
focu
clinic
cure
rate
coprimari
popul
patient
confirm
bacteri
infect
numer
higher
cpt
compar
cro
cpt
high
clinic
cure
rate
well
toler
safeti
profil
similar
ceftriaxon
cpt
potenti
effect
welltoler
treatment
option
cabp
j
r
vancheeswaran
mack
london
uk
object
invas
pneumococc
diseas
ipd
major
caus
morbid
mortal
unit
kingdom
pneumococc
polysaccharid
vaccin
ppv
recommend
adult
year
younger
adult
chronic
medic
condit
immunosuppress
sinc
pneumococc
conjug
vaccin
introduc
routin
childhood
immun
program
septemb
aim
look
pneumococc
bacteraemia
serotyp
pcv
immun
histori
district
gener
hospit
popul
method
patient
pneumococc
bacteraemia
octob
april
identifi
retrospect
isol
sent
unit
kingdom
health
protect
agenc
refer
laboratori
serotyp
clinic
detail
acquir
via
case
note
review
immun
statu
obtain
gener
practition
identifi
adult
pneumococc
bacteraemia
obtain
clinic
detail
patient
ppv
current
recommend
seven
immun
two
die
eight
histori
immun
two
die
three
case
immun
histori
obtain
total
mortal
group
pneumococc
serotyp
result
avail
patient
six
patient
receiv
ppv
four
acquir
infect
serotyp
cover
ppv
ten
patient
receiv
ppv
nine
serotyp
cover
ppv
total
isol
cover
ppv
isol
cover
ppv
total
number
isol
cover
ppv
tabl
small
studi
observ
high
rate
mortal
patient
ppv
recommend
similar
receiv
ppv
uptak
vaccin
recommend
suboptim
observ
four
case
appar
failur
ppv
vaccin
protect
ipd
pneumococc
serotyp
cover
ppv
keep
observ
ppv
incomplet
protect
ipd
isol
serotyp
cover
ppv
serotyp
may
spread
paediatr
adult
popul
may
repres
serotypereplac
follow
introduct
promot
vaccin
uptak
ongo
serotyp
monitor
warrant
object
evalu
distribut
serotyp
among
adult
pneumococc
commun
acquir
pneumonia
cap
netherland
order
determin
potenti
vaccin
coverag
prospect
observ
studi
dutch
hospit
patient
admit
er
clinic
suspect
cap
includ
januari
march
recent
hospit
wk
stay
longterm
care
facil
known
bronchial
obstruct
histori
postobstruct
pneumonia
primari
metastat
lung
cancer
aid
pcp
tbc
unconsci
exclus
criteria
histori
take
physic
examin
biochem
hematolog
blood
test
bloodand
sputum
cultur
binax
pneumococc
urinari
antigen
test
perform
patient
pneumococc
bacteremia
isol
serotyp
netherland
refer
laboratori
amsterdam
pneumococc
cap
defin
presenc
clinic
criteria
cap
radiograph
confirm
radiologist
isol
pneumonia
blood
sputum
domin
flora
posit
antigen
test
urin
result
includ
patient
radiograph
confirm
cap
pneumococc
cap
diagnos
isol
pneumonia
blood
cultur
n
bloodcultur
sputum
cultur
n
posit
urinari
antigen
test
n
bacteremia
isol
serotyp
serotyp
n
n
common
potenti
vaccin
coverag
pneumococc
conjug
vaccin
pcv
polysaccharid
vaccin
ps
conclus
base
bacteremia
isol
vaccin
coverag
would
pneumococc
conjug
vaccin
current
investig
doubleblind
placebocontrol
trial
netherland
serotypespecif
mortal
risk
among
patient
invas
pneumococc
diseas
swedish
populationbas
studi
p
j
darenberg
b
henriqu
normark
stockholm
se
object
investig
pneumococc
serotypespecif
mortal
risk
correl
serotyp
invas
diseas
potenti
among
patient
invas
pneumococc
diseas
ipd
method
sweden
mandatori
report
ipd
isol
collect
serotyp
molecular
type
episod
ipd
among
adult
report
jan
oct
total
isol
serotyp
questionnair
studi
perform
obtain
clinic
sociodemograph
inform
patient
serotyp
ipd
obtain
patient
preliminari
analysi
patient
assess
absolut
serotypespecif
mortal
risk
rel
risk
use
regress
model
group
level
accord
previous
defin
invas
diseas
potenti
high
serotyp
medium
serotyp
low
serotyp
individu
serotyp
risk
estim
adjust
potenti
confound
result
pneumococc
serotyp
preval
rang
serotyp
serotyp
stabl
observ
period
absolut
mortal
risk
highest
serotyp
low
invas
diseas
potenti
follow
serotyp
medium
high
invas
diseas
potenti
serotyp
low
invas
diseas
potenti
associ
increas
mortal
risk
unadjust
adjust
analys
rel
risk
ci
ci
respect
test
trend
accord
invas
diseas
potenti
signific
unadjust
pvalu
adjust
pvalu
analys
patient
infect
serotyp
lower
invas
diseas
potenti
older
like
diagnos
mening
suffer
chronic
diseas
immunosuppress
pvalu
serotyp
associ
increas
mortal
risk
crude
analys
serotyp
associ
increas
mortal
risk
adjust
analys
larg
populationbas
studi
host
risk
factor
appear
strongest
determin
risk
infect
serotyp
accord
invas
diseas
potenti
well
mortal
outcom
